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Summary
In this thesis, the construction and use of integrative vectors to express foreign 
genes in mycobacteria is described. These vectors are based on the transposition 
properties of the \S900 insertion sequence. Transformation by stable integration of 
multiple copies of the vector into the chromosome of Mycobacterium smegmatis, M. 
hovis BCG and M. vaccae was achieved. The M. leprae gene encoding the 18-kDa 
antigen was used to drive the expression of foreign antigens in mycobacteria. The 
major immunogenic site o f Foot-and-Mouth disease virus (FMDV) comprising amino 
acids 140-160 of the virus protein 1 (VPl) was inserted in the 18kD gene and 
expressed as a fusion protein. Guinea pigs were vaccinated with the recombinant BCG 
expressing the FMDV epitope and immune responses specific for the FMDV were 
detected.
A system for testing mycobacterial promoter strength in both extracellularly and 
intracellularly growing mycobacteria, as well as in E. coli was developed. It consists 
o f a shuttle vector containing a promoted ess reporter gene (lacZ). A  promoter library 
was constructed using M. hovis BCG chromosomal DNA and screened in M. 
smegmatis and Æ coli and a number of clones containing DNA inserts with promoter 
activity were isolated. The activity of each individual clone was measured in both, 
E. coli and M. smegmatis. Several previously characterized mycobacterial promoters 
including those of ûiQ Mycobacterium bovis BCG hspSO, the M. leprae 18kD and the 
putative iron regulated M. leprae 28kD gene were also cloned in front of the 
promoterless lacZ gene and the promoter strength was determined. To study 
intracellular expression, rBCG was used to infect murine macrophages and the activity 
o f the reporter gene was measured using a fluorescent substrate and a FACS can 
system. Relative differences in the expression of the reporter gene during intracellular 
and extracellular growth were detected for some promoters. The BCG hspGO promoter 
was shown to be the strongest of the characterized promoters also during intracellular 
growth. To obtain a higher level of expression of the 18kD/FMDV fusion, the 18kD 
promoter was replaced by the hsp60 promoter. A level of expression of the fused gene 
that in vitro was at least 10 fold higher was obtained with the hsp60 promoter in BCG.
"In the context of infectious diseases, there is no place in the world 
from which we are remote and no one from whom we are 
disconnected."
Barry R. Bloom
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Chapter 1
1 Introduction
1.1 - Mycobacterial diseases and vaccines
Mycobacteria cause two of the most prevalent infectious diseases in the world: 
tuberculosis (TB) and leprosy. An acute or chronic infectious disease of humans and 
various animals, tuberculosis is caused by members of the Mycobacterium tuberculosis 
complex, often called tubercle bacilli. One of the oldest diseases, it was known as 
consumption or the great white plague. Today, as it has been for centuries, 
tuberculosis remains the leading cause of death in the world from infectious disease. 
Approximately a third of the world's population has been infected With M y cobacterium 
tuberculosis and is at risk for developing disease. In most industrialized countries 
tuberculosis is a reemergent problem. Globally, tuberculosis accounts for almost three 
million deaths annually and over 25% of avoidable adult deaths in developing 
countries (Murray et al, 1990). Leprosy c?eiSQàhy Mycobacterium leprae continues 
to afflict approximately 20 million worldwide and, although it rarely causes death, the 
disease irreparably damages nerves and alters the lives of the afflicted (Bloom, 1989).
The genus Mycobacterium which includes M. tuberculosis and M. leprae, 
consists of nearly 50 different species. The relationship between the different species 
ranges from close to very diverse, as reflected in factors which include virulence, 
habitat, rate of growth, nutritional requirements, antigenicity and genetic relatedness. 
Mycobacteria can be found as saprophytes in soil, air and water. Some species, like 
the members of the MAIS complex (M  avium-intracellulare-scrophulaceum), have
now been associated with infection in immunocompromised patients and have also 
attracted a great deal of attention.
Mycobacteria are gram-positive, aerobic, acid alcohol fast bacteria with large 
amounts of lipid in their cell wall. The high lipid content causes mycobacteria to 
grow as hydrophobic colonies on solid media and as "fungal-like" pellicles in liquid 
media, hence the name mycobacteria. Their DNA is G+C rich (55-70%). They are 
often characterised as slow or fast growing by their growth rate in culture. Most 
pathogens, including Mycobacterium tuberculosis, are slow growing with a doubling 
time of 10 to 24 hours.
Many of the properties of mycobacteria such as their antigenicity, adjuvanticity, 
virulence, and anti tumour activity, are thought to involve components o f the 
mycobacterial cell wall. The structure of the cell wall consists of a peptidoglycan 
backbone covalently linked to branched chains of arabinogalactan esterified at their 
termini by mycolic acids. Several other lipids and glycolipids may also be associated 
with the cell wall (Fig 1).
The "tubercle bacillus" was isolated by Robert Koch in 1882 and shown to be 
the causative agent o f both human and bovine tuberculosis. In 1970 the bovine 
variant was given separate species status 3S Mycobacterium bovis. However M. bovis 
is very closely related to M. tuberculosis, and its status as a separate species is 
questionable. Both cause pulmonary tuberculosis in humans.
1.1.1 Tuberculosis
Infection with M. tuberculosis most commonly occurs by inhalation o f small 
infected droplets formed during coughing of an individual with the active form of the
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Figure 1-1. Schematic representation of the mycobacterial cell wall structure.
disease. The primary focus of infection is usually the middle or lower zones of the 
lung. Following inhalation of tubercle bacilli they are phagocytosed by unspecifically 
activated alveolar macrophages and are often killed. If the alveolar macrophages fail 
to destroy or inhibit the inhaled bacteria, the bacilli multiply until the macrophages 
burst. The bacteria are then ingested mainly by non activated macrophages, i.e., 
monocytes emigrating from the bloodstream, where tubercle bacilli multiply 
logarithmically. At this stage, which occurs about 3 weeks after infection, the host 
becomes tuberculin positive and the lesions undergo caseous necrosis in their centres. 
Tissue-damaging immune response (necrotizing DTH) is the main mechanism by 
which the host stops bacillary growth in non activated macrophages (Dannenberg and
Rook, 1994). This stage of the disease is usually clinically silent, and in most cases 
immunity develops within a few weeks. In a resistant host, T-cells stimulated by 
mycobacterial antigens release gamma interferon and lymphokines that activate local 
macrophages which accumulate around the caseous centre and ingest and destroy any 
bacilli that escape from the edge of the caseum. The primary tubercle eventually 
becomes walled off, and the disease is arrested, frequently for a lifetime. However 
a minority (about 5%) will at some stage in their lives, usually many years later, 
develop tuberculosis due to loss of host immunity associated with, e.g., old age, 
immunosuppressants, illness or malnutrition. The tubercle bacillus is therefore capable 
of remaining dormant but viable in the host for many years. The risk of progression 
to active TB among individuals infected with both HIV and TB increases to 5 to 10% 
per year (Narain et al, 1992). Tuberculosis may also be acquired from animals, as 
by drinking their unpasteurized milk, indicating that the pathogen is also infectious via 
the oral route.
Tuberculosis may spread from the lungs to any part of the body causing other 
forms of infection which include tuberculous meningitis and miliary tuberculosis, a 
rapidly fatal form causing disease in many organs. Tuberculosis may also affect 
lymph nodes, bones, joints, genital organs, kidneys, and skin. Typical symptoms of 
TB include fatigue, loss o f weight and appetite, night sweats and fever, and persistent 
cough. Sputum is often streaked with blood; sometimes massive haemorrhages occur 
as the lung tissue is destroyed by the disease. Fluid may accumulate in the pleural 
cavity. Gradual deterioration occurs and, if the disease is untreated, death is common. 
Treatment is with a combination of antituberculous drugs such as isoniazid, rifampicin, 
and streptomycin given for long periods.
1.1.2 Immune mechanisms of protection against tuberculosis
TB immunity, as with other intracellular pathogens, is principally cell mediated 
rather than humoral, with the major factors being macrophages and T lymphocytes. 
While the macrophages act as the main effectors, T cells serve as the predominant 
inducers of protection. All T-cell populations (CD4 a /p  T cells, CDS a /p  T cells, and 
y/6 T cells) contribute to protection (Izzo and North, 1992). A coordinated cross-talk 
between macrophages and T cells is essential for optimum protection. However, even 
in the face of coordinated immune response, full eradication of the pathogens is 
frequently not achieved and the individual remains infected without developing active 
disease.
Once the tubercle bacilli enter a macrophage cell, a complex battle begins 
between the invading organism and the host cell. In response to the infection, 
macrophages produce a characteristic pattern of cytokines including interleukin-1 (IL- 
1), IL-6, IL-10, tumour necrosis factor alpha (TNF-a), and transforming growth factor 
beta (TGF-P) (Valone et al, 1988; Barnes et al., 1992). During intracellular 
persistence, bacterial proteins are processed and expressed on the host cell surface in 
association with self molecules of the major histocompatibility complex (MHC), thus 
initiating T cell activation (Kaufmann, 1993). Proteins secreted by the bacteria or 
derived from bacteria killed inside the phagosome are degraded into peptides and 
expressed in association with MHC class II molecules which will be recognized by 
CD4^ T cells. Mycobacterial proteins translocated from the endosomal into the 
cytoplasmic compartment, or secreted into the cytoplasm by bacteria after its evasion 
of the phagosome, are degraded into peptides and expressed on the surface o f the cell 
in association with MHC class I molecules. These antigens presented on MHC class
I molecules will activate CD8^ T cells (Chan and Kaufmann, 1994). y/6 T cells, of 
which the majority are C D 4, C D 8, are also activated by antigens presented on 
macrophages, possibly associated with MHC-like molecules (Strominger, 1989).
CD4^ T cells play a dominant role in immune defenses against tuberculosis. 
Depletion of CD4^ cells by HIV infection markedly increases susceptibility to primary 
and reactivation tuberculosis (Barnes et al, 1991). CD4^ T cells comprise two 
functionally distinct subpopulation, Thl and Th2. They differ in patterns o f cytokine 
production and in requirements for costimulatory factors and antigen-presenting cells 
(Street and Mosmann, 1991). Thl produce gamma interferon (INF-y), IL-2, and 
lymphotoxin; enhance microbicidal activity of macrophages; and augment delay ed-type 
hypersensitivity responses, and so these T cells are particularly effective at combating 
viruses and intracellular bacteria and parasites. Th2 cells produce IL-4, IL-5, IL-6, 
and IL-10; support B-cell growth and differentiation; and augment humoral immune 
responses, what make them more effective against free-living bacteria. Both Thl and 
Th2 cells produce IL-3, granulocyte macrophage-colony-stimulating factor (GM- 
CSF),and TNF (Street and Mosmann, 1991). Table 1 shows the different cytokines 
produced by each cell population and the function of each cytokine.
Thl dominance over Th2 is associated with an effective immune response in 
mycobacterial diseases. In patients with leprosy, the Thl cytokines gamma interferon 
and IL-2 predominate in the skin lesions of tuberculoid leprosy patients who mount 
a resistant immune response to M. leprae, whereas the Th2 cytokines IL-4 and IL-10 
are prominent in lepromatous leprosy patients with ineffective immunity (Yamamura 
et al, 1991). Control on the Thl/Th2 cell population may be influenced by distinct 
microbial antigens (Scott et al, 1988), or by the interplay of cytokines. IL-12
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produced by alveolar macrophages infected with mycobacteria favours development 
of Thl cells (Zhang et ah, 1994).
CD4^ T cells not only mediate anti my cob acteri al effects through cytokine 
production and activation of macrophages, but are also involved in cytolytic activity 
(Lorgat et al, 1992). The mechanism by which cytolytic activity of T cells contribute 
to immune defense is through direct cytolysis of macrophages with low 
antimycobacterial potential and non phagocytic cells infected with M. tuberculosis, 
releasing bacilli to be engulfed and killed by macrophages with greater 
antimycobacterial activity (Barnes et al, 1994). Alternatively, cytolytic T cells may 
play a scavenger role by lysing dead macrophages containing large numbers of dead 
bacilli so that they can be catabolized by surrounding mononuclear cells (Orme et al.,
1992). y/ô T cells also play a role in the initial immune response to M. tuberculosis 
infection, although their precise function remains to be elucidated (Nathan and Hibbs, 
1991).
The role of CD8  ^ T cells in human antimycobacterial defenses remains 
uncertain. Murine CD8  ^ cells can lyse M. tuberculosis-inÎQcXQà cells in vitro 
(Kaufmann, 1988), and mice that lack functional CD8^ T cells exhibit severe 
manifestations of tuberculosis (Flynn et al, 1992). These data suggest that murine 
CD4^ and CD8  ^ T cells play complementary roles in the immune response to M. 
tuberculosis. However, human M. tuberculosis-spQCiüc cytolytic T cells evaluated to 
date are not CD8  ^ (Lorgat et al, 1992), CD8  ^T cells are not selectively concentrated 
at the site of disease in tuberculosis patients (Barnes et al, 1989), and the severity of 
tuberculosis in HIV-infected patients is unaffected by the CD8 cell count (Jones et al,
1993).
1.1.3 Survival of mycobacteria inside macrophages
Internalization of Mycobacterium species by macrophages is mediated by 
specific receptors. It has been shown that M. tuberculosis can enter macrophage 
through complement receptors CRl and CR3 (Schlesinger et al, 1990), and virulent 
but not attenuated strains can also bind directly to the mannose receptor via the cell 
wall-associated, mannosylated glycolipid LAM (Schlesinger, 1993). A mycobacterial 
invasin has recently been described (Arruda et cd., 1993) and may be involved in 
binding to these receptors.
Macrophages are potent effector cells that are able to engulf and kill many 
bacterial invaders. Therefore, intracellular bacteria have to exploit potent evasion 
mechanisms that allow their survival in this hostile environment. The mechanism by 
which M. tuberculosis survives within phagocytic cells may involve interference with 
antimicrobial effector functions of macrophages, such as phagosome-lysosome fusion, 
generation of reactive oxygen intermediates (ROI) by the oxidative burst, and 
production o f reactive nitrogen intermediates (RNI) via the L-arginine-dependent 
jcytotoxic pathway (Chan and Kaufmann, 1994).
The lysosome is a complex organelle containing enzymes that are capable of 
degrading a whole range of macromolecules. An acidic intralysosomal environment 
(pH~5) maintained by an ATP-dependent proton pump provide optimal conditions for 
the functioning of these degradative enzymes (Ohkuma et al, 1982). Fusion of the 
phagosome containing microorganisms to the lysosome normally results in degradation 
o f the ingested microorganism by the digestive enzymes. Production of ammonia 
(N H /) by the mycobacteria may inhibit phagolysosome fusion in macrophages 
(Gordon et al, 1980), or alternatively elevate the phagolysosomal pH attenuating the
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potency of lysosomal enzymes (Crowle et al, 1991).
The route of uptake may influence the course of events following ingestion of 
tubercle bacilli by macrophages. Phagocytosis mediated by certain cell surface 
molecules such as the Fc receptor, stimulates the production of ROI via activation of 
the oxidative burst, which are toxic for the bacteria. M. tuberculosis can interfere with 
the toxic effect of ROI by various mechanisms. First, various mycobacterial 
compounds including glycolipids, sulfatide, and LAM can downregulate the oxidative 
cytotoxic mechanism (Pabst et al, 1988; Brozna et al, 1991; Chan et al, 1991). 
Second, uptake via CRl and CR3 bypasses activation of the respiratory burst (Wright 
and Wilverstein, 1993).
The cytotoxic effect of nitric oxide (NO) and related RNI generated from the 
substrate L-arginine via the action of the inducible form of the enzyme nitric oxide 
synthase constitutes another important antimicrobial mechanism against intracellular 
parasites (Nathan and Hibbs, 1991). Cytokines that are involved in activation of the 
L-arginine-dependent pathway are IFN-y, TNF-a, IL-1, and lipopolysaccharide 
(Nussler et al., 1994); while IL-4, IL-10, and TGF-pl downregulate RNI production 
by murine macrophages (Oswald et al., 1992). Survival o f the mycobacteria from RNI 
cytotoxic effect may involve interference with cytokines that regulate this specific 
pathway. Furthermore, M. tuberculosis may elude the microbicidal mechanisms of 
macrophages by escaping from fused phagolysosomes into nonfused vesicles or the 
cytoplasm (McDonough et al, 1993).
1.1.4 The tuberculin test
Tuberculin skin test evaluates a delayed-type hypersensitivity response to
11
mycobacteria. This test consists of intradermal injection of a purified protein derived 
(PPD) from the bacillus. If  the person or animal has been infected with the tubercle 
bacilli, previously sensitized T cells (predominantly CD4^ Thl cells) are attracted to 
the skin test site where they proliferate in response to the mycobacterial antigens and 
produce a local swelling. The reaction is maximal at approximately 72 hours after the 
injection of tuberculin. The tuberculin test is neither specific nor sensitive. Because 
tuberculin contains many antigens that are shared with nontuberculous environmental 
mycobacteria, sensitization with these organisms can yield a positive skin test in the 
absence o f tuberculous infection. On the other hand, patients recently infected or with 
active tuberculosis may show a negative tuberculin skin test. The mechanism involved 
may include compartmentalization of T cells (Barnes et al, 1989), Th2 cell 
dominance, or suppressive cytokines from infected macrophages (Ellner and Wallis, 
1989).
1.1.5 Histoiy of BCG
The BCG vaccine (Bacille Calmette-Guérin) was developed at the Institute 
Pasteur in Lille, France, from the virulent bovine type Mycobacterium tuberculosis 
isolated in 1902 by Nocard from the tuberculosis mastitis of a heifer. Calmette and 
Guerin observed that they could prevent bacterial aggregation in culture on a potato- 
glycerin medium by the addition of ox bile, and after 39 passages, they noted a change 
in colony morphology. After a total of 231 subcultures of this strain on 5% 
glycerinated beef-bile potato medium they proceeded to test the virulence of this 
variant. During the years 1908 to 1921, they reported that infection of bovines, guinea 
pigs, mice, rhesus monkeys, and chimpanzees with this strain produced no evidence
12
of reversion to virulence but instead conferred resistance to challenge with virulent 
bovine or human tubercle bacilli (reviewed by Lugosi, 1992).
Many daughter strains have subsequently been derived from the original 
isolate; these are commonly identified by the country of manufacture or the production 
laboratory, e.g., BCG Glaxo, BCG Japan (BCG Tokyo), etc. BCG strains have been 
grown under very different conditions in different reference laboratories and 
production facilities and are known to differ in a variety of characteristics, including 
growth rate, morphology, antigen expression, viability and RFLP (Osborn, 1983; 
Milstien and Gibson, 1990; Fomukong et al, 1992). In order to prevent continued 
genetic changes in the strains, WHO in 1966 recommended that no batch of vaccine 
be prepared from any culture carried more than 12 passages beyond a defined frozen 
"seed lot" (World Health Organization, 1966).
The BCG vaccine has traditionally been grown as pellicles on the surface of 
liquid Sauton medium and harvested at 6 to 9 days. The semidry mass is then 
homogenized in a ball mill. Some producers have grown the bacilli dispersed in 
liquid cultures. Homogenized vaccine suspensions are now typically freeze-dried and 
suspended in saline before use.
1.1.6 Use of BCG
The first human peroral vaccination with the BCG strain to prevent tuberculosis 
was performed in 1921 in Paris. In 1928 BCG was recommended by the League of 
Nations for widespread use in the prevention of tuberculosis. In 1929-1930 the use 
of BCG as a vaccine received a severe setback when in Liibeck (Germany), 72 out of 
250 children died after receiving a BCG vaccine prepared at a local institute.
13
Subsequent investigation revealed that this incident was not due to reversion of BCG 
to virulence, but it was a consequence of accidental contamination of the BCG vaccine 
with a virulent strain o f M. tuberculosis. In spite of the objections following the 
Liibeck mal-practice, the BCG vaccination progressed. The use o f BCG vaccines 
increased in Europe after World War II and in developing countries starting in the 
1950s following BCG campaigns organised by WHO and UNICEF.
The number of BCG vaccinated subjects since 1950 is estimated at 3 billion, 
with a very low incidence of serious side effects (Bloom and Fine, 1994). Although 
originally administered orally, the more familiar use now is as an intradermal vaccine. 
More people alive today have been vaccinated with BCG than have received any other 
vaccine.
However, the protection against tuberculosis engendered by BCG appears to 
vary greatly in different areas of the world. A number o f trials have been carried out 
in different parts of the world to determine the effectiveness of the BCG vaccine in 
protection against tuberculosis. The result of major randomized BCG trials is 
summarized in table 2. The inconsistency in BCG's observed protection have long 
been the subject of debate. Methodological flaws, differences between vaccines, 
genetic differences within and between populations, and interference with or masking 
of protection by environmental mycobacterial infections are among possible 
explanations.
A critical question is the duration of protection afforded by BCG vaccination. 
Cell-mediated immunity (CMI) to tuberculoproteins can be demonstrated for 5 to 50 
years following vaccination suggesting that immunity may be similarly long-lived. It 
is thought that, as with virulent M. tuberculosis, BCG persists in a dormant state
14
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within the vaccinated host, maintaining immunity by continually presenting the 
immune system with small amounts of antigen. Nevertheless, repeated BCG 
vaccination to boost immunity is standard policy in many countries although its 
efficacy has never been assessed.
Killed BCG does not induce substantial levels o f CMI unless incorporated in 
a water-in-oil type of emulsion (complete Freund's adjuvant [CFA]) - Preparation too 
toxic for use in humans. Replication of BCG is therefore essential for development 
of effective immunity and can be demonstrated in vaccinated experimental animals. 
From studies in animals, it has been proposed that the protection induced by BCG 
vaccination results from its interference with the haematogenous spread o f tubercle 
bacilli. The corollary of this hypothesis is that vaccination would not prevent either 
the establishment of natural primary infection with M. tuberculosis or interfere with 
repeated vaccination.
The molecular basis of attenuation in BCG is completely unknown. 
Fortunately, there is no evidence of it ever having reverted to virulence in any host. 
The safety of BCG vaccination in HIV-infected individuals is more uncertain. A small 
number of cases of disseminated BCG-osis have been reported among children who 
received BCG vaccine and were subsequently found to be HIV seropositive (von Reyn 
et al., 1987; Weltman and Rose, 1993). However, several studies have revealed no 
increase in complications of BCG in HIV-seropositive compared to HIV-seronegative 
children (Lallemant Le Coeur et al., 1991). WHO currently recommends that BCG 
immunisation of new-boms continue, excluding only children showing overt signs of 
immunodeficiency (World Health Organization, 1987).
The potential value of BCG as a recombinant multivaccine is due to the well-
16
known immunostimulatory and adjuvant properties o f mycobacteria (Bekierkunst, 
1984). CFA, a killed and dried suspension of M. tuberculosis cells in a water-in-oil 
emulsion, can potentiate the immunological response of the host against unrelated 
antigens included in the oil phase. High levels of both cellular immunity and serum 
antibody directed against the foreign antigen are obtained and maintained for extended 
periods.
The potent immunostimulatory activities o f mycobacteria have suggested their 
use as immunotherapeutic agents. Injection of a mixture of live BCG plus killed M. 
leprae has been shown to convert a proportion of skin test-negative lepromatous 
leprosy patients to lepromin skin test positive (Convit et al, 1982). BCG plus killed 
M. vaccae has also been used for immunoprophylaxis and immunotherapy of 
tuberculosis and specially leprosy (Stanford et al, 1990b). Similar immunotherapeutic 
intervention has shown to be successful in the treatment o f cutaneous leishmaniasis 
using BCG plus killed Leishmania mexicana (Convit et al., 1987; Convit et al, 1989). 
Injection with both CFA and vaccination with live BCG enhances the resistance of 
experimental animals to a variety of unrelated pathogens including Brucella, Bacillus 
anthracis, staphylococci, salmonellae. Toxoplasma, and other pathogens (Bekierkunst, 
1984; Weiss, 1984) Both live and killed BCG have been shown to exert potent 
antitumour activities in man and animals (Weiss, 1984). Growth of tumour cells in 
mice is strongly inhibited if the mice are pretreated with either live or killed BCG. 
Both live and killed BCG have been used as therapeutic agents for cancer therapy in 
man (Weiss, 1984).
The development of BCG as a multivaccine vehicle has several advantages that 
can be enumerated as follow: (1) it is the most widely used vaccine in the world; (2)
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BCG can be given at or any time after birth; (3) a single inoculum can produce long 
lasting immunity; (4) it is a potent adjuvant; (5) BCG can be administered as an oral 
vaccine; (6) it is the most heat stable of live vaccines; and (7) it is inexpensive to 
produce.
BCG vaccination in domestic animals has not been used despite good 
experimental evidence that such treatment should be effective (Thoen et al., 1984). 
The main reason for this is the fact that vaccinated animals become tuberculin 
positive, thereby removing the primary diagnostic tool currently available (Monaghan 
et al, 1994). It is at least conceivable that a protective vaccine that does not 
compromise assessment of the risk of infection by skin tests could be developed. 
There is evidence that protection is not always associated with hypersensitivity to 
tuberculin, and BCG-induced tuberculin sensitivity does not correlate with vaccine- 
induced protection (Hart et al, 1967). One hopes, therefore, that if  antigens necessary 
for protection can be defined, they could be used selectively in assays of vaccine 
produced protective immunity. Conversely, it might also be possible to develop skin 
or other tests based on antigens that are not necessary for protection and which could 
thus detect tuberculous infection per se but could be excluded from a protective 
vaccine.
1.2 - Mycobacterial Genetics
The identification and characterisation of mycobacteria as etiologic agents of 
leprosy and tuberculosis was done over 100 years ago. Since then, substantial effort 
has resulted in the elucidation of much of the physiology, biochemistry, and
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immunology of the mycobacteria. However, efforts at describing the genetics of 
mycobacteria have been rewarded only very recently. It is less than a decade since 
the first characterisation of cloned mycobacterial genes were reported (Young et al., 
1985b; Young et al, 1985a; Clark Curtiss et al, 1985; Labidi et al, 1985; Thole et 
al, 1985). Initially E. coli was used as a host for cloning and expression of 
mycobacterial genes, but mycobacterial transcription initiation signals functional in this 
heterologous background were isolated very infrequently and Streptomyces was 
suggested as an alternative cloning host (Kieser et al, 1986). Subsequently, the goal 
of constructing a new generation of recombinant vaccines based on Mycobacterium  
bovis BCG promoted development of techniques for introducing and expressing genes 
in mycobacteria, opening up the possibilities for genetic manipulation of mycobacteria.
1.2.1 - Gene cloning systems for mycobacteria
The production of a recombinant vaccine requires an effective gene cloning 
system that has the ability to (1) introduce DNA into the host, (2) stably maintain and 
express the inserted DNA, and (3) contain a selectable marker for identification of 
selection of transformed cells. The difficulty with these parameters is that all three 
have to be available simultaneously; the absence of known plasmid-mediated antibiotic 
resistance in mycobacteria or established transformation systems proved a considerable 
obstacle. Although there were reports of successful transformation of mycobacteria 
using chromosomally encoded markers, a large number of similar experiments have 
failed (reviewed by Greenburg and Woodley, 1984). To evaluate optimum conditions 
for DNA introduction into mycobacteria, the transfection of DNA from lytic 
mycobacteriophages was used. By adapting the technology of protoplast preparation
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from Streptomyces for mycobacterial cells with the addition of polyethylene glycol to 
promote DNA entry, transfection efficiencies o f greater than lO'* plaque-forming units 
(pfu) per pg of DNA were obtained (Jacobs et a l, 1988). However some attempts to 
introduce plasmids containing selectable marker into mycobacterial protoplasts have 
failed (Snapper et al, 1990a). Consequently, the first mycobacterial gene transfer 
system was based on a mycobacteriophage (see below). Later on, transformation by 
high voltage electroporation was used as a more efficient alternative to spheroplast 
transformation and high transformation efficiency with plasmid vectors was also 
obtained (Snapper et al, 1988). The isolation of a mutant strain ofM . smegmatis mc^ 
named mc^l55 which is more efficiently transformed by plasmid vectors (Snapper et 
al., 1990b) has facilitated the development of more sophisticated cloning systems.
1.2.1.1 Phage-based systems
Mycobacteriophage have been used for many years to type mycobacterial 
isolates and have more recently been modified as vectors for efficient delivery of 
foreign DNA into mycobacteria. These modified phage vectors, termed "shuttle 
phasmids", were constructed by insertion of a portion of an E. coli cosmid cloning 
vector into the mycobacteriophage genome. The first shuttle phasmid was based on 
mycobacteriophage TM4 from M. avium that replicated as a ColEl-based plasmid in 
E. coli and as a phage in M  smegmatis (Jacobs et al., 1987). Subsequently a shuttle 
phasmid designated phAE15 was constructed based on the temperate 
mycobacteriophage LI. The kanamycin resistance gene from Tn903 was cloned into 
a unique restriction site and the resulting phasmid, phAE19, was introduced into M. 
smegmatis. It was capable of integrating as a single copy into the mycobacterial
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genome and maintaining itself as a stable element replicating with the bacterial 
chromosome. Most importantly, these shuttle phasmids conferred kanamycin- 
resistance upon lysogens, establishing kanamycin-resistance as the first selectable 
marker expressed in mycobacteria (Snapper ei al., 1988).
Many lysogenic bacteriophages integrate into the chromosome o f the infected 
bacterium by site-specific recombination between specific attachment sites on the 
phage DNA {attP) and bacterial chromosome {attB). Integration is mediated by the 
product of a phage gene {int). Excision requires an additional phage product, Xis. 
A vector carrying attP and int, but not xis, should therefore result in stable integration 
of the required genes into the bacterial chromosome.
An improvement in the versatility and capacity for foreign DNA of phage- 
based cloning systems was achieved when the minimal sequences containing the 
mycobacteriophage L5 int and attP genes were identified (Lee et al., 1991). The 
chromosomal attachment site {attB) was also characterized and revealed that 
integration occurs within a 43 bp core region that is identical to attP. A virtually 
identical sequence (with a single base change) occurs in the genome of BCG Pasteur 
(Lee et al, 1991). Cloning of a 2 kb fragment carrying attçi and int into a pUC vector 
carrying the kanamycin resistance gene from TnPOi resulted in an integration 
proficient plasmid, pMH94 (Lee et al, 1991). This vector was able to transform M. 
smegmatis at a high frequency and BCG Pasteur and M. tuberculosis H37Ra at a 
somewhat lower frequency. The vector was shown to be stably maintained in M. 
smegmatis in non-selective growth.
Stover at al. (1991) used the same approach to construct an integrative 
expression vector named pMV361. This vector contains the attP and int from L5, the
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kanamycin resistance gene from Tn903, an origin of replication functional in E. coli 
derived from pUC19, and an expression cassette containing 0.4 kb of the 5' end of the 
BCG|/zj;p60 gene, including the promoter region, ribosome-binding site, and the first 
six codons as well as a multiple cloning site and the E. coli rm AB^  transcriptional 
terminator. Expression of several foreign genes in mycobacteria have been obtained 
using this system (Stover et al, 1991b; de la Cruz et al, 1991). More recently, an 
integrative vector was constructed by cloning the attachment site and integrase gene 
from the temperate mycobacteriophage FRATl into the E. coli plasmid pJRD184 
(Haeseleer et al, 1993). This vector was used to express 2i Plasmodium falciparum  
antigen under the control of the hspSO promoter, inM . smegmatis andM . hovis BCG 
(Haeseleer et al, 1993).
1.2.1.2 Plasmid-based systems
Plasmid-based cloning systems extend the capabilities of phage-based systems 
by providing increased cloning capacity, increased copy number in the mycobacterial 
host, and ease of manipulation. Although plasmids have been identified in several 
species of fast-growing mycobacteria, plasmids native to or capable of replication in 
slow-growing mycobacteria were not known at the time the phage-based vectors were 
initially constructed. The first mycobacterial shuttle plasmids were constructed by 
randomly inserting pIJ666, an E. coli vector carrying chloramphenicol acetyltransferase 
and the kanamycin resistance genes from Tn5 (Kieser and Melton, 1988), into theM . 
fortuitum  plasmid pALSOOO (Labidi et al, 1985), resulting in a library o f vectors 
(Snapper et al, 1988). Transformation of M. smegmatis and BCG was achieved with 
these vectors. One pIJ666:pAL5000 vector designated pYUB12 has been widely used
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subsequently.
Other shuttle plasmids have been constructed using the mycobacterial origin 
o f replication derived from pALSOOO. The plasmid pRR3 (Ranes et ah, 1990) contains 
a 2.58 kb EcoRW-HpcH fragment from pAL5000, and a smaller (1.8 kb) fragment was 
used to construct the so called second generation of vectors which includes pMV261 
(Stover et ah, 1991a). Shuttle plasmids have also been constructed based on the 
Corynebacterium plasmid pNG2 (Radford and Hodgson, 1991), or using the origin of 
replication from the mycobacteriophage D29 (David et al, 1992). An E. coli- 
Mycobacterium  shuttle cosmid vector, pM SCl, which allows production of libraries 
containing large segments of cloned DNA (30-42 kb) was constructed by using the E. 
coli cosmid vector Lawrist4 and pAL5000 sequence subcloned from pYUB12 
(Hinshelwood and Stoker, 1992).
Although shuttle plasmids are convenient for laboratory work, their potential 
instability in absence of antibiotic selection makes them unsuitable for use in a 
recombinant vaccine. M. smegmatis transformed with pYUB12 and subjected to 
growth for 160 generations in unselective media resulted in loss of plasmid encoded 
kanamycin resistance in 95% of the bacteria (England et al, 1991). Similarly, 
comparison of plasmid stability (pMV261) to integrant stability (pMV361) revealed 
that after 120 generations without kanamycin selection in M. smegmatis 90% of the 
integrants retained integrated kanamycin resistance, whereas all plasmid recombinants 
had lost episomally encoded kanamycin resistance (Stover et al, 1991a). However, 
the same plasmid vector is claimed to be remarkably stable in BCG (Burlein et al, 
1994). Problems associated with plasmid stability has led researchers to search for 
further ways of integrating the foreign DNA into the mycobacterial chromosome.
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1.2.1.3 Integration by homologous recombination
Homologous genetic recombination involves the exchange of homologous 
regions of DNA between two DNA molecules. It is a powerful technique not only for 
investigating gene function by inactivating specific genes by allelic replacement with 
a disrupted gene, but also for integrating foreign genes into the chromosome. 
Homologous recombination inM . smegmatis was demonstrated by using thep y fp  gene 
disrupted by the aph gene from Tn903 which confers kanamycin resistance (Husson 
et al, 1990). Inactivation of the M. smegmatis p y fp  gene makes the bacterium uracil 
auxotrophic, and confers resistance to 5-fluoroorotic acid (5-FOA), facilitating 
selection of homologous recombination events. When wild-type, prototrophic M. 
smegmatis was electroporated with the plasmid carrying the disruptedp y fp  gene, with 
selection for kanamycin resistance, two classes of transformants were obtained. The 
first type were uracil prototrophs and sensitive to 5-FOA, and revealed the integration 
of the entire plasmid via a single homologous recombination event. The second class 
o f transformants were uracil auxotrophs and resistant to 5-FOA, showing that the 
intact parental pyrF gene had been replaced by the disrupted gene from the plasmid, 
presumably by a double cross-over event (Husson et al, 1990).
By inserting additional genes into the disrupted pyiP  gene, it is possible to use 
this approach to insert these genes into the M. smegmatis chromosome. The 
feasibility o f this was demonstrated by using the gene for the 65 kDa antigen of M. 
leprae, which was successfully expressed in M. smegmatis.
Homologous recombination in slow growing species like M. bovis BCG has 
proven more difficult to obtain. In an attempt to perform shuttle mutagenesis in BCG, 
Kalpana et al (1991) subjected the cloned BCG methionine gene to transposon
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mutagenesis with Tn5 seq 1, a derivative o f Tn5, in E. coli and reintroduced the gene 
into the mycobacteria. Surprisingly for prokaryotes, both BCG and M. tuberculosis 
were found to incorporate linear DNA fragments into illegitimate sites throughout the 
mycobacterial genomes at a frequency of 10'  ^ to lO*"* relative to the number of 
transformants obtained with autonomously replicating vectors.
In a similar experiment Aldovini et a l (1993) utilized the BCG gene encoding 
orotidine-5'-monophosphate decarboxylase (OMP-DCase) disrupted by a kanamycin 
resistance gene to investigate whether homologous integration can occur in M. bovis 
BCG. Transformation with a linearised DNA fragment resulted in integration into the 
BCG chromosome, but as before mainly in non homologous sites. It has been 
suggested that the reason for the difficulty in achieving homologous recombination in 
M. tuberculosis is associated with the unusual structure o f the M. tuberculosis RecA 
protein, which contains a protein intron (or 'intein') that has to be removed by a 
protein splicing mechanism (Davis et al, 1992; Davis et al, 1994; Colston and Davis, 
1994). The RecA protein of M. leprae also exhibits protein splicing, but those of 
other mycobacteria (including M. smegmatis) do not (Davis et al, 1994; Colston and 
Davis, 1994).
1.2.1.4 Transpositional integration
Transpositional integration in mycobacteria was first demonstrated by Martin 
et a l (1990). They have characterized a genetic region responsible for resistance to 
sulphonamides in M. fortuitum . Flanking the sulphonamide-resistance gene (sul3) and 
the orf2M which codes for an integrase, they found an insertion sequence named 
1S6100, which belongs to the IS6 family. The compound transposon-like element
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consisting o f orfZM, sul3 and the flanking 1S6100 was termed Tn610. The ability of 
Tn610 to transpose in M. smegmatis was demonstrated by replacing the sul3 gene 
by the kanamycin-resistance gene of Tn903. Upon Electroporation with the suicide 
vector, kanamycin resistance colonies were isolated and shown to contain the vector 
integrated into the chromosome (Martin et al, 1990).
Subsequently England et a l (1991) constructed an artificial transposon by 
cloning two copies of ISPOO, an insertion sequence isolated from M. paratuherculosis 
(Green et al, 1989), flanking a kanamycin resistance gene, into a non mycobacterial 
vector. Following electroporation into M. smegmatis, kanamycin resistant colonies 
were obtained at a frequency about 10'  ^ of that shown with the autonomously 
replicating shuttle plasmid pYUB12, giving an estimate o f the efficiency of 
transposition. Stable integration by either transposition or cointegrate formation was 
demonstrated (England et al, 1991). Integration mediated by \^986flS6110, a more 
typical insertion sequence found in M  tuberculosis and related organisms, including 
BCG (Zainuddin and Dale, 1989; Hermans et al, 1990; Thierry et al, 1990), was 
demonstrated in M. smegmatis and BCG using the same approach used with 1S900 
(Fomukong and Dale, 1993; Wall, S. Personal communication).
1.3 - Expression of foreign genes in mycobacteria
Exploitation of BCG for recombinant vaccine production demands not only 
stable inheritance of the cloned genes, but also formation of a product in a suitable 
form, and at an appropriate level, for generation of the required immune response. 
This require both transcriptional and translational signals, as well as, in some cases,
26
appropriate posttranscriptional modification. Unfortunately none of these parameters 
are established.
1.3.1 Transcriptional control
Analysis of potential promoter sequences of mycobacterial genes by computer 
algorithms based on prokaryotic consensus sequences can be used to predict the 
promoter sequences (Dale and Patki, 1990). However, very few mycobacterial 
promoters have been mapped, and those that have been mapped show, at best, weak 
homology to these consensus sequences (Burlein et al., 1994). Some mycobacterial 
genes are able to function in E. coli, apparently from their own promoters, but the 
prevailing view is that most mycobacterial promoters are not efficiently recognized in 
E. coli. The reverse situation, the recognition of foreign promoters by mycobacteria, 
is even less clear, although some foreign genes (notably the kanamycin resistance 
genes of Tn5 and Tn903) are expressed from their own promoters in mycobacteria. 
The development of expression systems in mycobacteria has therefore largely been 
empirical, using sequences derived from the region upstream from characterized genes 
to provide the required signals.
1.3.2 Translational control
One factor potentially influencing translation rate is the codon usage of foreign 
genes. Compilations of codon usages of genes of Mycobacteria (Dale and Patki, 
1990) and the mycobacteriophage L5 (Hatful 1 and Sarkis, 1993) show a bias for 
codons with G or C at the third position (as expected from the high C+C content of 
mycobacterial DNA). This is substantially different from the codon bias o f most other
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organisms and might be expected to limit the translational efficiency of genes from 
non mycobacterial sources.
Other factors likely to be important in influencing protein expression like the 
sequence around the ribosome-binding site, the structure of the 5' end of the mRNA, 
and the sequence around the initiation codon have not yet been examined 
systematically for mycobacteria. However, sequence analysis o f the 5' end of 
mycobacterial genes characterized to date has revealed that the putative Shine- 
Dalgamo sequence preceding the initiator codon appears similar in base content and 
position to the prokaryotic consensus sequence (Dale and Patki, 1990; Hatful 1 and 
Sarkis, 1993). Also, the nearly equal usage of AUG and GUG as potential initiator 
codons again reflects the high G+C content of mycobacterial DNA, but the effect of 
the choice of initiator codon on translation of foreign genes remains uncertain. Most 
expression systems used in mycobacteria supply translation initiation signals derived 
from the original mycobacterial genes as well as a promoter, so that an in-frame 
insertion of the required gene will be translated.
1.3.3 Posttranslational modifications
Posttranslational modifications affect the structure and function of proteins, and 
can also influence protein stability and expression levels. Expression o f foreign 
proteins with posttranslational modifications similar to those of the proteins in their 
native host may increase their stability in mycobacteria and aid in their adopting a 
more native conformation (Burlein et al, 1994). It is thought that surface antigens of 
mycobacteria may be more accessible to immune processing in the macrophage and 
may therefore be more immunogenic than internal antigens. Expression systems that
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incorporate posttranscriptional modifications like secretion or membrane association 
and lipid acylation of heterologous antigens by recombinant BCG have been reported 
(Matsuo et al., 1990; Stover et al, 1993).
1.3.4 Expression systems
The first foreign genes expressed in mycobacteria were the aph gene o f Tn903 
and the gene for M. leprae Hsp60 antigen, both expressed from their own promoters 
(Snapper et al, 1988). Among the first mycobacterial genes to be cloned and 
sequenced were those coding for the 65-kDa and 72-kDa antigens o f M. tuberculosis 
and M. bovis BCG, which are two of the dominant antigens in mycobacterial 
infections. The sequence of these genes revealed that they are members of the highly 
conserved hsp60 and hsplO families of stress proteins, and both genes have been used 
to provide signals for expression of cloned genes in BCG. Other expression systems 
have been based on the secreted a-antigen from M. kansasii (Matsuo et al, 1990), the 
heat shock promoter of the groES/groELl operon of Streptomyces albus (Winter et al, 
1991; Winter et al, 1992) a promoter region from M. paratuberculosis (Murray et al,
1992), and the 19-kDa antigen of M. tuberculosis (Stover et al, 1993). Table 1-3 
shows the foreign genes expressed in mycobacteria to date and the expression systems 
used.
1.3.4.1 Expression systems based on hsp6Q and hspl^S
In the construction of expression vectors, promoters of mycobacterial hsp60 
and hsplO genes were chosen as the first candidates to drive the expression o f foreign 
genes in mycobacteria. The reasons for this are that the sequence of these genes were
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Table 1-3. Foreign genes expressed in BCG and expression systems used.
Gene expressed in BCG Vector/Promoter used Reference
HIV-1 gag p l7  aa 12-19 pIS18/a-antigen (Matsuo et al, 1990)
E.coli LacZ pMV261/A^60 (Stover et al, 1991b)
pMV361//j5/?60
pRR3/pAN (Murray et al, 1992)
HIV-1 gag, rt,/?o/A pMV261/Ajy;60 (Stover et al., 1991b)
HIV-1 gp\20 pMV361//;5/760 (Stover et al, 1991b)
HIV-1 gpAl pMV273//?jp70 (Stover et al, 1991b)
HIV-1 gag, pol, gpl20 pYUB12/Ajp70 (Aldovini and Young, 1991)
Borrelia burgdorferi OspA ifMW26\lhsp60 (Stover et al, 1993)
pMV206//iA7?60’
pMV206/19kD
pMV206/a-antigen
Leshmania major gp63 pMV261//i5/?60 (Connell et al, 1993)
SIV„,<gag pMV261//?J7?60 (Yasutomi et al, 1993)
pMV271/Àjy;70
Plasmodium falciparum CSP pNIV2173//?jp60 (Haeseleer et al, 1993)
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among the first available (Young et al, 1985b; Thole et al, 1987; Shinnick, 1987), 
and expression of these genes is observed under all growth conditions. An expression 
cassette containing 404 bp of the 5' regulatory region plus the coding sequence for the 
first 6 amino acids of the BCG hsp60 gene was used to construct the expression 
vectors pMV261 and pMV361 (Stover et al., 1991b; Fuerst et al, 1991; Fuerst et al,
1992). These systems were evaluated using the E. coli lacZ gene, which was 
expressed at a high level in BCG containing the episomal vector pMV261 (15% of 
total cell protein), but the same gene was expressed 5 to 10 fold lower in the 
integrative vector pMV361 (Stover et al, 1991b; de la Cruz et a l, 1991). 
Subsequently a number of foreign antigens have been successfully expressed in these 
systems (table 1-3). The hsp60 gene promoter was also used to express the 
Plasmodium falciparum circumsporozoite protein (CSP; aa 1-412) in an integrative 
vector based on the temperate mycobacteriophage FRATl. The level of expression 
in BCG was about 1% of the total soluble proteins (Haeseleer et al, 1993).
TheM. tuberculosis hsplO gene promoter (155 bp upstream sequence including 
the start codon) was used in the shuttle plasmid pYUB12 to express the HIV-1 
antigens (Aldovini and Young, 1991). HIV-1 gag, po l (polymerase) and gpl20 were 
successfully expressed in BCG and were shown to induce antibody and T-cell 
responses in mice. Stover et al. (1991) have also referred to the successful use of the 
hsplO promoter to express HIV-1 gp41 antigen in a plasmid vector.
1.3.4.2 Expression system based on groES/groELl operon
In a similar study. Winter et al. (1991) developed an expression cassette 
carrying the heat shock promoter of the Streptomyces albuns groES/groELl operon,
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together with a synthetic ribosome binding site to express the HIV-1 n e f gene in BCG, 
using the shuttle vector pRR3. High level of expression of the n e f  product was 
detected, and lymph node cells from mice immunized with BCG n e f  recombinants 
proliferated vigorously in response to the Nef protein.
1.3.4.3 Secretion systems
It is thought that antigens secreted or expressed on the surface of the bacteria 
may be more accessible to immune processing in the macrophage and may therefore 
be more immunogenic than internal antigens. In addition, expression of foreign 
proteins with posttranslational modifications similar to those of the proteins in their 
native host may increase their stability in mycobacteria and aid in their adoption a 
more native conformation. Matsuo et al. (1990) established a foreign antigen secretion 
system in mycobacteria in which an extracellular a-antigen o fM  kansasii was utilized 
as a carrier. Introduction of aB-cell epitope (amino acids 12 to 19) of HIV-1 gag ^11  
into a site close to the 3' end of the a-antigen gene resulted in a fusion protein that 
was secreted from BCG transformed with a shuttle plasmid carrying the fused gene, 
but immune responses against viral antigens using this strategy have not been reported.
In an attempt to direct the expression, export, and lipid acylation of 
heterologous antigens by recombinant BCG, Stover et al. (1993) constructed 
expression vectors using the M tbl9 lipoprotein promoter and signal peptide sequence. 
Expression of outer surface protein A (OspA) antigen of Borrelia burgdorferi, the 
causative agent o f Lyme disease as a membrane-associated lipoprotein resulted in 
protective antibody responses in mice. Although the level of expression of OspA with
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the 19kD signal peptide driven either by the 19kD or the hsp60 promoter was lower 
than the expression obtained when the same gene was expressed cytoplasmically from 
the hsp60 promoter, the antibody responses were 100-1,000-fold higher (Stover et al,
1993).
1.3.4.5 Use of the promoter from M. paratuberculosis
Murray et al (1992) isolated and characterised a promoter sequence named 
Pan, from M. paratuberculosis. This promoter sequence lies adjacent to, and outside, 
the 3' end of one copy of the insertion sequence IS900 (Green et al, 1989). Using the 
vector pRR3 these workers demonstrated the expression of the lacZ gene in M. 
smegmatis and BCG under the control of P^N High resolution SI nuclease mapping 
confirmed that transcription in M. smegmatis was initiated from the expected site 
adjacent to the promoter.
1.4 Immunity induced by recombinant BCG
1.4.1 Immune responses to model antigens
The first immunological studies using rBCG were performed by using BCG 
expressing p-galactosidase (rBCG/p-gal) as a model system (de la Cruz et al, 1991; 
Fuerst e/ûf/., 1991; Stover e /a/., 1991b). Vaccination of Balb/c mice with rBCG/p-gal 
by either intradermal (ID), intravenous (IV) or intraperitoneal (IP) routes of inoculation 
resulted in the induction of high levels of anti-P-galactosidase antibodies that were 
sustained for many weeks (Stover et al, 1991b). Antibody levels increased slowly in 
comparison to administration of purified P-gal emulsified in incomplete Freund's
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adjuvant by any of the three routes, indicating that live rBCG cells were growing in 
the animal and that continued growth was necessary to induce a good immunological 
response (Fuerst et al., 1991), Cellular immune responses have been analysed in the 
C57BL/6 and Balb/c inbred strains of mice (de la Cruz et al, 1991). Splénocytes 
from C57BL/6 mice given rBCG/p-gal by the ID route produced gamma interferon 
and IL-2, but not IL-5, in response to stimulation with P-galactosidase, indicating 
specific stimulation of the Thl subset of T-helper cells (de la Cruz et al., 1991). 
Balb/c mice inoculated with rBCG/p-gal by the IV route gave high levels o f Cytotoxic 
T lymphocyte activity (Stover et al, 1991b). Inoculation of BALB/c mice with rBCG 
expressing a p-galactosidase fusion protein, driven by the promoter also induced 
a high humoral and cellular response against p-galactosidase (Murray et al, 1992). 
Lymph node cells from immunized mice proliferated in response to in vitro 
stimulation with p-galactosidase. The proliferation was inhibited by an anti-CD4^ 
mAb and partially inhibited by and anti-CD8^ mAb added to the lymph node cultures, 
suggesting that rBCG can stimulate both CD4^ and CD8^ cells.
A recombinant BCG vaccine expressing p-galactosidase has been used to 
investigate the influence of various routes of immunization on the immunogenicity of 
a foreign antigen expressed in BCG (Lagranderie et al, 1993). Guinea-pigs were 
immunized by oral route with 6 x 1 0 ^  CPU, respiratory or intradermal routes with 10  ^
CPU. Proliferative responses, delayed-type hypersensitivity and antibody responses 
specific for p-galactosidase were followed for 16 weeks. The results demonstrated 
humoral and cellular immune responses specific for p-galactosidase in all groups of 
guinea-pigs. However, the respiratory and especially the oral route o f administration 
induced higher local and systemic immune responses than the intradermal route of
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immunization. Moreover, the oral immunization of mice with 6 x 10* CFU of 
rBCG/p-gal induced IgA responses which could be detected in both sera and intestinal 
secretions (Lagranderie et al, 1993). This was the first study to demonstrate that oral 
immunization with recombinant BCG can induce strong cellular and humoral immune 
response.
The same system was used to investigate the affect of prior immunization with 
BCG on immunological responses to a foreign antigen delivered by these recombinant 
microorganisms (Gheorghiu e ta l, 1994). A small reduction of T cell responses against 
foreign antigens expressed in BCG (P-galactoside or HIV-1 Nef) was detected in mice 
primed with BCG as compared to naive mice. In contrast to these reduced T-cell 
responses, BCG primed mice developed higher levels of anti-p-galactoside antibodies 
after immunization with recombinant BCG expressing this antigen (Gheorghiu et al,
1994). These results indicate that priming with BCG will not be a limitation for the 
use of recombinant BCG vaccines in humans.
1.4.2 Recombinant BCG expressing viral antigens
Several studies have investigated mice immune responses to recombinant BCG 
expressing HIV or SIV antigens. Recombinant BCG expressing gp41 portion o f the 
HIV-1 envelope have been shown to induced a slowly developing antibody response 
that was nonetheless significant and still appeared to be increasing 16 weeks 
postinoculation (Stover a/., 1991b; Fuerst e/a/., 1991). rBCG expressing the gp 120 
(rBCG/gpl20) failed to induced antibody titers, but showed a cytotoxic T-lymphocyte 
(CTL) response associated to CD8^ lymphocytes (Fuerst et al, 1991). HIV Gag and 
Env expressed in BCG also induced a poor antibody response in mice, although a
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significant cell mediated immune response specific for the viral antigens was detected 
(Aldovini and Young, 1991). Mice immunized with BCG expressing HIV-1 Nef 
protein also showed a strong T cell response (Winter et ah, 1991). These results are 
consistent with the known biology of BCG where BCG induces a strong cellular 
immune response and increases in titer in vivo  for the first 4 weeks postimmunization 
and then gradually declines thereafter.
The SIV/rhesus monkey model has been employed to explore the use o f BCG 
as a vaccine vehicle to elicit AIDS virus-specific CTL (Yasutomi et ai, 1993). BCG 
was engineered to express SlV^g^ gag under the control of hsplO regulatory sequences. 
Immunization with this rBCG/SIV^ac Gag organism elicited MHC class I-restricted, 
CD8  ^ SlV^ac Gag-specific CTL in rhesus monkeys. However, the BCG/SIV^,g Gag 
immunized animal did not develop a detectable anti-Gag antibody response, even after 
boosting 19 weeks after the first immunization with 10* CFU (Yasutomi et al, 1993). 
For an antigen to be expressed on the surface of the cell in association with MHC 
class I molecules it has to reach the cytoplasm. M. tuberculosis, but not BCG, has 
been shown to escape from phagolysosomes into the cytoplasm (McDonough et al,
1993). It is not clear yet how mycobacterial proteins are translocated from the 
endosomal into the cytoplasmic compartment. All the experiments performed with 
rBCG expressing viral antigens have shown induction of a specific immune response, 
however, protection against challenge by a infectious virus has not yet been 
demonstrated.
1.4.3 Recombinant BCG expressing other antigens
A number of other foreign antigens delivered by rBCG have been shown to
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induce immune responses that can be protective in animal models of disease. 
Expression of a fragment of tetanus toxin (ToxC, fragment C of the tetanus toxin of 
molecular weigh 50-kDa and lacking toxic activity) on rBCG elicited antibody 
responses that protect approximately half of mice challenged with 100 50% lethal dose 
units of toxin. In comparison, heat-killed rBCG/ToxC did not induce any detectable 
antitoxin antibody, and the mice were not protected against challenge (Stover et al., 
1991b). BCG expressing the gp63 protein of Leishmania major can elicit cell- 
mediated immune responses that protect mice from cutaneous leishmaniasis (Connell 
et al, 1993). BCG expressing the OspA protein of Borrelia burgdorferi, the causative 
agent of Lyme disease, as a membrane-associated lipoprotein resulted in sterilizing 
immunity in mice to intradermal challenge with 100 50% infective doses of the 
virulent spirochete (Stover et al, 1993). This results show that BCG can also be 
useful for the development of new vaccines against diseases where humoral immunity 
is the protective response, although as an intracellular bacterium residing in 
macrophages, it is best suited for eliciting cellular responses and not antibody 
responses. Plasmodium falciparum antigens have also been expressed in rBCG, but 
immune responses to these antigens have been disappointing (Haeseleer et al, 1993).
Overall, these studies demonstrate that foreign proteins delivered by rBCG can 
elicit all three types of immune response necessary for protection against a variety of 
pathogens: antibody production; T-cell proliferation and lymphokine production; and 
MHC class I-restricted cytotoxic T lymphocytes. Live recombinant BCG is required 
to stimulate the immune response and immunity is not short-lived. One immunization 
by different routes with live recombinant BCG is sufficient to enable continued 
expression of a foreign antigen and stimulation o f an immune response. Immunity
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appears to be due to the continued growth of recombinant BCG in the mice. 
Unfortunately, some antigens are not good inducers of antibody, but most of the 
foreign antigens simulate a cellular immune response. For diseases where humoral 
immunity is the protective response, association of the foreign antigen with a 
membrane lipoprotein can greatly enhance the immune response.
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Chapter 2
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals, other materials and suppliers
Amersham International Pic.
Hybond^^-N Nylon membranes; Hybond™-C Super Nitrocellulose membranes.
Applied Biosystems
Reagents and other components for the synthesis of oligonucleotides.
BDH Chemicals Ltd.
Ammonium acetate (AnalaR); Ammonium persulphate; ortho-Boric acid 
(AnalaR); Bromophenol blue; Butan-2-ol; Calcium chloride 6-hydrate; D- 
Glucose; Propan-2-ol (Aristar); Liquid paraffin; Magnesium chloride 6-hydrate 
(AnalaR); Magnesium sulphate (AnalaR); Maltose; Sodium carbonate; Sodium 
dihydrogen orthophosphate dihydrate; Disodium hydrogen orthophosphate; 
Sodium acetate anhydrous (AnalaR); Sucrose (AnalaR); Phenol (AnalaR).
Bio-Rad
Pre-stained protein molecular weight markers (low range).
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Boerhinger Mannheim Biochemica (BCL)
Taq DNA polymerase; Calf intestine alkaline phosphatase (CIP); DNA 
labelling and detection kit Non-radioactive; Proteinase K; Restriction enzymes 
and 10 X buffers; Ribonuclease A; Trizma base.
Difco
Bacto Middlebrook 7H9 broth (dehydrated); Bacto Mycobacteria 7H11 agar 
(dehydrated); Middlebrook OADC enrichment.
FISION Scientific Equipment
Acetic acid (glacial); Sodium hydroxide (pellets); Sodium chloride; Boric acid; 
/ri-Sodium citrate; Glycine; Hydrochloric acid; Glycerol; Absolute Alcohol 
100; Methanol; Chloroform.
Fuji photo film Co.Ltd.
X-ray RX film; Polaroid films-type 665 (positive/negative); type 667 (positive 
only.)
DAKO
Peroxidase conjugated rabbit anti-mouse and goat anti-rabbit immunoglobulin.
DOW chemical Co.
Saran-wrap.
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Gibco-BRL
Agarose (ultra-pure); DNA molecular weight markers; Cesium chloride (optical 
grade); Restriction enzymes and 10 X React buffers; T4 DNA ligase.
Molecular Probe
FluoReporter LacZ detection kit
National Diagnostics
Protogel™ (30% acrylamide and 0.8% bisacrylamide stock solution [37.5:1]).
Oxoid
Agar Bacteriological N o.l; Nutrient broth No. 2; Tryptone; Yeast extract.
Pharmacia
pUC18; pUC19; pUC4k; pMC1871.
Promega
Promega magic miniprep system.
Sigma Chemicals Co.
Ampicillin; Bovine serum albumin (BSA) fraction V (nuclease-free); N;N- 
dimethylfbrmamide (DMF); D-L-dithiothreitol (DTT); Ethidium bromide; 
Ethylene diaminotetracetic acid (EDTA); Ficoll type 400; Formamide; HEPES; 
8-hydroxyquinoline; Kanamycin monosulphate; N-Lauroylsarcosine (Sodium
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salt); Lithium chloride (anhydrous); Lauryl sulphate (SDS) sodium salt; 
Lysozyme; Maleic acid; 2-mercaptoethanol; Urea (ultra pure); Tween 80; 
Tween 20; N;N;N'N'-tetramethyl ethylenediamine (TEMED); Ammonium 
persulfate; Ponceau S; Trichloroacetic acid; Sulfosalicylic acid; Comassie 
brilliant blue G; o-Nitrophenyl P-D-galactopyranoside (ONPG); Isopropyl 13- 
D -thiogalactopyranoside (IPTG); 5-bromo-4-chloro-3-indolyl-13-D- 
galactopyranoside (X-gal); RPMI-1640; fetal calf serum; glutamine; Hank's 
salt solution.
Stratech Scientific Ltd.
Gened ean™ II kit.
Whatman Laboratories Ltd.
Whatman 3MM filter paper.
Ultra-violet Products
Gel Documentation System (GDS).
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2.1.2 Strains employed
Table 2-1. Strains of bacteria used in this work
STRAINS Relevant characteristics Source/Reference
E. coli DH5a F , lacZ AMI5, end A l, Sambrook e/ûf/. (1989)
rec A I, sup E44, rel A \
M. smegmatis mc^l55 Efficient plasmid transformation Snapper et al. (1988)
mutant of mc^
M. vaccae R877R Strain used for immunotherapy Supplied by J Stanford
BCG Pasteur Vaccine strain Laboratory's collection
2.1.3 Plasmids
Table 2-2. Plasmids used in this work
PLASMIDS Relevant characteristics Source/Reference
pUC18/19 Amp R, Lac'POZ' (with poly linker) Yanisch Peron et al.
(1985)
pMB22 Recombinant containing 1S900 Green et al. (1989)
pML3 pUC18 recombinant containing the Booth et al. (1988)
M. leprae 18kD gene
pYUB12 pJJ666:pAL5000 derivative Snapper et al. (1988)
pAL5000 M. fortuitum  plasmid Labidi et al. (1985)
pMC1871 Plasmid containing a promoterless Pharmacia
LacZ gene
pUC4k Plasmid containing the kanamycin Pharmacia
resistance gene from TNP05
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2.1.4 Culture media
Media and solutions were sterilized by autoclaving at 121°C (15 p.s.i) for 15 
minutes or by filtration through a 0.2pm Minisart single use filter unit. For the 
preparation of all media and solutions Milli-Q water was used and referred as water 
through out the thesis.
(i) Luria-Bertani (LB) medium (agar).
Bacto tryptone 10 g
Bacto yeast extract 5 g
NaCl 10 g
water to 1000 ml, autoclaved.
LB agar contained 10 g/litre of Agar Bacteriological, autoclaved.
(ii) SOB
Bactoptryptone 20 g
Bacto-yeast extract 5 g
NaCl 0.5 g
250 mM KCl 10 ml
Water to 1000 ml. The pH was adjusted to 7.0 with NaOH. After autoclaving 
5 ml of a sterile solution of 2 M MgClj was added.
(iii) SOC
Bacto tryptone 2% (w/v)
Bacto yeast extract 0.5% (w/v)
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NaCl 10 mM
KCl 2.5 mM
MgClj 20 mM
MgSO^ 20 mM
Glucose 20 mM
pH 7.0
SOC was prepared and autoclaved in the absence of the magnesium salts and 
glucose. Filter sterilized magnesium salts and glucose were added prior to use.
(iv) Nutrient Broth No. 2 (NB) medium (agar)
25 g of Nutrient broth No. 2 in 1 litre of water containing 0.05% Tween 80 
and 2 ml of glycerol. For solid medium 10 g/litre of Agar Bacteriological was 
added before being autoclaved.
(v) Middlebrook 7H9 broth (Difco)
4.7 g of dehydrated 7H9 formula in 900 ml of distilled water containing 0.05% 
Tween 80 and 2 ml of glycerol. OADC enrichment was added to 10% after 
autoclaving.
(vi) Mycobacteria 7H11 Agar (Difco)
21 g of dehydrated 7H11 formula in 900 ml distilled water, dissolved by 
heating and autoclaved. OADC enrichment was added to 10% on cooling to 
55°C. The plates were then poured.
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(vii) Antibiotics
All antibiotic stock solutions were prepared with sterile water and filter 
sterilized.
(viii) IPTG
1 M IPTG was prepared in water, filter sterilized and stored in 1 ml aliquots 
at -20°C.
(ix) X-Gal
40 mg/ml X-Gal solution was prepared in DMF and stored at -20®C.
2.1.5 General buffers and solutions
(i) TE Buffer
Tris 10 mM
EDTA 1 mM
pH 8.0 with HCl, autoclaved.
(ii) Sodium acetate
3 M Na acetate
pH 5.2 with glacial acetic acid.
Autoclaved.
(iii) Ammonium acetate
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5 M Ammonium acetate solution was prepared in water and filter sterilized.
(iv) Phenol
Phenol stored at -20°C was allowed to warm to room temperature and then 
melted at 68°C. Melted phenol was saturated with 0.1 M Tris-HCl, pH 8.0 and 
stored in the presence of the antioxidant 8-hydroxyquinoline (0.1% w/v) in 
light-tight bottle at 4°C.
(v) Phenol:Chloroform
Phenol:Chloroform was prepared as a mixture consisting o f equal parts of 
equilibrated phenol and chloroform. The mixture was stored under 100 mM 
Tris-HCl (pH 8.0) in a light-tight bottle at 4®C.
(vi) Sodium chloride solution:
5 M sodium chloride was prepared in water and autoclaved.
(vii) EDTA
0.5 M EDTA was prepared in water and the pH was adjusted to 8.0 with 
NaOH pellets and autoclaved.
(viii) Tris-HCl
1 M Tris-HCl was prepared in water and the pH adjusted to the desired value 
by adding concentrated HCl. The solution was sterilized by autoclaving.
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(ix) Sodium dodecyl sulphate (SDS)
10% SDS solution was prepared with electrophoresis-grade SDS in water. The 
pH was adjusted to 7.2 with HCl and the solution was filtered sterilized.
(x) Magnesium chloride
1 M  MgClj was prepared in water and sterilized by autoclaving.
(xi) Sodium hydroxide
5 M NaOH solution was prepared in water and stored in a plastic bottle.
2.1.6 Enzyme buffers
(i) 10 X Kinase buffer
Tris-HCl (pH 7.5) 700 mM
MgCl^ 100 mM
KCl 1 mM
DTT 50 mM
Spermidine 1 mM
EDTA 1 mM
(ii) 10 X Calf intestinal alkaline phosphatase buffer 
Tris.HCl (pH 8.0) 500 mM
MgClj 10 mM
ZnCL 1 mM
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This buffer was supplied with CIP by BCL.
(iii) 10 X restriction endonuclease buffer
DNA restriction endonuclease buffers were supplied with the enzymes 
and used according to the manufacturer's instructions.
(iv) 5 X ligase buffer.
Tris.HCl (pH 7.5). 250 mM 
MgClj 50 mM
ATP 5 mM
DTT 5 mM
PEG8000 25%
This buffer was supplied with T4 DNA ligase by BRL.
2.1.7 Solutions for DNA electrophoresis
(i) 1 X TAE (Tris-acetate) buffer:
Tris-acetate 40 mM
EDTA 1 mM
pH to 8.0 with glacial acetic acid.
It was made as a 50 X stock solution which was diluted to 1 X before use.
(ii) 1 X TBE (Tris-borate)
Tris-borate 89 mM
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Boric acid 89 mM
EDTA 2 mM
It was made as a 10 X stock solution which was diluted to 0.5 X before use.
(iii) DNA loading buffer, (6 X).
Bromophenol blue. 0.25% (w/v)
Ficoll type 400 15% (w/v)
2.1.8 Solutions for DNA hybridization
(i) Denaturing solution
NaCl 1.5 M
NaOH 0.5 M
(ii) Neutralizing solution
NaCl 1.5 M
Tris HCl pH (7.2) 1.0 M
(iii) 20 X SSC
NaCl 3.0 M
/ri-Sodium citrate 0.3 M
(vi) Prehybridization/hybridization solutions:
SSC 5 X
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Blocking reagent (BCL) 1% (w/v) 
N-lauroylsarcosine 0.1% (w/v)
SDS 0.02% (w/v)
(vii) Low stringency post-hybridization wash
2 X SSC 
0.1% SDS
(viii) High stringency post-hybridization wash
0.1 X SSC 
0.1% SDS
2.1.9 Solutions for detection of hybridized DNA
(i) Buffer 1:
Maleic acid 100 mM
NaCl 150 mM
pH adjusted to 7.4 with solid NaOH.
(ii) Buffer 2:
1% Blocking reagent (BCL) in buffer 1.
(iii) Buffer 3:
Tris-HCl 100 mM
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NaCl
MgCl,
100 mM
50 mM
The pH was adjusted to 9.5 with HCl.
(iv) AMPPD/Lumigen solution
0.1 mg/ml stock diluted 1:100 in buffer 3
2.1.10 Solutions for plasmid DNA extraction
(i) Solution I 
Glucose 50 mM
EDTA pH 8.0 10 mM
(ii) Solution II 
NaOH 
SDS
0.2 M
1.0% (w/v)
(iii) Solution III
Sodium acetate pH 5.2 3 M
(iv) Solution IV
Tris HCl pH 8.0 50 mM
Sodium acetate 100 mM
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2.1.11 Solutions for SDS-PAGE
(i) Solutions for preparing resolving 12% gels for SDS-PAGE
Component vol. (ml) per gel vol. of 
Solution components 5 ml (small gel) 40 ml (large gel)
HjO 1.6 13.2
30% acrylamide mix 2.0 16.0
1.5 M Tris (pH 8.0) 1.3 10.0
10% SDS 0.05 0.4
10% ammonium persulfate 0.05 0.4
TEMED 0.002 0.016
(ii) Solutions for preparing 5% stacking gels for SDS-PAGE
Solution components
Component vol. (ml) per gel vol. of 
1 ml (small gel) 5 ml (large gel
H^O 0.68 3.4
30% acrylamide mix 0.17 0.83
1 M Tris (pH 6.8) 0.13 0.63
10% SDS 0.01 0.05
10% ammonium persulfate 0.01 0.05
TEMED 0.001 0.006
(iii) 1 X SDS gel-loading buffer
Tris-HCl (pH 6.8) 50 mM
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Dithiothreitol (DTT) 100 mM
SDS 2%
Bromophenol blue 0.1%
Glycerol 10%
1 X SDS gel-loading buffer lacking DTT was stored at room temperature. 
DTT was added just before the buffer was used, from a 1 M stock solution 
stored at -20°C.
(iv) Tris-glycine electrophoresis buffer
Tris 25 mM
Glycine (pH 8.3) 250 mM
SDS 0.1%
A 5 X stock was made by dissolving 15.1 g of Tris base and 94 g of glycine 
in 900 ml of water. Then, 50 ml of a 10% (w/v) stock solution of SDS was 
added, and the volume was adjusted to 1000 ml with water.
2.1.12 Solutions for Western blot
(i) Transfer buffer
Glycine 39 mM
Tris base 48 mM
SDS 0.037 %
Methanol 20 %
One litre of transfer buffer (pH 8.3)
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5.8 g of Tris base, 0.37 g o f SDS, and 200 ml of methanol.
(ii) 10 X Ponceau S stock solution
Ponceau S 2 g
trichloroacetic acid 30 g
sulfosalicylic acid 30 g
HjO to 100 ml
(iii) 10 X Tris buffer saline (TES)
NaCl 1.5 M
Tris-HCl (pH 7.5) 0.5 M
This solution was sterilized by autoclaving and diluted to 1 X before use.
(iv) Blocking solution
5% (w/v) nonfat dried milk in TBS
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2.2 Methods
2.2.1 Ethanol precipitation of nucleic acid
DNA was precipitated employing one of the following methods:
Method A. Addition of 0.1 volume of 3 M  sodium acetate (pH 5.2) followed by two 
volumes of ethanol.
Method B. As for method A, except that one volume of isopropanol (2-propanol) was 
used instead of ethanol.
After the addition of ethanol (or isopropanol) the solutions were mixed and 
incubated on ice for 30 minutes (room temperature for 5 min in the case of 
isopropanol) or for shorter time periods at -20°C or -70°C. The DNA was precipitated 
by centrifuging at top speed in a microcentrifuge at 4°C for 10 min. The DNA pellet 
was washed in 70% (v/v) ethanol and dried in a vacuum desiccator prior to 
resuspending in TE buffer pH 8.0 or distilled water. For precipitation of small 
amounts of DNA, 1 pi of glycogen (20 pg/ml) was added and incubated at -20®C 
overnight.
2.2.2 Extraction of DNA with phenol:chloreform
An equal volume of phenol-chloroform was added to the nucleic acid solution 
and mixed by gently inverting the tube. The aqueous and organic phases were 
separated by centrifugation in a microcentrifuge for 5 min and the aqueous phase was 
transferred to a fresh tube. The extraction procedure was repeated until the interphase
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was clear of debris. A final extraction was performed using an equal volume of 
chloroform.
2.2.3 Quantitation of nucleic acid in aqueous solution
The concentration and purity of nucleic acid in aqueous solutions was 
estimated by measuring the UV absorbance of the solution at the wavelength of 260 
and 280 nm. A pure solution of DNA has a peak absorbance at 260 nm, and a 260 
nm/280 nm ratio of 1.8 (Sambrook et ah, 1989). The concentration of nucleic acid 
was calculated employing A26q=1 equivalent to 50pg/ml for double stranded DNA, 
while using the value Ajgo^l equivalent to 33pg/ml for oligonucleotides.
Alternatively, when the amount of DNA available was not enough for 
quantitation by spectrophotometry (< 500 ng), a comparative intensity method was 
used. This is a rapid and convenient way to measure the quantity o f DNA and to 
analyse its physical state at the same time. The DNA sample of interest was 
electrophoresed on an agarose gel alongside a known amount of lambda ff/wcTII DNA 
molecular weight marker. The gel was stained with ethidium bromide and analysed 
under UV light. The intensity of fluorescence of the DNA of interest was compared 
with that of the lambda HindHl DNA and the quantity of DNA in the sample was 
estimated.
2.2.4 Agarose gel electrophoresis
In general, gels were run at 100 volts for a time dependent on the gel
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dimensions and the agarose concentration. Gels were cast and run in 1 X TAE or 0.5 
X TBE, with samples loaded in 1 X loading buffer. After electrophoresis, gels were 
stained by soaking them in a solution containing ethidium bromide (0.5pg/ml) for 20 
min and washed with water for 10 min. DNA bands were visualized under UV light 
and photographed using either a Polaroid camera or the Gel Documentation System 
(Ultra-violet Products).
2.2.5 Extraction of DNA bands separated on an agarose gel
The geneclean kit (GeneClean II) prepared by BIO 101 was used for extracting 
DNA separated on a gel. The kit contains sodium iodide, glassmilk and New Wash 
buffer. The DNA sample was electrophoresed through agarose gel, stained with 
ethidium bromide and the gel slice containing the DNA fragment(s) o f interest was 
excised from the gel and weighed. Three volumes of Nal stock solution was added 
and incubated at 55®C for 5 min to dissolve the agarose. If  TBE had been used as the 
electophoresis buffer, 0.5 ml of TBE modifier and 4.5 ml of Nal was added to 1 g of 
gel. This was necessary to aid the melting of agarose gel in Nal and neutralize the 
inhibitory effects of TBE buffer on the binding of DNA to the silica matrix 
(glassmilk). Five pi of glassmilk suspension was added, mixed thoroughly and placed 
on ice for 5 min to allow binding of the DNA to the silica matrix. The silica matrix 
was pelleted by centrifuging for 5 sec. The supernatant was discarded and 200 pi of 
ice cold New Wash buffer was added. The pellet was resuspended well by pipetting 
back and forth while digging into the pellet with the pipet tip. After complete 
resuspension, it was centrifuged for 5 sec and the supernatant was discarded. The
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wash with New Wash buffer was repeated twice and after the last wash the 
supernatant was removed completely to avoid diluting the elute.
The washed pellet was resuspended in 10 pi of TE buffer and incubated at 
55°C for 2-3 min. The DNA was recovered by centrifuging the tube for 30 sec and 
collecting the supernatant in a clean eppendorf tube. This procedure was repeated 
with a further 10 pi of TE buffer and the supernatant was combined. The DNA was 
either used immediately or store at -20®C until required. Typical recovery o f DNA 
was between 70-90% depending on the size of the DNA.
2.2.6 Restriction endonuclease digestion of DNA
Restriction enzymes were obtained from BRL and BCL, and the digests were 
performed according to the manufacturer's instructions. Restriction analysis was 
performed using 0.2-1 pg of DNA and 5-10 units of enzyme in a volume of 10-20 pi. 
The digestion products were then analysed by agarose gel electrophoresis.
2.2.7 End filling of recessed 3* termini
This exercise was carried out to create blunt ended fragments for cloning. To 
1 pg of staggered-cut DNA, 2 pi of React buffer 3 (BRL), 2 pi of dNTP solution 
(containing each of the four dNTPs at a concentration of 2 mM), and water was added 
to a volume of 19 pi. One pi of Klenow enzyme was then added and the mixture was 
mixed and incubated at room temperature (22®C) for 15 min. The end filled DNA 
fragment was then phenol:chloroform extracted, ethanol precipitated, and the pellet
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was resuspended in water and stored at -20°C until required.
2.2.8 Removing protruding 3* termini
In a 20 pi reaction, 0.2-3 pg of DNA were digested with the appropriate 
restriction enzyme. One pi of a solution containing each of the dNTPs at a 
concentration o f 2 mM and 1 pi of T4 DNA polymerase were added. After incubation 
at 12°C for 15 min the T4 DNA polymerase and restriction enzyme were inactivated 
by phenol:chloroform extraction and the DNA was collected by ethanol precipitation. 
The pellet was resuspended in water and used immediately in a ligation reaction or 
stored at -20®C until required.
2.2.9 Alkaline phosphatase treatment
The vector was treated with calf intestine alkaline phosphatase (CIP) to prevent 
self ligation. The digested vector DNA was heat treated at 65°C for 5 min to 
inactivate the restriction enzyme. If  the enzyme was resistant to heat, it was removed 
by phenol:chloroform extraction. The vector was then precipitated in ethanol, washed 
in 70% ethanol and the pellet was resuspended in 17 pi TE buffer pH 8.0. Two pi 
of 10 X CIP buffer were added, followed by the addition of Ipl of CIP enzyme. This 
was mixed and incubated at 37°C for 60 min. In the case of blunt-ended DNA the 
solution was incubated at 37°C for 15 min, a further 1 pi of CIP was added and the 
incubation was continued at 55°C for 45 min. The reaction was stopped by adding 
EDTA to a final concentration of 5 mM and the enzyme was inactivated by incubation
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at 75°C for 10 min. Eighty pi of TE buffer were added to the CIP treated DNA which 
was then phenol:chloroform extracted and ethanol precipitated. The pellet was 
resuspended in 10-20 pi o f TE.
2.2.10 DNA ligation
DNA ligation was performed using T4 DNA ligase according to the 
manufacturer's instructions. Generally, cohesive end ligations were carried out in a 
volume of 20 pi, whereas blunt-end ligations were performed in a volume of 10 pi 
employing between 100 and 400 ng of a dephosphorylated vector at an insert:vector 
molar ratio of 2:1. Cohesive end ligations were incubated at 14°C while blunt-end 
ligations were carried out at 9°C overnight. One pi of the ligation products was added 
directly to competent cells for transformation.
2.2.11 Transformation of bacterial cells (K coli)
2.2.11.1 Prepaiution of competent cells
Competent cells were prepared using the method described by Han ah an et al. 
(1991). A colony of E. coli strain DH5a was used to inoculate 25 ml SOB in a 250 
ml flask and incubated at 20®C in a shaker to an OD 600 nm value of between 0.6 and 
0.7. This was usually achieved in about 24 hours. The culture was then chilled on 
ice for 10 min. Prechilled bottles and solutions were used subsequently. The chilled 
culture was transferred into a 50 ml Falcon tube and centrifuged at 2500 g for 10 min 
at 4°C. The supernatant was decanted and the pellet was resuspended in 8 ml of TB 
(10 mM Pipes, 15 mM CaClj, 250 mM KCl, 55 mM MnClj) and incubated on ice for
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10 min. This was centrifuged at 2500 g for 10 min at 4°C. The supernatant was 
decanted and the cells were resuspended in 8 ml of TB containing 140 pi o f DMSO. 
This was incubated on ice for 10 min before being aliquoted in 0.5 ml amounts into 
prechilled cryotubes and immediately stored immersed in liquid nitrogen.
2.2.11.2 Transformation of R  coli competent cells
Competent cells were removed from liquid nitrogen, thawed on ice and 
aliquoted (20-50 pi) into chilled polypropylene tubes (Falcon 2059). One to two pi 
o f DNA from ligation reactions or control DNA (0.05 ng/pl) were added to the cells, 
gently mixed by tapping the tubes, and incubated on ice for 30 min. The cells were 
then heat-shocked for 45 sec in a 42®C water bath, and placed one ice for 2 min. 0.9 
ml of room temperature SOC medium was added and the tubes were shaken at 225 
rpm (37°C) for 1 h. 10-100 pi were then plated on selective media and incubated at 
37°C overnight.
2.2.11.3 Plating of transformed bacteria
L-agar was melted in a microwave oven and allowed to cool to 55°C. 
Ampicillin or kanamycin was added to a final concentration of 50-100 pg/ml. The 
agar was swirled to mix its contents. About 20 ml amounts were poured per plate and 
allowed to set. The plates were then dried in an oven for about 10 min before 
spreading 100 pi of diluted bacterial cells with the use of a glass spreader. When the 
vector allowed blue and white selection, IPTG (isopropylthiogalactoside) and X-gal 
(3,4,5,bromochloroindolyl-13-d-galactoside) were added to the medium with the 
antibiotic to final concentrations of 30 pg/ml and 50 pM respectively.
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2.2.12 Small scale plasmid Preparation
This method was employed to isolate plasmids from E. coli strains. It is a I 
modification of the procedure described by Bimboim and Doly (1979). It has the 
advantage of being fast, and many cultures can be easily handled at the same time. On 
the other hand, th^ere is the n s k ^ f  somej;hromosomal DNA and ENA contamination.
A single colony of a plasmid-containing strain was used to inoculate 2 ml 
L-broth containing the appropriate antibiotic. The culture was incubated at 37°C for 
about 16 hours with shaking. 1.5 ml of the culture was pipetted into an eppendorf 
tube and centrifuged at top speed for 5 min in a microcentrifuge at room temperature. 
The supernatant was discarded and the pellet was resuspended in 100 pi of solution 
I (25 mM Tris HCl pH 8.0, 10 mM EDTA, 50 mM glucose). The suspension was 
incubated at room temperature for 5 min, then 200 pi of solution II (1% SDS [w/v], 
0.2 M NaOH.) were added followed by incubation on ice for 5 min. 150 pi of 
solution III (3 M sodium acetate [pH 5.2]) were added to the suspension and mixed 
by gently inverting the tube several times, followed by incubation on ice for 5 min. 
The lysate was centrifuged in a microcentrifuge at top speed for 5 min at room 
temperature. 400 pi of supernatant were carefully transferred to a new tube and 1 ml 
of cold (-20° C) absolute ethanol was added. This was gently mixed and incubated 
at room temperature for 3 min. The suspension was centrifuged for 5 min at room 
temperature. The supernatant was carefully discarded, the pellet was resuspended in 
100 pi of solution IV containing 10 pg/ml of RNAse, and incubated at 37°C for 15 
min. The plasmid DNA was ethanol precipitated and the pellet resuspended in 50-100 
pi of water or TE buffer and stored at 4 °C.
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2.2.13 Laige scale plasmid preparation
Large amounts of DNA of high purity were obtained by large scale plasmid 
extraction followed by cesium chloride/ethidium bromide gradient purification. 150 
ml of LB in a conic flask, containing the appropriate antibiotic was inoculated with
1.5 ml of an overnight E. coli culture containing the appropriate plasmid, and 
incubated overnight at 37°C with shaking. The cells were harvested by centrifugation 
at 10000 g for 10 min at 4°C, and resuspended in 10 ml of solution I (25 mM Tris pH 
8.0, 10 mM EDTA, 50 mM glucose). The suspension was incubated at room 
temperature for 10 min, then 20 ml of solution II (1% SDS [w/v], 0.2 M NaOH) were 
added followed by incubation on ice for 10 min. 15 ml of solution III (3 M sodium 
acetate [pH 5.2]) were added to the suspension and mixed by gently inverting the tube 
several times, followed by incubation on ice for 10 min. The lysate was centrifuged 
at 10000 g for 10 min at 4°C. The supernatant was carefully transferred to a new tube 
and 100 ml of cold (-20° C) absolute ethanol was added. This was gently mixed and 
incubated at room temperature for 5 min. The suspension was centrifuged for 10 min 
at 4°C. The supernatant was carefully discarded, the pellet was resuspended in 10 ml 
of solution IV (50 mM Tris pH 8.0, 100 mM sodium acetate). The plasmid DNA was 
reprecipitated with the addition of 20 ml of ethanol followed by centrifugation at 
10000 g for 10 min at 4°C, and the pellet was resuspended in 4 ml of water. Exactly 
1 g of CsCl was added and dissolved by inverting the tube several times. 0.4 ml of 
ethidium bromide 10 mg/ml was then added, and the solution was transferred to 13.6 
ml ultracentrifuge tube. The tube was filled up with liquid paraffin, sealed using a 
quick sealer and centrifuged in a Beckman L5 ultracentrifuge using the Ti 70.1 rotor
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(fixed angle), at 55.000 rpm for 20 h at 20°C.
After ultracentrifugation the DNA bands were visualized using a short wave 
hand held UV lamp. The bottom band corresponding to the plasmid band was 
collected by puncturing the side of the tube with a 19 gauge needle on a 2 ml syringe. 
Ethidium bromide was removed by 3 extractions with 2 volumes o f butanol saturated 
with water. The caesium chloride/DNA solution was then aliquoted in 250 pi in 
eppendorf tubes. To this solution, 250 pi of water, 50 pi of 3 M sodium acetate pH 
5.2, and 500 pi of isopropanol were added. After incubation at room temperature for 
30 min, it was centrifuged at 10000 g for 15 min at 4°C. The pellet was resuspended 
in 200 pi of water and the DNA was reprecipitated by adding 20 pi of 3 M sodium 
acetate and 400 pi of ethanol followed by centrifugation at 10000 g for 10 min at 4°C. 
The pellet was resuspended in a total of 500 pi of TE and the concentration of DNA 
was determined by spectrophotometry. The yield resulting from a 150 ml culture was 
between 100 pg and 500 pg depending on the plasmid.
2.2.14 Isolation of genomic DNA from mycobacteria
Total DNA was extracted from 10 ml of liquid culture containing 15-100 
pg/ml of kanamycin. After growth to the stationary phase cycloserine was added to 
1 mg/ml and the incubation was continued for a further 4 h or overnight. Cells were 
harvested by centrifugation and the pellet resuspended in 500 pi of TES (10 mM Tris 
pH 8.0; 1 mM EDTA; 0.3 M sucrose) containing 3 mg/ml of lysozyme and incubated 
at 37°C for 1 h. EDTA, SDS and proteinase K were then added to a final 
concentration of 5 mM, 1% and 200 pg/ml respectively, and the mixture was
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incubated for 1 h at 55°C. This was followed by one phenol, one phenol:chloroform 
and one chloroform extraction. The DNA was then precipitated by adding 0.1 volume 
of 3 M sodium acetate pH 7.0 and 2 volumes of ethanol. After centrifugation for 10 
min at 4°C in a microfuge, the pellet was resuspended in 100 pi of 50 mM tris pH 8.0, 
and 100 mM sodium acetate containing 10 pg/ml of RNase and incubated for 15 min 
at 37°C. The DNA was extracted again with phenol:chloroform and precipitated with 
2 volumes o f ethanol. The pellet was resuspended in 100 pi of TE (10 mM Tris pH 
7.4, 1 mM EDTA) and 5 pi were run on a gel to check the DNA concentration.
2.2.15 Southern transfer of DNA
One pg of genomic DNA was incubated with 20 units of restriction enzyme 
in a volume of 30 pi, at 37°C for 2 hours. The DNA was then run on a 0.7% agarose 
gel, stained with ethidium bromide and visualised under UV light. The DNA was 
denatured by soaking the gel for 45 min in several volumes of denaturing buffer (1.5 
M NaCl; 0.5 M NaOH) with constant agitation. The gel was then rinsed briefly in 
water and neutralized by soaking it for 45 min in several volumes of neutralization 
solution (1 M Tris pH 7.4; 1.5 M NaCl) with a change of the solution after 30 min. 
After this, the gel was placed inverted on a 20 X SSC presoaked Whatman 3MM 
paper, supported by a glass plate with both ends of the paper dipped in 10 X SSC. 
A piece of positively charged Boehringer nylon membrane cut exactly the same size 
as the gel was placed on top of it followed by two pieces of presoaked 3MM paper. 
Tissues were piled on top of the blot, followed by a weight of roughly 500 g. The 10 
X SSC passed through the gel, drawn by the capillary action accompanying the
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progressive wetting of the dry paper stack, and in so doing eluted the denatured DNA 
from the gel and onto the oppositely charged nylon membrane. The blot was left 
overnight, after which the membrane was rinsed in 2 X SSC, and baked at 120°C for 
30 minutes or at 80°C for 2 h to permanently immobilise the DNA on the membrane.
2.2.16 DNA labelling with digoxigenin-dUTP
DNA was labelled by random primed incorporation of digoxigenin-labelled 
deoxyuridine-triphosphate. The dUTP is linked via a spacer-arm to the steroid hapten 
digoxigenin (dig-dUTP). This method allows efficient labelling of small (10 ng) and 
large (up to 3 pg) amounts of DNA per standard assay.
From 50 ng to 1 pg of DNA was linearized with a restriction enzyme and 
denatured by heating in boiling water for 10 min and chilling quickly on ice/ethanol. 
To the DNA solution contained in 15 pi or less, it was added 2 pi of hexanucleotide 
mixture, 2 pi of dNTP labelling mixture 1 pi of Klenow enzyme and water to 20 pi. 
The incubation was carried out at 37°C for at least 1 h. Longer incubation time (up 
to 20 h) was used to increase the amount of labelled DNA when the amount of 
template available was limited. The reaction was stopped by adding 2 pi EDTA 200 
mM, pH 8.0. The labelled DNA was precipitated with 2.5 pi of LiCl 4 M, 1 pi of 
glycogen, and 75 pi of prechilled (-20°C) ethanol. This was mixed and incubated at - 
70°C for at least 30 min or -20°C overnight. It was then centrifuged at 10000 g for 
10 min at 4°C. The pellet was washed with cold ethanol 70% (v/v), dried under 
vacuum and dissolved in 50 pi of TE. The labelled DNA was denatured prior to use.
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2.2.17 DNA hybridization
Prehybridization and hybridization were carried out in Hybaid^^ bottles. The 
membrane was sandwiched between two pieces of nylon filter mesh and placed in the 
bottle. Prehybridization solution was added and the bottle rotated in a Hybaid^^ 
hybridization oven for 1-4 h at 68°C. The prehybridization solution was then replaced 
by 15-20 ml of hybridization solution containing 50-100 ng of denatured digoxigenin- 
labelled probe, and hybridization was continued under the same conditions overnight. 
The probe was then poured into a plastic bottle and stored at -20°C to be re-used after 
renewed dénaturation. The membrane was removed from the bottle, placed in a 
plastic box and washed twice in low stringency conditions (2 X SSC; 0.1% SDS for 
5 min at room temperature), followed by two washes in high stringency conditions 
(0.1 X SSC; 0.1% SDS for 15 min at 68°C). The membrane was then ready for 
chemiluminescent detection.
2.2.18 Chemiluminescent detection using tiie digoxigenin system
The membrane was washed for 1 min in buffer 1 (100 mM maleic acid; 150 
mM NaCl, pH 7.5) and then incubated for 30 min with about 100 ml buffer 2 (1% 
blocking reagent in buffer 1). After washing again briefly in buffer 1 it was incubated 
with 20 ml of diluted antibody-conjugate solution for 30 min. Unbounded antibody- 
conjugate was removed by washing 2 X 1 5  min with 100 ml of buffer 1. The 
membrane was then equilibrated for 2 min with 20 ml of buffer 3 (100 mM Tris HCl 
pH 9.5, 100 mM NaCl, 50 mM MgClj) before being incubated with 10 ml of
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Lumigen^^ [3-(2'-spiroadamantane)-4-methoxy-4-(3-phosphoryloxy)-phenyl-l,2- 
dioxetane] diluted 1:100 in buffer 3, for 5 min. Excess Lumigen solution was allowed 
to drip off. The membrane was then wrapped in Saran wrap, incubated at 37°C for 
10 min and exposed to X-ray film for twenty minutes. Depending on the strength of 
the signal, further exposures were done.
2.2.19 Transformation of mycobacteria
2.2.19.1 Preparation of competent cells
M. smegmatis mc^ 155 and M. vaccae R877R cells for electroporation were 
prepared as follows: 50 ml of Nutrient broth No. 2 supplemented with 0.05% Tween 
8 and 0.2% glycerol in a 250 ml flask were inoculated with 0.5 ml of a saturated 
culture and incubated on a shaker for 48 h at 3TC  forM . smegmatis or 4 days at 30°C 
for M. vaccae. BCG was grown at 37°C for 5 days in a 250 ml tissue culture flask 
containing 50 ml of 7H9 medium. After incubating on ice for 30 minutes, cells were 
harvested by centrifugation at 4,000 rpm for 10 minutes. The pellet was resuspended 
and washed in 25 ml of ice cold 1 mM Hepes, pH 7.0 and then recentrifuged. The 
cells were washed once more with 10 ml of 10% glycerol, then the pellet was 
resuspended in 2 ml of 10% glycerol and stored at -70°C in 400 pi aliquots.
2.2.19.2 Electroporation of competent cells
The BIO-RAD gene puiser was used for electroporation. Competent cells were 
thawed on ice. Aliquots (100 pi) of cells were electroporated with 0.05-0.2pg of 
DNA in 0.2 cm electroporation cuvettes, using the Bio-Rad Gene Puiser set at 2.5 KV,
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25pF and 600 ohms. The cells were immediately diluted in 0.9 ml of NB, transferred 
to a polypropylene tube (Falcon 2059) and incubated at 37°C for 2 h before plating 
on media containing 15 pg/ml o f kanamycin. Antibiotic resistant transformants were 
selected after 3 days of growth at 37°C for M. smegmatis or 5 days at 30°C for M. 
vaccae. For BCG transformation, 7H9 medium supplemented with OADC (Difco), 
Tween 80 and glycerol was used. After electroporation the cells were incubated for 
4 h at 37°C with shaking and then plated on 7H11 containing 15 pg/ml of kanamycin 
and incubated at 37°C for 3 weeks. Positive colonies were then isolated and screened 
for the possession of the required construct.
2.2.20 Synthesis of oligonucleotide primers
Oligonucleotide primers were synthesized using the Applied Biosystems 381A 
DNA synthesizer. All reagents and instructions for synthesis were obtained from 
Applied Biosystems.
2.2.20.1 Oligonucleotide deprotection
The oligonucleotide was extracted from the column in 2 ml of cold ammonia 
solution passed through the column slowly during a period of two hours. The 
ammonia/oligonucleotide solution was then incubated in a water bath set at 55°C for 
twelve hours. It was allowed to cool to room temperature before ethanol precipitation 
was carried out.
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2.2.20.2 Precipitation of oligonucleotides
This was done in three volumes 100% ethanol and 1/10 volume 3 M sodium 
acetate. The suspension was mixed and incubated at -70°C for 30 minutes. It was 
then centrifuged at 12000 g for 20 minutes at 4°C. The supernatant was discarded and 
the pellet was washed in 70% ethanol, desiccated under vacuum and resuspended in 
sterile distilled water. The concentration of the oligonucleotide was estimated using 
a spectrophotometer.
2.2.21 Polymerase Chain Reaction (PCR)
The procedure was adapted from Perkin Elmer Cetus specifications for running 
a PCR reaction. A mixture having each of the four deoxynucleotide triphosphates 
(dNTP) to a final concentration of 1.25 mM was made. To make up ten PCR mixes, 
330 pi of sterile distilled water, 80 pi of dNTP mix, 50 pi 10 X reaction buffer, 10 
pi of each primer (300 ng per pi), and 10 pi of Taq polymerase (2.5 units per pi) 
were added in the order they appear. This was mixed and distributed in 49 pi 
amounts. 50 pi of liquid paraffin was added to each mix and then 1 pi of template 
DNA (0.1 to 1.0 ng/pl) or 1 pi of water (negative control) was added. This was 
centrifuged at 7000 g for 2 sec (pulse spin). The outside of the tubes was lightly 
greased and the tubes were slotted into the programmed heating block.
2.2.22 Western blot analysis
2.2.22.1 Sample preparation
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During sample preparation, proteins were fully denatured by reduction with 
DTT, and saturated with SDS. SDS eliminates charge variability between proteins, 
giving them all the same charge-to-mass ratio and forcing them into rod-like shapes. 
Separation in SDS-PAGE is based on molecular weight, eliminating conformational 
and charge density variability.
Bacteria were grown in liquid medium supplemented with 15 pg/ml of 
kanamycin, to the stationary phase. A volume of three ml was centrifuged, the cells j
washed with 0.5 ml of 50 mM Tris, pH 7.5, resuspended in 50 pi of loading buffer 
(50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% sodium dodecyl sulfate, 10% glycerol 
and 0.1% bromophenol blue), heated at 100°C for 15 min, and the lysate was cleared 
by centrifugation for 10 min. The supernatant was loaded immediately on a SDS- 
Polyacrylamide gel or stored at -20°C for future use. Samples stored at -20°C were 
re-heated at 100°C for 5 min before being loaded onto the gel.
2.2.22.2 SDS-polyaciylamide gel electrophoresis
SDS-PAGE gels were prepared using a BRL Vertical kit (model V I6-2), or a 
Bio-Rad mini gel (Mini-PROTEAN® II dual slab cell) system. The mini gel system 
has the advantage that it is faster, but the volume and number of samples that can be 
loaded is smaller. A gel concentration of 5% for the stacking gel and 12% for the 
separating gel was used which has an effective range of separation of 14 to 50 kD. 
The gel was casted according to the manufacture instructions using the recipe 
described in 2.1.11. A sample volume of 25 pi for the large gel or 10-12 pi for the 
mini gel system was used. For comparison of molecular weights, an aliquot o f the 
Bio-Rad low range prestained molecular weight marker was loaded in all the gels.
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Electrophoresis was carried out at 150 V for 4 h, i.e. until the tracking dye 
was within 1 cm from the bottom of the gel, when the large gel kit was used or for 
approximately 45 min at 200 V when using the mini gel system.
2.2.22.3 Transfer of proteins to nitrocellulose filters
Following electrophoresis, the SDS-PAGE gel was removed and incubated with 
several volumes of transfer buffer for 30 min. Two sheets of Whatman 3MM filter 
paper and a nitrocellulose filter Hybond-C super (Amersham International) were cut 
to the size of the gel and were incubated with transfer buffer. For the transfer of 
proteins from the SDS-PAGE gel to the nitrocellulose filter, the gel, filter papers and 
nitrocellulose membrane were placed in an electroblot gel holder (Bio-Rad Trans-blot® 
cell) in the following order: filter pad; a sheet o f buffer saturated filter paper; the 
buffer saturated SDS-PAGE gel; buffer saturated nitrocellulose filter; a second buffer 
saturated filter paper followed by a second filter pad. The electroblot gel holder was 
then closed and placed within the elctroblotting tank with the gel facing the negative 
pole. The tank was filled with 1 X transfer buffer and blotting was carried out at 30 
V overnight at 4°C, followed by 60 V for 1 h at the same temperature.
For the minigel, the Bio-Rad Trans-Blot® SD semi-dry electrophoretic transfer 
cell was used. Following electrophoresis, the gel was equilibrated in transfer buffer. 
A piece of nitrocellulose filter Hybond-C super (Amersham International) and two 
pieces of thick filter paper were cut to the size of the gel and saturated by soaking in 
transfer buffer. The transfer unit was assembled by stacking onto the platinum anode 
the following: filter paper, nitrocellulose membrane, SDS-PAGE gel, and filter paper. 
Care was taken to avoid trapped air bubbles between the layers. The cathode was
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carefully placed onto the stack followed by the safety cover and the unit was 
connected to the Model 200/2 power supply. Mini gels were transferred for 24 min 
at 15 V.
2.2.22.4 Ponceau S staining of proteins on nitrocellulose filters
Ponceau S staining was used to provide visual evidence that electrophoretic 
transfer of proteins had taken place and to locate molecular-weight markers. It is 
completely compatible with all methods of immunological probing because the stain 
is transient and is washed away during processing of the western blot.
The nitrocellulose filter was rinsed in water and then transferred to a tray 
containing a working solution of Ponceau S stain and incubated for 5-10 min with 
gentle agitation. The filter was washed in several changes of deionized water until the 
protein bands were clearly visible. A colour photograph was taken before removing 
the stain by washing in TBS (50 mM Tris pH 7.5, 150 mM NaCl) and proceeding 
with immunological probing.
2.2.22.5 Immunological detection
Following Ponceau S staining, the filter was incubated for 60 min in 100 ml 
o f blocking solution (5% nonfat dried milk in TBS) to saturate non-specific protein 
binding sites on the filter. The filter was then incubated for 1 h with 20 ml of 
blocking solution containing an appropriate dilution of the primary antibody. This was 
followed by 3 washes with TBS for 10 min each and then the filter was incubated for 
1 h in 20 ml o f blocking solution containing a dilution of 1:1000 of the secondary 
antibody conjugated with Horseradish peroxidase. Unbound secondary antibody was
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removed by three washes with TBS for 10 min each and freshly prepared colour 
development solution (45 ml TBS; 30 mg 4-chloro-l-naphthol in 5 ml of methanol; 
30 mg of DAB in 5 ml of methanol; 15 pi HjOj) was added. When the desired bands 
were detected (usually after 1-5 min) the reaction was stopped by washing the filter 
in water. A permanent record of the result was made by photographing the wet filter.
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3 Construction o f mycobacterial Integrative vectors 
based on 1S900
3.1 Introduction
3.1.1 Mobile genetic elements
A large number of different mobile genetic elements have been discovered in 
prokaryotes. The most basic are known as insertion sequences (ISs). These are 
usually 0.8 to 2.5 kb in length, possess inverted repeats at their termini, and contain 
at least one open reading frame (ORF) encoding the transposase. Transposons are 
larger elements containing additional genes not involved in the transposition process 
(usually encoding antibiotic resistance) that are flanked by ISs in direct or inverse 
orientation. Artificial compound transposons can be constructed by cloning two copies 
of an insertion sequence flanking a selectable marker and other genes of interest.
3.1.2 Mechanisms of transposition
Transposable elements can move by either conservative or replicative 
mechanisms. These mechanisms are represented in figure 3-1. Conservative 
transposition leads to the insertion of the element into its new site without replication 
of the element. In this case, the donor molecule is generally lost and DNA repair 
occurs, leading to a repetition of the target site. Replicative transposition leads to a 
duplication of the element and the formation of a cointegrate consisting of the 
transposon donor molecule with an extra copy of the element. The two copies o f the
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I)
II)
in)
Cointegrate ^
Donor
Recipient
Shapiro
intermediate
V)
IV)
Resolution ^
r \
J
Replicative transposition Conservative transposition
Figure 3-1. The Shapiro model for intermolecular transposition. (I) The transposon, 
represented by thick blue lines, is cleaved at its 3' extremities. A staggered cleavage 
of the target site (thick red lines) leads to 5' protruding ends. (II) The 5' end of each 
target DNA strand is ligated to a 3' end of the transposon DNA creating the "Shapiro 
Intermediate". (Ill) Replication across the transposon DNA leads to the formation of 
a cointegrate (Replicative transposition). (IV) This structure can be resolved either by 
a site-specific resolvase or by the general homologous recombination pathway of the 
host. Alternatively, (V) a specific cleavage of the 5' ends of the transposon and filling 
in of the target site leads to a simple insertion of the transposon (Conservative 
transposition)
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transposon are then in direct orientation. These mechanisms have been well studied 
in in vitro systems (reviewed by Mizuuchi, 1992). Some transposons contain a 
resolvase able to perform site-specific recombination of the cointegrate, resulting in 
restoration of the transposon donor molecule and insertion of one transposable element 
into the recipient molecule.
3.1.2 Transposition in mycobacteria
In mycobacteria, transposition was first demonstrated by Martin et ai. (1990). 
They isolated the transposon Tn610 during a search for antibiotic resistance genes in 
a M. fortuitum  strain exhibiting various antibiotic modifying enzyme activities. This 
transposon contains a sulphonamide resistance gene {suî) and a truncated site-specific 
integrase, int, flanked by two insertion sequences, which were both named 1S6100. 
Transposition was demonstrated by replacing the sulphonamide resistance gene with 
a kanamycin resistance gene. The recombinant transposon was cloned on a non 
replicative plasmid and transferred into M. smegmatis by electroporation. Colonies 
having a kanamycin resistance phenotype were shown to contain a single copy of the 
transposon and in some cases the entire plasmid sequence integrated into the 
chromosome randomly with no specific target sites (Martin et al, 1990).
Several IS elements have been found in mycobacteria (McAdam et al, 1994). 
1S900 was the first example (Green et al, 1989). This IS was identified in a clone, 
pMB22, derived from z, Mycobacterium paratuberculosis genomic library (McFadden 
et al, 1987). 1^900 consists of 1451 bp of which 66% is G + C. It is an atypical 
insertion sequence as it lacks terminal inverted repeats, does not appear to produce 
target-site duplication on insertion, and shows a degree of target-site sequence and
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orientation specificity (Green et al, 1989). A single open reading frame (ORF 1197) 
coding for 399 amino acids is predicted. The amino acid sequence, and to a lesser 
extent the nucleotide sequence, show significant homology to transposable elements 
from Streptomyces spp, including IS770 (Bruton and Chater, 1987), IS776 (Leskiw et 
al, 1994) and the minicircle/IS117 (Henderson et al, 1989). More recently several 
ISPOO-related insertion sequences have been isolated from M. avium, namely 1S90I 
(Kunze et al, 1991), 1S902 (Moss et al, 1992), and IS7770 (Hernandez Perez et al, 
1994), composing the 1^900 family. The ORF of ISPOO has been expressed in E. coli 
under the control o f the TAG promoter, confirming that this ORF does encode a 
polypeptide (Tizard et al, 1992). An analysis of the sequences surrounding different 
copies of 1S900 has demonstrated similarities in the insertion sites of this element. 
These insertion sites share a consensus sequence: C A T C N C C T T  (the asterisk 
corresponds to the insertion site). As a consequence, transposition mediated by this 
element is not random. 1S900 is repeated 15 to 20 times in the Af. paratuberculosis 
genome, no major polymorphism has been found in the location of this element inM . 
paratuberculosis strains (McFadden et a l, 1987), indicating that insertion is stable, at 
least in the M. paratuberculosis genome.
Transposable elements in mycobacteria are potentially useful sources of genetic 
tools for the manipulation of mycobacteria in general and for the investigation of 
virulence mechanisms in pathogenic strains. In E. coli many transposons, or slightly 
modified derivatives of them, have been widely exploited as genetic tools (Berg et al, 
1989). The insertion of a transposable element into a gene can lead to inactivation of 
the gene. Owing to the ability of some transposons to insert randomly into DNA, they 
are important in creating mutants to identify genes by selecting for the loss of a
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certain phenotype. Insertion elements for the development of mutagenesis systems for 
mycobacteria should have a high frequency of transposition and exhibit no site or 
regional specificity. Transposition of Tnd77, a derivative oîTnôlO  from M . fortuitum, 
carrying a kanamycin resistance gene, on a temperature sensitive plasmid (Young, 
1993) as a delivery system allowed the construction of representative M. smegmatis 
insertion libraries. Of 30,000 insertion mutants tested, 80 auxotrophic mutants with 
15 different phenotypes were obtained (Guilhot et al, 1994). 1S900, having a
specificity of integration, cannot be used for transposon mutagenesis. Nevertheless, 
this mobile element can be useful for integrating copies of a gene into a mycobacterial 
chromosome. In streptomycetes, IS 117, an insertion sequence homologous to 1S900, 
has been used to develop an integration system (Kieser and Hopwood, 1991).
In order to detect transposition and to utilize 1S900 as an integration vector
England et a l (1991) constructed an artificial mycobacteria transposon by placing two
copies o f the insertion sequence 1S900 flanking a kanamycin resistance gene into a
non replicating vector. Constructs were introduced into mycobacteria by
electroporation and transposition events conferring kanamycin resistance were selected.
Integration of ISPOO into several genomic sites was shown to involve both, cointegrate
formation (fig. 3-2) and simple insertions (fig. 3-3), suggesting that 1S900 can
transpose by a replicative mechanism. The small number of transformants analysed
revealed that 1S900 mediated integration into a number of different sites in the M.
smegmatis genome, however, some independent integration events occurred at the
same site. An integration site of nine bp sequence would be expected to occur
approximately 10-20 times in a mycobacterial genome and therefore theM . smegmatis
genome would be expected to contain a similar number of possible sites for \S900  
integration. The 1S900 compound transposon has been shown to be very stable in M.
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CATGNNNNN CNCCTT 
GTACNNNNN GNGGAA
-CATGNNNNNi
OTACNNNNW 1S900
1 CNCCTT- 
JGNQGAA-
Figure 3-2. Integration mediated by replicative transposition o f a single copy of 
IS900. Transformation results in cointegrate formation.
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Vector
-CATGNNNNN CNCCTT- 
GTACNNNNN GNGGAA- Target site
Cointegrate
OR
-CAratNNNNr--------------
• qtACNNNTW* ............ <
-~l-------------- a^cN C C rr-
-4E ------------------ 'CWGCIAA
Conservative transposition
-  CATOWNMW r-...—^GIACNNNNN*------ ^
Replicative transposition 
Figure 3-3. Transposition of the 1S900 composite transposon.
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smegmatis in unselective media, what is an essential feature for a vector to be used 
in a recombinant vaccine (England et al, 1991).
In this study I developed IS900 integrative vectors into expression systems for 
mycobacteria. To direct expression of any foreign gene, as well as synthetic epitopes, 
in mycobacteria the gene encoding theM . leprae 18-kDa antigen (Booth et al, 1988) 
was used. The M. leprae 18-kDa protein has been shown to be related to the alpha 
crystalline family of low-molecular-weight, heat-shock proteins (Nerland et al, 1988). 
Antibody responses to this antigen can be detected in mouse and man, and 
proliferative T cell responses to this antigen are found in a high proportion of leprosy 
contacts, presumed to be immune to M. leprae (Dockrell et al, 1989); indicating that 
it is efficiently presented and recognised by the host immune system and that it is an 
important antigen in the immune response to leprosy. Although a homologous 
sequence is found in M. avium and M. intracellulare, there is no similar sequence in 
M. tuberculosis (Booth et al, 1993), minimising the potential for homologous 
recombination and interference with protein expression in this specie. A M . leprae- 
specific monoclonal antibody L5 recognizes the antigen and the antigenic epitope has 
been mapped (Doherty et al, 1989). Finally, the small size of the gene facilitates the 
construction of vectors of a manageable size and with useful unique restriction sites.
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3.2 Material and Methods
3.2.1 Bacterial strains, plasmids and media
Bacterial strains and plasmids used in this study are described in section 2.1.2 
and 2.1.3 respectively. E. coli D H 5a was grown in LB media with addition of 
required antibiotic. M. smegmatis mc^ 155 and M. vaccae R877R were grown in 
Nutrient Broth (NB) number 2 supplemented with 0.05% Tween 80 and 0.2% glycerol. 
For solid media agar bacteriological was added at 1%. M. bovis BCG Pasteur was 
grown in 7H9 or 7H11 Midlebrook media supplemented with OADC enrichment, 
0.05% Tween 80 and 0.2% glycerol. E. coli and M. smegmatis were incubated at 
37°C for 16 h and 48 h respectively, whereas M. vaccae was incubated at 30®C for 4 
to 6 days and BCG was incubated at 3TC  for three weeks.
3.2.2 Construction of integrative vectors
First the kanamycin resistance gene in a Pstl fragment from pUC4K was 
cloned into the PM  site o f pUC19, then the resulting plasmid (pUS900) was digested 
with Sphl and the 5' ends filled in with Klenow fragment of DNA polymerase I. A 
Nrul fragment from pMB22 containing the entire 1S900, plus 8 bp (left end) and 66 
bp (right end), was cloned into it in both orientations generating plasmids pUS901 and 
pUS902. These plasmids were digested with Ndel, blunt-ended by 5' end-filling and 
a second Nrul fragment containing the IS900 sequence was ligated into them, 
generating pUS903, pUS904, pUS905 and pUS906.
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3.2.3 Construction of expression vectors
The 611 bp Sacl-BcmiYQ. fragment from pML3 containing the sequence of the 
18kD gene from M. leprae plus 136 bp of upstream sequence was cloned into Sacl- 
BamlS. sites of pUS903 and the resulting plasmid was designated pUS909. Using the 
prim ers Ml 1 (5'-ATGGATCCGCAGCGACGGCAC-3') and Ml 2 (5'-
GCTGGATCCGCAAACAACAG-3') containing BamHH recognition sites, a 731 bp PGR 
fragment corresponding to the entire coding sequence of the 18kD gene plus 256 bp 
of upstream sequence was generated using M. leprae genomic DNA as template. The 
amplification conditions were as follow:
Dénaturation 94°C 1 min 1 cycle
Dénaturation 94"C 1 min
Annealing 55®C 1 min 30 cycles
Synthesis 72®C 2 min
Annealing 55"C 2 min
Synthesis 72®C 5 min 1 cycle
The PGR product was run on an agarose gel, Geneclean purified and cut with BamHl. 
This fragment was cloned into the BamHl site of pUS903 in both orientations, 
generating plasmids pUS930 and pUS931.
To compare the level of expression of the 18 kDa gene in integrative vectors 
to the level of expression when the gene is in a plasmid vector, the entire pAL5000 
mycobacterial plasmid was cloned into pUS909. The plasmid pAL5000 was extracted 
in large scale from M. fortuitum, linearized with EcoRY, and ligated into Seal site of 
pUS909 generating pUS926. This plasmid was electroporated into mycobacteria at
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a similar frequency to the pYUB12 vector.
3.2.4 Vector stability test
After transformation by electroporation and selection of kanamycin resistant 
colonies, one M. smegmatis pUS909 transformant named msslQOH, was sub cultured 
for 20 passages (200 generations) in unselective media. Every 2 days 10 pi o f the 
culture were used to inoculate 10 ml of NB and then incubated at 37°C. Dilutions of 
10'  ^ to 10'^ were plated out on media with and without kanamycin. After 3 days at 
37°C the colonies on each plate were counted.
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3.3 Results
3.3.1 Construction of the integrative vectors
A family o f integrative vectors (pUS903-906) with useful cloning sites was 
constructed, based on the E. coli plasmid pUC19 and containing two copies of IS900 
in inverted or direct repeat orientation, flanking the kanamycin resistance gene from 
Tn903 (fig. 3-4). These plasmids containing an artificial ISPOO compound transposon, 
were introduced into mycobacteria by electroporation and kanamycin-resistant 
transformants selected. Since pUC19 is unable to replicate in mycobacteria, 
transformation is due to ISPOO-mediated integration into the mycobacterial 
chromosome via transposition or cointegrate formation (England et al, 1991). The 
transformation efficiency of each of the integrative vectors is shown in table 3-1, in 
comparison with the shuttle plasmid pYUB12. Although the four integrative vectors 
were of the same order of magnitude in their efficiency of transformation, the result 
with pUS903, which has two copies o f ISPPP in directly repeated orientation, was 
somewhat higher than the others and it was therefore selected for further development. 
As demonstrated by England et a l (1991), a single copy of IS900 can mediate 
integration of the vector by a replicative mechanism resulting in cointegrate formation 
(fig. 3-2). When two copies of ISPPP are present in the same orientation (directly 
repeated), simple insertion of the composite transposon can also occur (fig. 3-3), 
resulting in a higher transformation efficiency.
3.3.2 Insertion and expression of the M. leprae 18-kDa antigen gene
In order to provide mycobacterial signals for expression of any cloned gene,
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Figure 3-4. Construction of IS900 integrative vectors.
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Table 3-1. Transformation efficiency of M  smegmatis, M. vaccae and BCG Pasteur 
transformed with pYUB12 or integrative vectors.
Transformants per pg of DNA
M. smegmatis M. vaccae BCG Pasteur
pYUB12 5.0x10* 1.1x10" 2.1x10*
pUS903 2.0x10^ 8.0x10' 0.3x10'
pUS904 7.0x10' 3.0x10' NT
pUS905 0.6x10' 0.5x10' NT
pUS906 1.1x10' 0.8x10' NT
The result shown are averages obtained in three separate electroporations. NT, not 
tested.
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the M. leprae gene coding for the 18-kDa antigen was inserted into the multiple 
cloning site of pUS903 to generate pUS909 (fig. 3-5). The fragment used, from pML3 
(Booth et al, 1988), contained the coding sequence plus 136 bases o f upstream 
sequence. As there was some doubt over the location o f the promoter, a fragment 
containing the coding sequence plus 256 bp of upstream sequence was generated by 
PCR using M. leprae DNA as template, and cloned into the BamHl site o f pUS903 
in both orientations generating pUS919 and pUS920. Each of these plasmids was 
electroporated into AT. smegmatis resulting in a transformation frequency similar to the 
parent plasmid pUS903. Southern blot analysis showed that the vectors integrated into 
the chromosome and the copy number ranged from 1 to 5 per cell (fig. 3-6). Since 
the enzyme used cuts only once in the vector, each copy of the vector integrated into 
the chromosome produces two hybridizing bands of variable size.
Western blot analysis confirmed that theM . smegmatis transformants obtained 
with pUS909, pUS919 and pUS920 made a product that reacted with the M. leprae- 
specific monoclonal antibody L5. This confirms that the 18kDM. leprae gene can be 
expressed in M. smegmatis, and is therefore a suitable candidate for an expression 
system. However, the level of expression with these clones was low when compared 
to that obtained with the 18kD gene cloned into the multicopy shuttle plasmid pUS926 
(not shown). We considered it likely that intracellular replicative transposition o f the 
composite transposon would lead to an increase in copy number, which would in turn 
lead to increased levels of kanamycin resistance, and of expression of the foreign 
antigen. Twelve of the initial transformants designated w 5^15/1-12, were therefore 
subcultured in liquid media containing increasing concentrations of kanamycin, from 
15 pg/ml to 100 pg/ml. Western blotting of these
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Figure 3-5. Construction of ISPOO integration/expression vectors.
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Figure 3-6. Southern hybridization of M. smegmatis transformants probed with 
pUS909. Genomic DNA (Ipg) from untransformed M. smegmatis (lane 1) and 
pUS909 transformants (lanes 2 to 13), digested with BamYH, hybridized to 
digoxygenin-labelled pUS909.
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strains named ma^jlOO/1-12 did indeed show a significant increase in expression of the 
18kD gene when compared to the parental strain. Figure 3-7, lane 1 shows the 
increase in the level of expression of the 18kD gene from strain msslOO/l in 
comparison to the parental strain in lane 2. Southern blotting of DNA
extracted from the m ss\0 0 l\-\2  strains also showed the presence of multiple extra 
bands, indicating that selection at high levels of kanamycin did select for additional 
transposition events but that a heterogeneous population was generated. The result 
from strains m ss\5 l\ and w^^lOO/l is shown in figure 3-8 lanes 2 and 3 respectively.
To examine transposition and expression in individual clones, the initial 
transformants named tw 5^100/1, which originally contained only one copy o f the vector 
pUS909, was subcultured in liquid media at 100 pg/ml of kanamycin, and then plated 
out. Isolated colonies were grown in liquid media with a low concentration of 
kanamycin (15 pg/ml) and western blotting of these clones (tm^^IOO/KI-tw^^IOO/KIô) 
showed varying levels of expression of the 18kD gene (fig. 3-7). A weak band 
slightly bigger than the 18kD antigen was also detected in untransformed M. 
smegmatis (fig. 3-7, lane Ms), which shows that the L5 monoclonal antibody, 
previously thought to be specific forM . leprae andM. habana (Lamb g/ ah, 1990) can 
also cross-react with the endogenous 18-kDa protein of M. smegmatis. The copy 
number of the vector in the M. smegmatis chromosome was examined by Southern 
blotting. It was expected that the increase in the level of expression would correlate 
with an increase in the copy number. Surprisingly however, five out of six clones that 
expressed the 18kD at high level contained only a single copy of the vector, identical 
to the parent clone, tm5^15/1 (fig. 3-8). All three clones that expressed the I8kD at 
relatively low levels were found to contain one extra copy of the vector. These results
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Figure 3-7. Western blot analysis of derivatives of a pUS909 M. smegmatis 
transformant selected at high levels of kanamycin. The monoclonal antibody L5 was 
used for detection. Lane 1, strain msslOO/\ grown in 100 pg m f’ of kanamycin; lane 
2, parental strain grown at 15 pg ml ' of kanamycin; lanes K1 to K16,
individual colonies from m55100/1 grown in 15 pg ml ' of kanamycin; Ms, 
untransformed M. smegmatis.
96
K b  1 2 3 4  5 6 7 8 9 10 11 12
7 .6 .
6.1 ■
4 . 0 -  «  «
2 ,2 -
1 . 4 -
Figure 3-8. Southern hybridisation of 5 a7«HI-digested DNA isolated from colonies 
selected at high levels of kanamycin, probed with pUS909. 1, Untransformed M.
smegmatis, 2, parental W55l 5/1 grown in 15 pg ml ' of kanamycin; 3, parental 
7M55100/1 grown in 100 pg ml ' of kanamycin; 4, W55100/K1; 5, mss\00/K3', 6, 
W55100/K5; 7, /W55l00/K9; 8, W55l00/K14; 9, W55IOO/KI6; 10, /W55l00/K2; 11, 
W55100/K4; 12, /W55100/K8.
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suggest that in this experiment M. smegmatis became resistant to high levels of 
kanamycin by two distinct mechanisms: (1) increasing the copy number of the 
kanamycin gene as part of the 1^900 compound transposon by intracellular 
transposition; and (2) increasing the expression of a single copy of the kanamycin 
gene. In the latter case, concurrent high level expression of the 18kD gene was 
obtained. The mechanism for this effect does not appear to be due to activation of 
an upstream promoter, since the same effect was observed using vectors containing the 
fragment encoding the 18-kDa antigen in either orientation with respect to the 
kanamycin resistance gene (data not shown). Selection on higher concentrations of 
kanamycin was also possible. However, all the colonies selected on 1 mg/ml of 
kanamycin had a single copy of the vector and showed high levels of expression of 
the 18kD gene. Strains that had extra copies of the vector and low expression of the 
18kD gene after selection at 100 pg/ml of kanamycin failed to grow on kanamycin 
concentrations higher than 200 pg/ml, whereas those with a single copy, but 
expressing the 18kD at high levels were resistant to at least 500 pg of kanamycin.
After growing M  smegmatis transformed with pUS909 in media without 
kanamycin selection for 200 generations, no difference in the number of colonies on 
plates with or without kanamycin was detected. The level of expression of the 18kD 
was also unchanged after 200 generation without selection indicating that the vector 
is very stable. No apparent difference in level of expression was detected, as judged 
by the intensity of the bands on Western blots, between vectors containing the short 
611 bp fragment from pML3 (pUS909) or the large 731 bp PCR fragment (pUS930, 
pUS931), indicating that the promoter is present in the fragment from pML3.
M. vaccae was also transformed with the integrative vector pUS909. In M.
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vaccae the frequency of transformation was 10 times lower than inM . smegmatis, but 
sufficient to give a large number of transformants. Transformation o fM  vaccae with 
pUS909 shows that IS900 can transpose in mycobacterial species other than M. 
smegmatis. Southern blot analysis of kanamycin resistant transformants revealed that 
the vector integrated into the chromosome. Most o f the transformants had only a 
single copy of the vector, but as in M. smegmatis, some had multiple copies (not 
shown). Intradermal injection of a suspension of killed M. vaccae promotes cell- 
mediated responses to antigens common to all mycobacteria, and switches off the 
tissue-necrotizing aspects of the Koch phenomenon (reviewed by Stanford et al., 
1990b). These properties led to the use of the suspensions as an improved vaccine, 
either alone or in combination with BCG. The same properties led to the employment 
of the suspension in immunotherapy as an adjunct to chemotherapy in the treatment 
of both leprosy and tuberculosis (Stanford et al, 1990a). The vectors described here 
constitute another tool that can be used to manipulate M. vaccae in order to improve 
its immunological properties.
BCG has proven more difficult to be transformed. Initial transformations 
attempts with the autonomously replicating plasmid pYUB12 or pUS926 were only 
partially successful with a transformation efficiency of about 10  ^ to 10  ^ transformants 
per pg of DNA. No transformants were obtained with integrative vectors as the 
frequency of transformation of the latteris approximately 10'  ^of the pYUB12 (England 
et al, 1991). Cultures ofM. bovis BCG and other slow growing mycobacteria contain 
large numbers of cells that are inviable. Even when nutrients are available some 
mycobacterial cells have an unusual ability to enter and maintain a dormant state. We 
reasoned that maintenance of BCG cultures in mid-log growth might maximize the
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viability and as a result increase the transformation efficiency. An experiment was 
performed in which BCG cultures were diluted 1:10 every 4 days. A healthy, "fast" 
growing culture was then used to inoculate 80 ml o f medium in a 250 ml tissue 
culture flask and after four days of incubation at 37°C the bacteria were harvested and 
used for electroporation. It has also been demonstrated that cell wall degrading 
agents, like glycine and isonicotinic acid hydrazide (INH), can enhance the 
transformation efficiency of M. auntm (Hermans et al., 1990). The effect of INH on 
transformation efficiency of BCG was therefore investigated. INH was added to 4 
pg/ml to the BCG culture 4 hours before harvesting. A significant increase in 
I  transformation efficiency was observed with the INH treatment, which combined with 
[growth in tissue culture flasks, instead of conical flasks, resulted in transformation 
efficiency greater than lO'* transformants per pg of pYUB12. With the integrative 
vector pUS909 a total of 0.3 x 10' transformants per pg of DNA was obtained. 
Southern blot analysis of 16 transformants revealed that in BCG integration o f the 
1^900 composite transposon did not involve cointegrate formation as the pUC19 part 
o f the vector was not integrated. The transformants analysed had one, some times two 
copies of the composite transposon integrated by simple insertion at different sites, 
however, as in M. smegmatis, some independent integration events occurred at the 
same site.
The expression of the 18kD gene in BCG andM . vaccae in comparison to M. 
smegmatis after exposing it to high levels of kanamycin is shown in figure 3-9. This 
shows the suitability of the expression system to express foreign genes also in these 
two species. In BCG and M. vaccae the level of expression of the 18kD was not 
affected by selection in high concentrations of kanamycin and they were resistant to 
a maximum concentration of 200 pg/ml.
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Figure 3-9. Western blot showing the expression of the 18kD gene in mycobacteria 
transformed with pUS909 and detected with L5 monoclonal antibody. Lanes 1, 3 and 
5, untransformed M. smegmatis, M. vaccae and BCG respectively; lanes 2, 4 and 6, 
pUS909 transformed M. smegmatis, M. vaccae and BCG respectively.
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3.4 Discussion
The results demonstrate the use of integrative vectors based on 1S900 for 
obtaining stable expression of foreign genes in mycobacteria. In contrast to site- 
specific integrative vectors based on the phage attachment system where the copy 
number is one per cell (Jacobs et al, 1987; Snapper et al, 1988; Lee et al., 1991), the 
vectors described can be present in several copies per cell. This can potentially 
enhance the expression of foreign genes, although with the 18kD gene in M. 
smegmatis the level of expression is not associated with copy number. Another 
feature that adds to the versatility of the vector is that it can be used to transform the 
same bacterium more than once provided that a different selectable marker is used.
The molecular mechanism for transposition of ISPOO has not yet been 
established. The lack of terminal inverted repeats and target-site duplication, 
characteristic shared with other members of the \S900 family, suggests a different 
mechanism from that described for replicative transposition (Galas and Chandler, 
1989). However, the results previously obtained with ISPPO-based integrative vectors 
indicate that in M. smegmatis integration is through replicative transposition o f a 
single copy of 1S900 resulting in cointegrate formation (England et al, 1991). 
Alternatively, when two copies are present as direct repeats in the vector, simple 
insertion of the composite transposon can also occur. In the present study, selection 
for increased level of kanamycin resistance revealed intracellular transposition o f the 
composite transposon by a replicative mechanism, as the original copy was always 
present in strains that had acquired extra copies. In BCG, the mechanism for 
transposition of ISPOP seems to differ from M. smegmatis as no cointegrate formation
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was detected. All the transformants analysed had only the composite transposon 
integrated with no extra copies of the IS element.
The stability test performed by growing the bacteria for many generations 
under unselective conditions shows that unlike ISl lJO,  a member o f the IS900 family 
recently described (Hernandez Perez et al, 1994), ISPOO-mediated integration is 
extremely stable and not very mobile. This stability in the absence of positive 
selection is an essential feature for a vector to be used in a recombinant vaccine. A 
possible disadvantage of the integrative vectors described here over phage-based 
integrative vectors (Snapper et al, 1988; Lee et al, 1991; Stover et al, 1991b) is the 
fact that the location of the integration is unknown. Mutation caused by the insertion 
of the composite transposon may alter genes that interfere with the virulence of the 
bacteria. Furthermore, it may inactivate genes that are important for the 
immunogenicity or adjuvanticity of the of the bacteria.
In order to provide signals for expression of foreign genes in mycobacteria the 
M. leprae gene encoding the 18-kDa antigen was chosen. For expressing synthetic 
epitopes, as well as complete genes, as fusion proteins we judged it undesirable to use 
the conserved hsp6(3 or hsplO genes previously described (Stover et al, 1991b; Fuerst 
et al, 1992; Aldovini and Young, 1991). The 18-kDa protein contains 148 amino 
acids, and the mAb L5 (Britton et al, 1985) binds to an epitope mapped to position 
110-115 within the sequence (Doherty et al, 1989). In the vectors described here, a 
unique B glll restriction site located downstream from the L5-binding epitope 
represents a convenient place to insert foreign epitopes or complete genes, without 
disrupting the L5 epitope. Consequently, fusion proteins can be detected with this 
monoclonal antibody, as well as with antibodies specific for the foreign antigen. The
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18-kDa protein is known to be highly immunogenic and therefore fusion proteins 
based on it are also likely to produce a good immune response.
A high level of expression of the 18kD gene in M. smegmatis was achieved 
after subculturing in high levels of kanamycin. Although the regulation mechanism 
is obscure, the high level of expression is maintained even when sub cultured in the 
absence o f selection. It has been shown that the M. smegmatis RNA polymerase 
enzyme has a strong dependence on supercoiling of the DNA substrate for 
transcription from mycobacterial promoters (Levin and Hatful1, 1993). It is possible 
that in this experiment growth at high level of kanamycin may have selected local 
changes in DNA supercoiling resulting in increased expression of surrounding genes. 
In M. vaccae and BCG the level of expression of the 18kD was not changed upon 
selection in high concentrations of kanamycin. Further studies will be required to 
elucidate the regulation of expression of the 18kD in M. smegmatis.
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Chapter 4
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4 A recombinant vaccine against Foot-and-Month Disease
4.1 Introduction
Foot-and-mouth is a highly contagious viral disease that can affect all 
cloven-hoofed animals. Symptoms of the disease include fever, watery blisters in the 
mouth, excessive drooling, blistering between the hoof claws, and lameness. 
Occasionally, the disease will devastate a herd; more often, it does not kill but causes 
enormous economic losses through weight loss, quarantine, and poor performance of 
infected cattle. Although it is not prevalent in many industrialized countries, it is 
constantly guarded against because it could easily be introduced through the import 
of live animals, fresh or frozen beef, or even animal bones used as fertilizer.
Control of the disease is by slaughter in those countries where it does not 
normally occur but vaccination is used where it is endemic. Currently used 
chemically inactivated virus vaccine induces solid protection; however, immunity is 
short lived, making multiple vaccinations necessary to protect livestock. The whole- 
virus vaccine preparations are unstable and require refrigeration. Additionally, the 
escape of viruses from vaccine production centres or use of improperly inactivated 
vaccines present a constant risk of new outbreaks (Brown, 1992). Consequently, much 
effort is being focused on the development of synthetic antigens and recombinant 
vaccines.
4.1.1 Virus and virus-specified antigens
Foot-and-mouth disease virus (FMDV) belongs to the aphthovirus genus of
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Picornaviridae. These non-enveloped RNA viruses have a capsid of icosahedral 
symmetry made up of 60 copies each of viral proteins V Pl to VP4 (Rueckert and 
Wimmer, 1984). The structural proteins VP 1-3 are known to contribute to the 
antigenicity of the intact virus particle, however, the major immunogenic activity is 
associated with V Pl. This conclusion resulted form observations that treatment of 
virus of serotype O with trypsin, which only affects V Pl, greatly reduce its 
immunogenic activity (Wild and Brown, 1967). Moreover, V Pl isolated from virus 
particles possesses low but significant immunogenic activity whereas the other proteins 
are devoid of activity. Recombinant V Pl prepared in E. coli has been shown to 
protect both pigs and cattle (Kleid et al, 1981). However, the immunity induced was 
inferior to inactivated virus and required approximately 1000-fold higher dose of the 
immunogen to induce comparable protection to that of conventional vaccines 
(McKercher et al., 1985).
4.1.2 Peptide vaccines
Observations that a portion of V Pl will elicit neutralizing antibody have led 
to attempts to develop a synthetic peptide vaccine. Different approaches used to 
identify the active fragments on the virus particle have highlighted the importance of 
the 141 -160 region of V Pl (Strohmaier et al., 1982; Bittle et al, 1982; Pfaff et al, 
1982; Geysen et al, 1984). Immunization with synthetic peptides derived from this 
sequence induced neutralizing antibodies (Bittle et al, 1982; Pfaff et al, 1982). 
Subsequent studies by X-ray crystallography have shown that this dominant 
immunogenic site is located within a prominent disordered loop (Acharya et al, 1989), 
which is in accord with the contention that immunogenicity is greater in those
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segments of protein molecules which are flexible. Moreover, the V Pl region 200-213 
which has also been shown to be an epitope for neutralizing antibody is located close 
to the loop region providing structural evidence for the enhanced immunogenicity 
which has been reported for the hybrid peptide comprising residues 141-160 and 200- 
213 (Dimarchi et al, 1986).
Synthetic peptides based on 141-160 of FMDV strain Oj Kaufbeuren (OjK), 
with or without carrier proteins, have been used to raise antibodies in mice, rabbits, 
and guinea pigs and to protect the latter from challenge against homologous virus 
(Bittle et al, 1982; Francis et al, 1985; Francis et al, 1987). Furthermore, the 
immunogenicity of this peptide was increased when fused with hepatitis B core protein 
(Clarke et al, 1987), or when presented as an octamer or a tetramer (Francis et al, 
1991). The 141-160 peptide contains not only important immunogenic B-cell 
recognition sites but also sites capable of eliciting T-cell activity (Francis et al, 1985; 
Collen et al, 1991; Zamorano et al, 1994) A peptide comprising residues 135-160 
of FMDV stain 01 Campos, administered free or conjugated to bovine serum albumin, 
has been shown to induce complete protection in guinea pigs and a strong neutralizing 
antibody response in cattle (Thierry et al, 1990). However, protection of cattle has 
only been reported by DiMarchi et al. (1986) using a synthetic peptide that contained 
residues 141-158 and 200-203 of OjK linked by a diproline-serine spacer.
4.1.3 Recombinant vaccines
Kitson et al. (1991) constructed poliovirus/FMDV chimeras in which the V Pl 
p B -p C  loop (antigenic site 1) of poliovirus type 1 Sabin was replaced with sequences 
derived form the V Pl p G -p H  loop (antigenic site 1) of FMDV 0,K . One chimera
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containing residues 140-160 was neutralized by FMDV-specific polyclonal serum and 
monoclonal antibodies directed against this epitope. Immunization of guinea pigs with 
this chimera induced site-specific FMDV-neutralizing antibodies and was capable of 
inducing a protective response against FMDV challenge in some guinea pigs (Kitson 
et al, 1991). More recently, Ruppert et ai. (1994) expressed fragments of the FMDV 
V Pl gene fused with outer membrane protein A (OmpA) of Shigella dysenteriae for 
production and transport o f the foreign polypeptide to the outer membrane of E. coli. 
OmpA fusion proteins with large insertions from sequences of the FMDV protein VPl 
were shown to elicit virus-specific immune responses in rabbits.
In this study I synthesized, cloned and expressed in mycobacteria the sequence 
coding for the major immunogenic site (residues 140-160) of FMDV strain OjK 
(FMDV epitope). We reasoned that the unique immunoadjuvant properties of 
mycobacteria can improve the host responses to this specific immunogenic site making 
it possible to be used as a recombinant vaccine against FMDV. In addition, FMDV 
is well characterized and this vaccine can be used as a model system to help our 
understanding of the immune responses elicit by rBCG expressing viral antigens. If  
successful the same approach may be used to produce novel recombinant vaccines 
against other diseases like AIDS.
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4.2 Material and Methods
4.2.1 Sequence of the FMDV V Pl 140-160
Mrus cDNA and amino acid sequences
140 160
V D A V P N  L R G D L Q V L A Q K V A R T  L P K
5'-CTG GAC GGT GTG CCC AAC TTG AGA GGT GAC CTT CAG GTG TTG GCG CAA AAA GTC GCA CGG ACG CTG CTT AAA-3'
; Synthesized sequence i
5'-GTG GAC GOT GTG CGG AAC CTG CGC GGC GAC CTG CAG GTG CTG GCC CAG AAG GTG GCC CGC ACC CTG CCG AAG-3' 
* * * * * * * * » * * * * * * *  * * *
(♦) Changes to the sequence to allow for mycobacterial codon usage.
4.2.2 Synthesis of oligonucleotides
Two 50 bases oligonucleotides overlapping by 12 bases at their 3' ends and 
containing BgUl recognition sequences were synthesized using the Applied Biosystems 
381A DNA synthesizer. These sequences correspond to the FMDV V Pl residues 140- 
160; FM I (5 '-c c a g a t c t c c g t c g a c g c c g t c c c g a a c c t g c g c g g c g a c c t g c a a g t c c -3') 
and FM2 (5 '-c c a g a t c t t c g g c a g g g t c c g g g c c a c c t t c t g g g c c a g g a c t t g c a g g t -3').
4.2.3 Purifîcation of syndic tic oligonucleotides
The oligonucleotides were purified by electrophoresis through a denaturing 
polyacrylamide gel and visualized by UV shadowing. Ten OD (330 pg) of each 
oligonucleotide were evaporated to dryness in a speedvac. The pellet was resuspended 
in 12 pi of formamide and loaded on a 12 % denaturing polyacrylamide gel (15 cm 
X 30 cm X 1.5 mm) prepared as follows:
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Reagents Amounts of reagents
Urea 31.5 g
Aciylamide stock (38:2) 23.5 ml
5 xT B E 15.0 ml
Water 14.0 ml
10 % ammonium persulfate 0.45 ml
TEMED 35.0 pi
One track was loaded with a mixture of formamide plus 0.05 % xylene cyanol 
and 0.05 % bromophenol blue. In a 12 % gel xylene cyanol runs as a 40 bases 
oligonucleotide and bromophenol blue as 15 bases. The gel was run at 15 W (wattage 
constant) which corresponds to 420 V and 37 mA, for 3.5 h. The gel was then placed 
on a piece of Saran Wrap and on a fluorescent thin layer chromatographic (TLC) 
plate. The bands were visualized by illumination from above using a hand-held long- 
wavelength UV lamp. The DNA in the gel absorbs the ultraviolet radiation and 
appears as dark bands against a uniform fluorescent background contributed by the 
chromatographic plate. The slowest-migrating band from each track, which is the full 
length oligonucleotide, was cut out and transferred to plugged 10 ml syringes.
The DNA from the gel slices was eluted and isolated by reversed-phase 
chromatography on a silica gel using Sep-Pak C,g cartridge. Three ml of Sep-Pak 
loading buffer (100 mM tris, 0.5 M NaCl; 5 mM EDTA, pH 8.0) were added to the 
plugged 10 ml syringe containing the gel slices. The top was sealed with paraffin film
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and the sample was vortexed vigorously and then incubated at 60°C overnight. The 
Sep-Pak Cjg cartridge was flushed once with 10 ml of HPLC grade methanol and once 
with 10 ml of water. The syringe containing the gel slices was connected to the 
cartridge and the liquid was drawn onto the Sep-Pak cartridge by using a 30 ml 
syringe attached to the bottom of the cartridge. The gel slices were rinsed with 3 x 
1 ml of loading buffer, and the buffer was added to the Sep-Pak cartridge. Salts were 
removed by addition of 20 ml of water, and the oligonucleotide was eluted with 3 ml 
of 100 mM TEA-Ac (pH 7.3) and methanol, 1:1, and collected in eppendorf tubes. 
The solvent was evaporated in a speedvac, the pellet was rinsed with 90 % ethanol, ; 
redried, and resuspended in 100 pi of TE. The concentration of the purified 
oligonucleotides was estimated by spectrophotometry.
4.2.4 Synthesis of FMDV epitope
Approximately 2.5 pg of each purified oligonucleotide were mixed together, 
heated in a boiling water bath for 3 min, quickly chilled and then allowed to form the 
desired annealing at their 3' termini. The annealed fragments were then extended with 
Klenow fragment of DNA polymerase I and dNTPs in the following reaction:
Oligonucleotide FM I 6 pi (2.5 pg)
Oligonucleotide FM2 12 pi (2.5 pg)
10 X Buffer (React 2) 5 pi
dNTP 2 mM 5 pi
Klenow (6 U/pl) 2 pi
Water to a final volume of 50 pi
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After incubation for 3 h at room temperature, 5 pi were run on a 12 % non­
denaturing polyacrylamide gel to check the efficacy of the reaction. The DNA in the 
remaining 45 pi was precipitated with ethanol and resuspended in 20 pi of TE buffer. 
Ten pi o f the newly synthesised DNA fragment were digested with 30 U of BglU  in 
a 30 pi reaction with overnight incubation at 37°C. The completion of the digestion
was checked by running 5 pi on a 12 % non-denaturing polyacrylamide gel (15 cm
X  30 cm X  1.5 mm) prepared as follow:
Reagents Amounts of reagents
Aciylamide stock (38:2) 15 ml
5 X TBE 10 ml
Water 25 ml
10 % ammonium persulfate 0.4 ml
TEMED 35 pi
The remainder 25 pi were phenol : chloroform extracted, ethanol precipitated and 
resuspended in 20 pi of TE.
4.2.5 Cloning of flie FMDV epitope
The expression vectors pUS909, pUS919, and pUS920 were cut with BgîU. and 
dephosphorylated by treatment with calf intestine alkaline phosphatase (CIP). The 
BgJil digested FMDV epitope was then ligated to these vectors. After transforming 
E. coli D H 5a competent cells, clones containing insert were identified by colony 
hybridization. The orientation of the insert was determined by SaB digestion followed 
by electrophoresis on a 8 % non-denaturing polyacrylamide gel.
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4.2.6 Colony blotting
E. coli cells transformed with the product of the ligation of BgBl linearized 
pUS909 with the FMDV epitope were plated on LB-agar plates containing 50 mg/ml 
of kanamycin, to form individual colonies. A marked circular nylon membrane 
(Hybond-N 82 mm in diameter) was placed on the agar plate containing colonies. 
After 1 min the filter was carefully removed and placed, colony side up, on a 3MM 
paper soaked in lysis solution (10% SDS). After 3 min the filter was transferred to 
a 3MM paper saturated with dénaturation solution (0.5 M NaOH, 1.5 M NaCl) for 5 
min, then to one saturated with neutralization solution (1.5 M NaCl, 0.5 M Tris HCl 
pH 7.4) for the same length of time, and then to one saturated with 2 X SSC. The 
filter was allowed to dry on a sheet of dry 3MM paper for 30 min and then the DNA 
was fixed to the filter by baking for 2 h at 80®C in an oven. This was followed by 
hybridization to the 88 bp FMDV fragment labelled with digoxigenin, and detection 
using the non-radioactive method as described in chapter 2.
4.2.7 Expression of the FMDV epitope
A rabbit polyclonal antibody against a synthetic peptide comprising FMDV 
V Pl residues 200-213 pro-pro-ser 140-160 (FMDV 15) was used as the primary 
antibody to detect expression of the FMDV epitope in M. smegmatis and BCG by 
western blotting. This antibody was kindly supplied by Dr Tim Doel from the Animal 
Health Institute, Pirbright, Surrey, UK. Expression of the 18-kDa antigen either intact 
or carrying the FMDV epitope was detected with the L5 monoclonal antibody.
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4.3 Results
4.3.1 Cloning of the FMDV epitope.
A benefit of the use of the M. leprae 18kD gene to drive the expression of 
foreign genes is the potential for cloning and expressing defined epitopes or small 
immunogenic peptides inserted into the 18-kDa protein. This was demonstrated using 
the immunogenic site sequence of the FMDV V Pl, corresponding to amino acids 140- 
160 (Kurz et al, 1981). Two 50 base oligonucleotides, overlapping by 12 
complementary bases and containing BglW recognition sequences were synthesised to 
correspond to this sequence, allowing for mycobacterial codon usage (Dale and Patki, 
1990). After purification, the oligonucleotides were annealed and extended with 
Klenow fragment of E. coli DNA polymerase I. This resulted in a 88 bp DNA 
fragment which was visualized on a non-denaturing polyacrylamide gel (fig. 4-1 A). 
The fragment was digested with BglU  (fig. 4-IB) and ligated with ^g/II-cut pUS909, 
pUS919, and pUS920, in frame at both ends with the 18kD gene. A schematic 
representation of the insertion of the FMDV epitope into the 18kD gene is shown in 
figure 4-2. E. coli transformants were screened by colony hybridization using the 
synthetic fragment as a probe, and the plasmids recovered were checked for the 
orientation of the insert by employing the asymmetric placed Sail recognition site. 
The resulting plasmids with the insert in the right orientation were named pUS921, 
pUS922, and pUS923 respectively (fig. 4-3). The sequence of the inserts was later 
confirmed by DNA sequencing using the Applied Biosystems A3 81 automated DNA 
sequencer and the dye terminator method, according to manufacture's instructions.
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Figure 4-1. Synthesis of the sequence coding for the FMDV VPl 140-160. A: Non 
denaturing polyacrylamide gel showing the product of annealing and extension 
reaction. Lane 1, oligonucleotide FM I; lane 2, FMI + FM2 annealed and extended; 
lane 3, oligonucleotide FM2; lane 4, (j)X Haelll molecular weight marker. B: BgBl 
digestion of the 88 bp synthesized DNA fragment. Lane 1, (})X Haelll molecular 
weight marker; lane 2, DNA after overnight digestion with BgTll\ lane 3, undigested 
DNA.
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ATG
140
VDAVPNLRGDLQVLAQK VARTLPK
FMDV VPl 140-160 EPITOPE
B
Kg/U Bgm
S'-AAG  ATC TCC GTG GAC GOT GTG CCG AAC CTG CGC GGC GAC CTG CAG GTG CTG GCC CAG AAG GTG GCC CGC ACC CTG CCG AAG ATC TCC-3'
K I S V D \ ^ V  P N L R G I) L Q V L A Q K V A R T L P^^^K I ^ ^
18kD FM D V  V P l 18kD
Figure 4-2. Cloning of the FMDV epitope. A: Schematic representation of the 
insertion of the FMDV epitope into Bglll site of the 18kD gene. The amino acid 
sequence of the FMDV VPl 140-160 epitope is shown in the box. B: DNA structure 
and polypeptide sequence of the FMDV epitope inserted into M. leprae 18kD gene.
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4.3.2 Expression of the FMDV peptide in M. smegmatis
The vectors carrying the FMDV insert coding for the major immunogenic site 
of V Pl were initially used to transform M. smegmatis and kanamycin resistant 
colonies were isolated. Individual colonies were grown in high concentration of 
kanamycin and expression of both the 18-kDa epitope (using the L5 monoclonal 
antibody) and the FMDV epitopes (using anti-FMDV15 polyclonal antibody) was 
examined by Western blotting. A product of the expected size (~ 21kDa) was detected 
with either the L5 or the anti-FMDV15 antibody, indicating that the insertion of the 
FMDV peptide had been successful. As before, selection on high concentration of 
kanamycin (100 pg/ml) resulted in a considerable increase in the level of expression 
of the 18-kDa-FMDV fusion (not shown). As there was no apparent difference in the 
level of expression between the vector containing the 18kD gene with the small 
promoter (pUS921) and the vectors with the large promoter (pUS922 and pUS923), 
all the subsequent experiments were performed with pUS921.
In o rd er to ob ta in  a h ig h e r level o f  ex p ress io n  o f  the  18-kD a/FM D V  
fu s io n , the  m y co b ac te ria l o rig in  o f  rep lic a tio n  from  pALSOOO w as c loned  
in to  pU S921. T his tran sfo rm ed  the in te g ra tiv e  v ec to r in to  a m u ltico p y  
p lasm id  v ecto r. The m y co b ac te ria l p lasm id  pALSOOO w as ex tra c te d  from  
M . fo r tu i tu m , l in ea rized  w ith  Eco'K'W and c loned  in to  S ea l s ite  o f  pU S921 
o rig in a tin g  pU S925 (fig . 4 -4). M . sm eg m a tis  tran sfo rm ed  w ith  th ese  
v ec to rs  w ere found  to express the 18-kD a an tigen  and its  fu s io n  in a h igh  
level ( -5 %  o f  the to ta l p ro te in ). S tab ility  te s ts  show ed th a t the  p la sm id  
w as su rp ris in g ly  s tab le . A fte r g row th  fo r 350 g e n e ra tio n s  in M . 
sm eg m a tis  w ith o u t an tib io tic  se lec tio n  m ore than  70 % o f  the
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Figure 4-4. Cloning of pAL5000 into the integrative vector pUS921. The 
mycobacterial replicon contained in pALSOOO enables the resulting vector (pUS925) 
to replicate as a plasmid in mycobacteria.
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bacteria were still resistant to kanamycin. The result shown in figure 4-5 demonstrates 
concurrent expression of both the M. leprae and FMDV epitopes in M. smegmatis.
4.3.3 Expression of the FMDV epitope in BCG
BCG was transformed with the vectors pUS921 and pUS925, and kanamycin 
resistant colonies were selected. Of a total of 8 kanamycin resistant colonies obtained 
after electroporation with 1 pg of DNA of the integrative vector pUS921, only 3 
colonies were true transformant and had a single copy of the vector integrated into the 
chromosome. This was revealed by Southern blotting of total DNA extracted from the 
transformants and probed with the entire vector. With the plasmid vector pUS925 
transformation efficiency was comparable to that obtained with pYUB12 (lO'* 
transformants per pg of DNA).
Western blotting of BCG transformed with pUS921 revealed a faint band of 
the expected size when detected with the monoclonal antibody L5. Detection with the 
anti-FMDV 15 polyclonal antibody resulted in a high background and no specific 
bands could be seen. However, with the plasmid vector pUS925 a specific band was 
detected also with the polyclonal antibody, as the level of expression was several fold 
higher than with pUS921 (not shown).
4.3.4 Vaccination of guinea pigs with rBCG expressing FMDV epitope
The successful expression of the FMDV epitope in BCG prompted us to investigate 
the immunogenicity of this recombinant vaccine in an animal model of the disease. BCG 
transformed with pUS925 and expressing the FMDV epitope (rBCG/FMDV) was grown in 
liquid media in a tissue culture flask for 5 days. The bacteria were harvested
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Figure 4-5. Western blot analysis of M. smegmatis transformants expressing the 18kD 
and the 18kD/FMDV fusion. A: Lane 1, pre-stained molecular weight markers; lane 
2, untransformedM. smegmatis; lane 3, transformed with the plasmid vector pUS926 
(18kD only); lane 4, transformed with the plasmid vector pUS925 (18kD/FMDV); lane 
5 transformed with the integrative vector pUS909 (18kD only); lane 6, transformed 
with the integrative vector pUS921 (18kD/FMDV), detected with the anti-18kDa 
monoclonal antibody L5. B: The same as A, but detected with anti-FMDV 15 
antibody.
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by centrifugation and resuspended in PBS containing 0.05% of Tween 80 to a final 
concentration of approximately 10  ^CFU/ml. Untransformed BCG was prepared in the 
same way and was used as a negative control. All subsequent experiments were 
performed at the AFRC Institute for Animal Health, Pirbright, Surrey, UK, by Len 
Pullen and Paul Barnett. Guinea pigs were divided in 2 groups of 5 animals each and 
one group of 2. The first group with 2 animals was not vaccinated; the second group 
with 5 animals received untransformed BCG; and the third group also with 5 guinea 
pigs was vaccinated with rBCG/FMDV. Each animal was inoculated intradermally 
with 100 pi containing approximately 10  ^ CFU, as determined afterward by colony 
count. At day 21, 40 and 55 post inoculation blood samples were collected from each 
animal and the level of antibody against the viral particle was measured by ELISA. 
One animal out of five from the control group that received untransformed BCG 
showed a relatively high anti-FMDV titre at 21 days post inoculation but the level 
declined thereafter (fig. 4-6A). In the group that received rBCG/FMDV, one guinea 
pig fail to produce detectable levels of anti-FMDV antibodies. The remainder four 
showed a significant anti-FMDV titre that was still raising after 55 days (fig 4-6B). 
At day 55 the animals were challenged with infective viral particles. One out o f the 
five animals vaccinated with rBCG/FMDV survived the challenge, whereas all the 
animals in the control groups died.
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Figure 4-6. Antibody responses against FMDV induced by rBCG. On day 0, guinea 
pigs were immunized with 10  ^ CFU (i d.) of untransformed BCG (A), or 
rBCG(pUS925) expressing the FMDV VPl 140-160 (B). Guinea pigs were bled on 
days 21, 40, and 55 post immunization and the anti-FMDV antibody titre was 
determined by ELISA. The antibody titres are expressed as antibody dilutions which 
gave an optical density value of 0.5 above the background.
124
4.4 Discussion
The DNA coding for the major immunogenic site of FMDV V Pl comprising 
residues 140-160 of FMDV strain Oj Kaufbeuren was successfully synthesized and 
cloned into BglU. site of integrative expression vectors. Expression o f the 18kD gene 
with the in frame FMDV epitope resulted in a product of approximately 21kDa in size. 
Both, the intact 18-kDa and the 18-kDa containing the FMDV peptide could be 
detected with the L5 monoclonal antibody as the BglU  cloning site is located 
downstream from the L5 binding site. Antibody anti-FMDV 15 recognized only the 
18kD/FMDV fusion. Expression of the fused gene was obtained inM . smegmatis and 
BCG.
Transformation of BCG with the integrative vector resulted in integration of 
the vector into the chromosome. Expression of the 18kD gene and its fusion was 
detected, but at a such low level that it was unlikely that it would be sufficient to 
induce a detectable immune response against FMDV in guinea pigs. We therefore 
decided to transform the integrative vector into a multicopy plasmid vector by cloning 
the mycobacterial replicon from the pALSOOO plasmid (Labidi et al, 1985). This 
alteration resulted in a significant increase in the level of expression of the 
18kD/FMDV fusion in both, M. smegmatis and BCG as the copy number of plasmids 
derived from pAL5000 is estimated at 5-6 per cell. Although this strategy resulted in 
a large plasmid, more than 12 kb in size, stability tests performed by growing the 
bacteria in unselective conditions showed that in M. smegmatis, and presumably also 
in BCG, it is very stable.
Immunization of guinea pigs with rBCG expressing the 18-kDa/FMDV fusion
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at a high level elicited a humoral immune response that was specific against the 
FMDV epitope and protective in one out of five animal vaccinated. Untransformed 
BCG did not elicit a detectable anti-FMDV antibody response. O f all the viral 
antigens expressed in BCG to date, only a low level of antibodies against gp41 portion 
of the HIV-1 envelope has been reported (Fuerst et al, 1991; Stover e/ al, 1991b). 
Several rBCG stains expressing other viral antigens have failed to induce detectable 
antibody responses, although a significant cell mediated immune response specific for 
the viral antigens was detected (Fuerst et al., 1991; Aldovini and Young, 1991; Winter 
et al, 1991; Yasutomi et al, 1993). A B-cell epitope comprising amino acids 12-19 
of HIV-1 gag p l7  has been fused to the secreted a-antigen of M. kansasii and 
expressed in BCG (Matsuo et al, 1990), but the immunogenicity of this rBCG strain 
has not been investigated. This is the first report of the induction o f high levels of 
antibodies against a viral epitope expressed in BCG. It is also the first time that 
protection against challenge with infective viral particles is demonstrated following 
vaccination with rBCG.
The fact that animals vaccinated with rBCG/FMDV produce antibody that 
recognize intact viral particles, and not only synthetic peptide, is very significant as 
it demonstrates that the V Pl immunogenic site fused with the 18-kDa antigen is 
properly presented to the immune system. Fusion of the same FMDV epitope with 
p-galactosidase and expressed in vaccinia virus fail to induce anti-FMDV antibodies, 
although anti-p-gal antibodies were detected (Newton et al, 1986). Similarly, fusion 
o f the FMDV V Pl 140-160 with outer membrane protein A (OmpA) of Shigella 
dysenteriae and expression in E. coli fail to induce VPl-specific antibodies in animal 
vaccinated with either irradiated recombinant bacteria or partially purified fusion
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proteins (Ruppert et al, 1994). The insertion site for the FMDV peptide into the 
18kD was chosen because of the availability of a suitable cloning site {Bglll). It is 
possible that by inserting the peptide in a different site, the immunogenicity of the 
epitope can be increased even more. Additionally, tandem insertion may enhance the 
immune responses to this foreign immunogenic site.
Another alternative to obtain a better immune response against the FMDV 
peptide inserted into the 18-kDa antigen is to increase the level of expression of the 
fusion protein. This could be achieved by using a stronger promoter to drive the 
expression of this gene in mycobacteria. Although several promoters have been used 
to drive the expression of foreign genes in mycobacteria, no comparative study has 
been done to determine the relative strength of different promoters.
The occurrence of FMDV as seven distinct serotypes poses considerable 
problems in the control of the disease (Brown, 1992). Animals vaccinated with a 
monovalent vaccine are still susceptible to infection with viruses from the remaining 
six serotypes. It has been shown that the greatest variability occurs within the 
sequence coding for V Pl 140-160. To overcome this problem, V Pl 140-160 
sequences from other serotypes may be cloned at the same or different sites o f the 18- 
kDa antigen, resulting in a vaccine that would protect against several serotypes.
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Chapter 5
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5 Intracellular and Extracellular Expression of 
Mycobacterial Promoters
5.1 Introduction
5.1.1 Gene expression and regulation
The first stage in gene expression and the principal step at which it is 
controlled is transcription. The specific recognition of promoter sites by RNA 
polymerase, associated with sigma factor, plays an important role in the control of 
DNA transcription. The nature of the promoter influences the affinity of the RNA 
polymerase for that site, and hence determine the efficiency of transcription which is 
ultimately the major determinant of the level of gene expression. A typical 
prokaryotic promoter has three components, consisting of consensus sequences at -35 
and -10, and the transcription start point. The E. coli consensus sequence at -35 is 
TTGACA, separated by 16-18 bp from the -10 which is TATA AT. This promoter is 
recognized by RNA polymerase associated with one specific sigma factor, sigma 70. 
Under certain circumstances, for example "heat shock" or nitrogen starvation, sigma 
70 is replaced by other sigma factors, and the promoter specificity o f the RNA 
polymerase is altered so that a different group of genes is expressed.
Although the -35 and -10 regions are crucial for the binding o f the RNA 
polymerase, the enzyme initially makes contact to some 77-80 bp, extending from -55 
to +20. The nature of the DNA sequence over this region is likely to have some 
influence over the affinity of the RNA polymerase for the promoter site, and its ability
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to initiate transcription from this position. A third recognition element in bacterial 
promoters named UP element has recently been described and consists of a DNA 
sequence rich in (A+T), located at position -40 to -60 (Ross et al., 1993). The 
sequence immediately around the startpoint influences initiation; and the initial 
transcribed region (from +1 to +30) controls the rate at which RNA polymerase clears 
the promoter, and therefore influences promoter strength. The efficiency of some 
promoters is also influenced by supercoiling of the DNA. In general RNA polymerase 
can initiate transcription more efficiently when the template is supercoiled, presumably 
because the supercoiled structure requires less free energy for the initial melting of 
DNA in the initiation complex. M. smegmatis RNA polymerase has been shown to 
be extremely dependent on DNA supercoiling for transcription from mycobacterial 
promoters in vitro (Levin and Hatfull, 1993).
Regulation of gene expression results from the interaction of a regulatory 
macromolecule with a sequence of nucleic acid. This interaction normally occurs in 
the vicinity o f the promoter. The ability of RNA polymerase to initiate at the 
promoter may be prevented or activated by a repressor or an activator respectively. 
Regulation can also occur at translational level, but in bacteria it is thought to be less 
significant than transcriptional control. Stability of the mRNA molecule and the 
translated product are other factors that also play a role in gene expression.
5.1.2 Gene expression in mycobacteria
The development of expression systems in mycobacteria has been achieved by 
using sequences derived from the region upstream from characterized mycobacterial 
genes. Among the genes that have been used to provide signal for expression of
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cloned genes in BCG are the members of the conserved hsp60 and hsplO families of 
stress proteins (Aldovini and Young, 1991; Stover et ah, 1991b; Fuerst et al, 1992; 
Connell et al, 1993; Yasutomi et al, 1993), the secreted a-antigen from M. kansasii 
(Matsuo et ai., 1990), a promoter region from M. paratuberculosis named P^n (Murray 
ei al, 1992), the promoter o f the gwES/groELl operon of Streptomyces albus (Winter 
et al, 1991), and the 19kD lipoprotein promoter and signal peptide sequence form M. 
tuberculosis (Stover et al, 1993).
Several of these systems have been shown to induce immunological response 
against specific antigens when recombinant BCG was used to vaccinate experimental 
animals, indicating that the promoters are active during infection. However, the level 
o f expression of these promoters during intracellular growth is unknown. Host 
physiological signals (low pH, oxidative stress, iron deficiency, etc) encountered by 
mycobacteria inside macrophages may influence the expression of mycobacterial 
genes; this is known to occur with other pathogenic bacteria (Griffiths, 1991).
Attempts have been made in the past to isolate mycobacterial promoters either 
in E. coli (Sirakova et al, 1989; Thomas et al, 1992), S. lividans (Kieser et al, 1986), 
orM . smegmatis (Das Gupta e/ al, 1993). Heterologous systems are unlikely to lead 
to selection of promoters which function exclusively in mycobacteria and even a 
homologous system, used in vitro, may not select promoters that are expressed 
effectively during intracellular growth. The possibility of studying mycobacterial 
promoters and gene regulation in an environment encountered by mycobacteria during 
infection will allow not only the identification of strong promoters to drive the 
expression of foreign antigens in a recombinant vaccine, but will also assist in 
developing a better understanding of mycobacterial pathogenesis.
131
In this study, the development and use of a system for testing mycobacterial 
promoter strength in both extracellularly and intracellularly growing mycobacteria, as 
well as in E. coli is described. A shuttle vector pUS933 containing a promoterless reporter 
gene (/ocZ) was constructed allowing both transcriptional and translational aspects to be 
examined. Several previously characterized mycobacterial promoters including those of the 
Mycobacterium bovis BCG hsp60, the M. leprae 18kD and the putative iron regulated M. 
leprae 28kD genes were cloned in front of the promoterless lacZ gene of pUS933 and the 
recombinant plasmids were used to transform E. coli, M. smegmatis and BCG. To isolate new 
mycobacterial promoters a promoter library was constructed usingM bovis BCG chromosomal 
DNA. Clones containing DNA inserts with promoter activity were isolated and the activity was 
measured in both, E. coli andM. smegmatis. In order to assess the promoter strength 
in an intracellular environment, murine macrophages were infected with recombinant 
BCG or M. smegmatis containing the lacZ gene under expression from different 
promoters. The level of expression of the reporter gene was determined by using a 
fluorescent substrate and a FACScan system. Intracellular expression of the reporter 
gene was demonstrated for a number of mycobacterial promoters examined, indicating 
that the genes under their control are actively expressed during growth inside 
macrophages. Relative differences in the expression of the reporter gene during 
intracellular and extracellular growth were detected for some promoters.
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5.2 Material and Methods
5.2.1 Bacterial strains and plasmids
M. bovis BCG used as a source of DNA was the Glaxo strain. M. smegmatis 
mc^l55 and E. coli DH5a were used for isolation of BCG promoters. For 
transformation with recombinant plasmids, BCG Pasteur was used. When necessary 
the solid medium was supplemented with 50pg of kanamycin per ml for plasmid 
selection and 40pg of X-Gal ml ’ for identification of recombinant clones with 
promoter activity. The promoterless lacZ gene was obtained by BamliU digestion of 
pMC1871 (Pharmacia LKB). BamEU digestion of pUC4K (Pharmacia LKB) was used 
to obtain the kanamycin resistance (aph) gene from Tn903. The plasmid pALSOOO 
was extracted from M. fortuitum  and digested with EcoBN.
5.2.2 Construction of the promoter probe vector
Initially the promoterless E. coli lacZ gene was cloned into the BamEU site of 
pUC18. The resulting plasmid pUS928 was digested with SmcH, and the BamEU 
fragment containing the kanamycin resistance gene from Er\903 was blunt-ended with 
Klenow fragment of DNA Polymerase I and ligated into it. The resulting plasmid 
(pUS929) was then digested with Seal and the pAL5000 plasmid digested with EcoECsl 
was ligated into it generating the shuttle vector named pUS933.
5.2.3 Cloning of previously characterized mycobacterial pro mo te
A DNA fragment containing the hsp60 promoter from M. bovis BCG was 
amplified by PGR using BCG DNA as template and the primers PI
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( 5 ' - T G G C G G A T G C G A C C  A C  A A C G - 3 ' )  a n d  P I I  ( 5 ' -  
GTACGCATGCGTCTTGGCCA-3'). The 404 bp PGR product was digested with 
Sphl and ligated into the Sphl site of pUS933 generating pUS934. The M. leprae 
18kD Large promoter (including 256 bp of upstream sequence) was obtained by Eco?l 
digestion of pUS920 and the 18kD Small promoter (including only 136 bp of upstream 
sequence) was similarly obtained by EcoRI digestion of pML3 (Booth et al, 1988). 
Both DNA fragments were blunt-ended by Klenow fragment o f DNA polymerase I . 
The vector pUS933 was digested with Sphl, the 5' end was filled in with Klenow, and 
the 18kD promoters were separately cloned into it. The 28kD promoter from M. 
leprae was also generated by PGR using M. leprae genomic DNA as template and 
cloned into Smdi site of pMG1871. The resulting plasmid was digested with Sail and 
the fragment containing the 28kD promoter and the lacZ gene was blunt-ended and 
ligated into EcoKW site of pYUB12. The resulting plasmid was designated pUSlTO.
5.2.4 Construction of die BCG promoter libraiy
A genomic DNA library of BGG Glaxo was produced by cloning DNA 
digested with Sphl into pUS933 linearised with the same enzyme and 
dephosphorylated with calf intestine alkaline phosphatase. The library which 
contained approximately 2,300 recombinant clones was amplified in E. coli before 
being used to transform M. smegmatis. Blue colonies of E. coli were checked for the 
presence of insert and the recombinant plasmids were individually transferred to M. 
smegmatis. Similarly, isolatedM. smegmatis colonies were subjected to plasmid DNA 
extraction and the plasmids were used to transform E. coli.
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5.2.5 fi-galactosidase assay using ONPG
Assay for 13-galactosidase was performed basically as described by Miller 
(1992). A volume of 0.1 ml of a late exponential phase culture (ODgoo 0.8-1.2) was 
added to 0.9 ml of Z buffer (6 mM Na2HP04, 40 mM NaH2P04, 10 mM KCl, 1 mM 
MgS04, 50 mM P-mercaptoethanol) and permeabilized with 20 pi of chloroform and 
10 pi of 0.1% SDS. After vortexing for 10 sec and 5 min incubation at 28°C, 0.2 ml 
of o-nitrophenyl-13-D-Galactoside (ONPG - Sigma) at a concentration o f 4 mg/ml was 
added and the incubation was continued at 28°C. When sufficient yellow colour had 
developed, the reaction was stopped by adding 0.5 ml of 1 M Na2C03 and the 
incubation time was recorded. After centrifuging for 2 min at 10,000 x g, the OD420 
was measured and the calculation of 13-galactosidase activity in Miller units was made 
using the formula:
OD42» X 1000 = units of 13-galactosidase 
 ^ X  V X  ODgoo
where t is the incubation time and v is the volume of culture used. At least three 
separate assays were performed for each recombinant clone.
5.2.6 Tissue Culture
The mouse macrophage cell line J-774 was grown in RPMI-1640 (Sigma) 
containing 10% fetal calf serum and 2 mM glutamine. Five millilitres of a suspension 
of cells at 5 X 10  ^ viable cells per ml were used to inoculate a 25 cm^ tissue culture 
flask, followed by overnight incubation at 37°C in 5% CO2
5.2.7 Infection of monolayers
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Bacterial cultures were diluted directly into fresh tissue culture medium to 
achieve a rate of infection of approximately 50 bacteria per macrophage. This 
inoculating medium was used to replace the growth medium and phagocytosis was 
allowed to occur for 4 hours at 37°C and 5% CO^ The monolayers were then 
washed twice with Hank's salt solution (Sigma) to remove non-phagocytosed bacteria, 
and returned to the incubator with fresh medium for 24 hours.
5.2.8 Assay of 0-galactosidase activity in infected macrophages
The B-galactosidase activity of macrophages infected with recombinant 
mycobacteria expressing the lacZ gene from different promoters was detected by using 
the FluoReporter LacZ Detection Kit (Molecular Probes) according to the 
manufacturer's instructions. Briefly, the infected macrophage cells were removed from 
the tissue culture flask by trypsin treatment and resuspended in staining media 
(phosphate buffered saline, 4% fetal calf serum, 10 mM HEPES, pH 7.2) containing 
300 pM chloroquine (an inhibitor of the endogenous B-galactosidase) at 10  ^ cells/ml 
One hundred microlitres of cells were transferred to a flow cytometer tube and placed 
in a 37®C water bath for 20 min. The substrate, 2 mM fluorescein di-B- 
galactopyranoside (FDG) in water, was loaded by adding 100 pi of pre-warmed (37®C) 
solution to the 100 pi of cells. After exactly 1 min at 37®C, the FDG loading was 
stopped by adding 1.8 ml ice-cold staining media and the cells were kept on ice. 
After 10 min, 40 pi of 50 mM phenethylthio-B-D-galactopyranoside (PETG) was 
added to stop the reaction and the cells were analysed by using a flow cytometer 
FACScan, equipped with an argon ion laser and FACScan research software (Becton 
Dickenson).
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5.3 Results
5.3.1 Construction of the vectors
The truncated E. coli lacZ gene which lacks a promoter, a ribosome binding 
site and an ATG start codon was used for cloning expression signals from 
mycobacteria. This gene had already been successfully used as a reporter gene in 
mycobacteria (Barietta et al, 1992) allowing the identification o f recombinant clones 
which express enzymatically active B-galactosidase fusion proteins. The kanamycin 
gene from Tn903 was used as a selectable marker in mycobacteria and E. coli, and the 
pAL5000 plasmid (Labidi et al, 1985) provided the mycobacterial origin of 
replication. The vector pUS933 contains two unique restriction sites (Sphl and Xbdl) 
upstream of the promoterless lacZ gene, that are useful for cloning expression signals 
(fig 5-1).
In order to evaluate the use of this promoter probe vector, the putative 
promoter-containing regions upstream from characterized mycobacterial genes were 
cloned in frame with the lacZ gene. These genes were BCG hsp60 (Thole et al, 
1987), M. leprae gene coding for the 18-kDa antigen (Booth et al, 1988) and th e M  
leprae 28kD antigen (Cherayil and Young, 1988) believed to be iron regulated (Dale 
and Patki, 1990). For the 18kD gene two fragments were used: one containing 256 
bp of the 5' regulatory region plus the first 29 codons was referred to as the Large 
promoter; the other one containing only 136 bp of the 5' regulatory region plus the 
first 29 codons was referred to as the Small promoter. The sequence for the putative - 
10 and -35 region, as well as the ribosomal binding site and the start codon for this 
genes is shown in figure 5-2. Only the hsp60 promoter has been mapped by primer
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Seal
Hindin 
Sph 
Xbal BfflnK 
Smal 
Kpnl 
Sad 
EcqRI
Promoterless lacZ
BamHl
Ndel Sphl
Seal
pUS928
57.6 Kb
Km-R
EcoRf'
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pALSOOO
Xbal
/B a m H l N ddSeal
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/B am H I
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Sad
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Figure 5-1. Construction of the promoter probe vector
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18kD promoter from M. leprae, 0.34 Kb fragment containing 
256 bp of the 5' regulatory region, plus the first 29 codons.
Promoterless /acZ
18kD promoter from M. leprae, 0.27 Kb fragment containing 
136 bp of the 5' regulatory region, plus the first 29 codons.
Promoterless lacZ
28kD promoter from M  leprae, 0.3 Kb fragment containing 
276 bp of the 5' regulatory region, plus the first 8 codons.
Promoterless lacZ
Figure 5-3. Schematic representation of plasmids construction. Plasmid pUS933 was 
used as vector and all the promoters were cloned into Sphl site.
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extension analysis (Stover et al., 1991b). The others have been located by sequence 
homology to the E. coli consensus sequence. The cloning of the hsp60, 18kD 
Large, 18kD Small and the 28kD promoter sequences into pUS933 generated the 
plasmids pUS934, pUS935, pUS936 and pUS170 respectively (fig. 5-3). These 
plasmids were used to transform E. coli, M. smegmatis and BCG.
5.3.2 Strength of mycobacterial promoters
The promoter activity of the cloned fragments in E. coli, M. smegmatis and 
BCG was determined by measurement o f 13-galactosidase activity in cell extracts. A 
comparison of promoter strength in these species is shown in figure 5-4. Surprisingly, 
the 18kD promoters (Large and Small) drive relatively high levels of expression in E. 
coli but show a very low level of expression in M. smegmatis and BCG, compared to 
the other mycobacterial promoters. The 18kD Large promoter DNA fragment which 
contains 265 bp of upstream sequence gave significantly higher level of expression 
than the 18kD Small promoter in E. coli, M. smegmatis and BCG. These results 
suggest that the second putative promoter sequence contained in the 18kD Large DNA 
fragment but not present in the 18kD Small promoter may be functional; a similar 
situation has been reported for the hsp60 promoter (Stover et al, 1991b). 
Alternatively, sequence elements binding a positive regulator of RNA polymerase 
activity may be present in the larger DNA fragment. The promoters tested in BCG 
showed no significant difference to the level of expression of the same promoters in 
M. smegmatis, indicating that for this limited range of promoters, signals controlling 
expression in BCG and M. smegmatis are recognized similarly.
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PÜS936 (MLlSkDS)
PÜS935 (MLlSkDL) 
PÜS934 (/*ap60)
pUSlTO (ML28kD)
PÜS933
(Promoterless)
1 □  BCGWMsmsanctLsMLEcdi
Units of fi-Galactosidase
Figure 5-4. Comparative activity of mycobacterial promoters in E. coli, M. smegmatis 
and BCG. The 13-galactosidase activity was determined as described in material and 
methods and is expressed in Miller Units.
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5.3.3 Isolation of BCG promoters and activity in K  coli and M. smegmatis
Further evaluation of the promoter probe shuttle vector was supplied by the 
isolation and testing of BCG DNA fragments with promoter activity. For this purpose, 
a library of Sph\-cuX BCG DNA fragments in pUS933 was transformed into E. coli, 
yielding approximately 2,300 recombinant clones; of these, 12% showed some 
13-galactosidase activity on X-gal plates. Sixty of the blue colonies were picked for 
further tests; most had single inserts ranging from 0.6 kb to approximately 10 kb 
(mean 4.2 kb). These 60 clones were designated E e l-60; plasmid DNA from each of 
these clones was subsequently introduced, individually, into M. smegmatis. The 
13-galactosidase activity conferred by each plasmid in E. coli and inM . smegmatis was 
determined by the ONPG assay. Eighty-two per cent of the plasmids with promoter 
activity in E. coli were also active in M. smegmatis; 14% were stronger in E. coli 
then in M. smegmatis, and 12% had approximately the same 13-galactosidase activity 
in E. coli as in M. smegmatis. However the average 13-galactosidase activity of the 
promoters isolated in E. coli was only 40 units whereas the same promoters in M. 
smegmatis had an average activity of 70 units (fig. 5-5).
A similar experiment was also performed involving initial selection of 
promoter-active clones in M  smegmatis rather than in E. coli. The total library, after 
amplification in E. coli, was used to transform M. smegmatis; 12% of the 
transformants produced blue colonies on X-gal containing agar. A total o f 36 blue M. 
smegmatis colonies were isolated out of approximately 2x10^ transformants. Plasmid 
DNA was extracted and used to transform E. coli, producing the set of clones 
denominated Msl-36. These clones were thus selected on the basis of their ability to 
promote the expression of 13-galactosidase in M. smegmatis. Quantitative assay of
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13-galactosidase expression showed that only 39% of the clones with promoter activity 
initially isolated in M. smegmatis (clones M sl-36) showed activity in E. coli. This 
result is consistent with previous studies (Kieser et ah, 1986; Barietta et ah, 1992) 
indicating that mycobacterial promoters are often inactive in E. coli. In the case of 
the promoters isolated inM . smegmatis, the average 13-galactosidase activity was 170 
units compared to 5.6 units in E. coli; indicating that this screening procedure isolated 
mycobacterial-specific promoters. Figure 5-5 shows the results for selected clones.
5.3.4 Environmental regulation
Genes involved in macrophage survival and virulence would be expected to 
respond to environmental signals that regulate gene expression during in vitm/in vivo  
growth. We therefore assayed the activity of the previously characterized gene 
promoters and a small group of the library-isolated promoters under conditions 
designed to mimic aspects of the intracellular environment. M. smegmatis cultures 
were exposed to stress conditions such as high temperature (45®C), low pH (pH 5.0) 
with the addition of H2PO4, 0.002% H2O2, 2% ethanol or iron depletion with the 
addition of 200pM dipyridyl iron chelator (Sigma). No significant differences in level 
of expression were found (fig. 5-6).
5.3.5 Strength of mycobacterial promoters in BCG during in vitro and intracellular 
growth
The in vitro activity of the characterized mycobacterial promoters cloned into 
BCG was measured (fig. 5-7A). These recombinant BCG strains were then used to 
infect murine macrophages and the promoter strength during intracellular growth
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M 
yca
'o
M. smegmatis
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M
Figure 5-5. Comparison of strength of mycobacterial promoters in E. coli and M. 
smegmatis. Ecn: selection of BCG promoters isolated in E. coli; Ms«: selection of 
promoters isolated in M. smegmatis; EC: average activity of the total number of 
promoters isolated in E. coli; MS: average activity of promoters isolated in M. 
smegmatis. These results are the average of three separate experiments.
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pUS933 pUS170 pUS934 pUS935 pUS936 Ms2 Ms28 Ms36 Ec2
Figure 5-6. Activity of mycobacterial promoters under stress conditions in M. 
smegmatis. Cultures grown to mid log-phase at 37°C were divided into aliquots and 
submitted to stress conditions for 1 hour before the 13-galactosidase activity was 
determined. The results shown are the average of four separate experiments. The 
variation between experiments was less the 20%.
146
determined. In order to measure intracellular promoter activity it was necessary to 
incubate infected cells with a 13-galactosidase substrate capable o f penetrating both 
macrophage cell membrane and the mycobacterial cell wall. The fluorescent substrate 
fluorescein di-13-galactopyranoside (FDG) has previously been shown to be capable of 
penetrating live mammalian cells in tissue culture (Ikenaka et al, 1990). Preliminary 
experiments (not shown) demonstrated that the substrate was also capable o f staining 
live BCG cells expressing 13-galactosidase constructs.
The mouse macrophage cell line J-774 (Snyderman et al, 1977) used in this 
experiment was infected with approximately 50 bacteria per macrophage. After 4 
hours of infection at 37°C the cells were rinsed twice with Hanks balanced salt 
solution to remove extracellular bacilli. Ziehl-Neelsen staining confirmed the absence 
o f extracellular bacteria and revealed that 75%-80% of macrophages were infected (fig
5-8A). The number of mycobacteria per cell was similar for each of the BCG strains 
tested and varied from 5 to more then 50. Macrophages were incubated for 24 hours 
in media containing gentamicin to kill any uningested bacteria. The cells were then 
incubated with FDG and examined by fluorescent microscopy. Intracellular 
mycobacteria were clearly visible as brightly staining fine rods within the macrophages 
infected with the recombinant BCG strains (fig. 5-8B). No fluorescence was seen with 
macrophages similarly infected with control BCG cells.
A total of 10"* cells from each sample were analysed by flow cytometry. The 
same number of macrophages infected with non-recombinant BCG was also analysed. 
The relative intensity of fluorescence obtained with control BCG was subtracted from 
that obtained with the recombinant BCG to give a value for 13-galactosidase activity 
within the infected macrophages. The results for three separate experiments are shown
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in figure 5-7B.
It is not possible to directly correlate the units of in vitro 13-galactosidase 
activity values with the intracellular activity measured by fluorimetry. In order to 
compare intracellular and extracellular expression, we divided the value (in arbitrary 
units) obtained for intracellular expression with the in vitro 13-galactosidase activity 
value for each gene. This ratio, the relative intracellular activation (RIA), was 
arbitrarily set to one for hsp60 promoter and expressed as a ratio of this value for the 
other promoters. The RIA values obtained essentially measure the level of activation 
of the gene promoter during intracellular growth, relative to the activation of the hsp60 
promoter (fig. 5-7C). TheM . leprae 18kD promoters showed the highest level of 
intracellular activation.
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Figure 5-7. Comparison of strength of mycobacterial promoters expressed in BCG 
during extracellular and intracellular growth. A: Extracellular activity. Recombinant 
BCG cells were grown in vitro and incubated with the B-galactosidase substrate 
ONPG. The in vitro expression of B-galactosidase is expressed in Miller units. B; 
Intracellular activity. Recombinant BCG cells were used to infect macrophages. The 
B-galactosidase activity of BCG cells growing within macrophages was measured by 
fluorimetry. Enzyme activity is expressed as an arbitrary unit of relative intensity of 
fluorescence obtained using the FACScan system. C: Relative intracellular activation 
(RIA) of mycobacterial promoters. The RIA was calculated by dividing the B- 
galactosidase activity value obtained during intracellular growth by the in vitro 
activity. The RIA of the hsp60 promoter was normalized to one and the RIA of other 
genes are expressed as a ratio of this value.
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Figure 5-8. Intracellular expression of mycobacterial promoters. A: Zeihl-Neelsen 
staining of macrophage cells infected with recombinant BCG strain. B: Macrophage 
infected with BCG expressing the B-galactosidase gene under the control of the hsp6^ 
promoter. Cells were incubated with FDG substrate and photographed using a 
fluorescent microscope.
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5.4 Discussion
We have established conditions for isolation and characterization of 
mycobacterial translation signals in an homologous or heterologous environment using 
the E. coli B-galactosidase reporter gene. In this system, a promoter, a ribosome 
binding site, and a start codon in the correct reading frame must be provided by the 
cloned DNA to generate B-galactosidase activity. A similar system had been 
successfully used before to isolate promoters from mycobacteriophages (Barietta et al, 
1992). Since the consensus sequence and the strength of mycobacterial 
ribosome-binding sites are not fully characterized we used a translational rather than 
a transcriptional probe previously used to study mycobacterial promoters (Kieser et al, 
1986; Sirakova et al, 1989; Thomas et al., 1992). A number of promoters including 
theM . leprae 18kD promoter showed higher levels of in vitro expression in E. coli 
than in mycobacteria, suggesting that their expression may be normally repressed by 
mycobacterial-specific signals during in v/7ro-growth of M. smegmatis.
The ratio o f blue/white colonies in the initial screening of the promoter library 
was similar in both M. smegmatis and .E. coli (about 12%). This is a high frequency 
considering that the maximal expected frequency of active fusions would be one in six 
(16.7%), assuming that all DNA is coding, that the DNA must be fused in the correct 
orientation and reading frame, and that every hybrid protein is enzymatically active 
or degraded to an active form intracellularly; this result is consistent with previous 
studies (Kieser et al, 1986; B arietta et al, 1992), and may arise from the presence of 
multiple promoter active regions on the comparatively large fragments used, as well 
as the detection of active fragments that are not genuine promoters. The percentage 
of BCG DNA fragments with promoter activity isolated in M. smegmatis that also
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show activity in E. coli (39%) was the same as that detected by Barietta et ah (1992), 
but higher than the 12% detected by Das Gupta et al. (1993) using the CAT gene as 
the reporter gene. This difference might be due to the different sensitivity of the two 
systems.
The system described here was also used to study previously characterized 
promoters, namely the BCG hspSO which is the most commonly used mycobacterial 
promoter for driving the expression of foreign genes (de la Cruz et al., 1991; Fuerst 
et al., 1991; Stover et a l, 1991); the M. leprae 28kD which has a high degree of 
homology to other iron regulated promoters and therefore was believed to be regulated 
by iron (Dale and Patki, 1990); and theM . leprae 18kD promoter which we have been 
using to express foreign genes in mycobacteria. None of the genes tested showed any 
significant response to 'stress' conditions. This was surprising since the Hsp60 protein, 
the mycobacterial analogue of E. coli groEL is one of the major mycobacterial heat 
shock proteins and induction of this protein has been demonstrated in BCG cells 
subjected to heat shock (Patel et al, 1991). The results are however consistent with 
previous studies (Stover et al, 1991b; Curcic et al, 1994) where it was shown that the 
hsp60 promoter only responded to stress conditions when it was integrated into the 
chromosome as a single copy. It has been suggested that DNA supercoiling may be 
involved in the regulation of the mycobacterial heat shock response (Levin and 
Hatfull, 1993) and differences in the superhelical state of plasmid and chromosomal 
DNA may account for these findings. The M. leprae 28kD promoter when subjected 
to iron depletion condition (0.2 mM Dipyridyl) did not show any response. Although 
this result does not eliminate the possibility that this gene is iron regulated, it does 
cast doubt on this hypothesis. However it is possible that M. smegmatis does not
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provide the signals necessary for regulation of this M. leprae gene.
Although the hspSO and other mycobacterial promoters have been shown to 
induce an immune response against antigens expressed by them in animal models (de 
la Cruz et ah, 1991; Stover et ah, 1991; Murray et ah, 1992), no studies had been 
done to determine the promoter strength during intracellular growth. Additionally, 
since the hsp60 promoter gives high levels of expression in vitro, it may be difficult 
to use this system to clone genes that are toxic to in vj/ra-grown mycobacteria. 
Attempts to clone the HIV env gene under the control of the hsp60 promoter using a 
mycobacterial plasmid vector, were unsuccessful; suggesting that in vitro expression 
of this gene was toxic to BCG (Stover et ah, 1991). For the development of a 
recombinant vaccine it would be useful to have a mycobacterial promoter that is 
specifically activated during growth inside macrophages, the environment found by the 
bacteria once the vaccine is administered. By infecting mouse macrophages with 
recombinant BCG containing the lacZ reporter gene under expression from different 
promoters, and measuring the level of B-galactosidase produced under this condition 
using a FACScan, we were able to determine the strength of several different 
promoters.
As expected, the hspGO promoter showed a high level of expression also during 
intracellular growth. The 18kD promoter, although showing relatively low activity 
during in vitro growth gave proportionally much higher activity during intracellular 
growth. This suggests that the 18kD gene is upregulated during intracellular growth, 
which is consistent with the known characteristic of the protein as a major antigen in 
natural infection. The reason for the difference in the level of expression between the 
18kD Large and the 18kD Small promoters is not presently known. The failure in
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detecting this difference by Western blotting (chapters 3 and 4) can be attributed to 
the fact that Western blot is not a quantitative technique. Both promoters contained 
136 bp of regulatory sequence that would be expected to include the -10 and -35 
regions that characterize promoters in E. coli. However a third recognition element, 
called the UP element and a region adjacent to the UP element that contains binding 
sites for the activator protein Fis have been found to extend some E. coli promoter 
regions to 150 bp upstream (Ross et ah, 1993). Alternatively, the second putative 
transcription initiation site found in the large promoter may be functional. The hspSO 
gene has been shown to contain two transcription start sites (Stover et ah, 1991). 
Further analysis by primer extension or SI mapping will be necessary to establish the 
structure o f this promoter.
The ideal promoter for the expression of foreign genes in a multi valent 
recombinant BCG vaccine would be active at low levels in E. coli and BCG grown 
in vitro to allow cloning of potentially lethal genes, and be expressed at a high level 
inside macrophages to induce a good immune response. The 18kD M. leprae 
promoter may be such a promoter and may therefore provide an effective expression 
system for recombinant BCG vaccines. The system described here will also allow a 
large number of potential promoters from the library to be screened in order to isolate 
further potentially useful promoters. Identification of genes that are selectively 
expressed during intracellular growth may also be used to identify virulence genes of 
M. tuberculosis and to investigate the involvement of specific genes in survival ofM . 
tuberculosis within macrophages.
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6 Further improvements to the rBCG/FMDV vaccine
6.1 Introduction
The results obtained with the immunization of guinea pigs with rBCG/FMDV 
were very promising, and encouraged us to look for ways of augmenting the immune 
response against FMDV. A low level of expression of an immunogenic antigen is 
some times enough to elicit strong and protective immune responses, provided that the 
antigen is presented to the immune system in the right form, but in general, the higher 
the level of expression, the stronger the immune responses. A higher level of 
expression may also allow a reduction in the inoculum, therefore reducing the risk of 
adverse reactions to the vaccine. Expression of foreign proteins in recombinant 
organisms is influenced by many factors. At the transcription level the promoter 
strength dictates the frequency of transcription of a particular gene. At the translation 
level, accumulation of protein is dictated by the balance of peptide synthesis rate, 
posttranslational modification and protein folding, and degradation by endogenous 
proteases. At present, we have very limited ways of addressing the factors that 
influence gene expression at the translation level in mycobacteria, therefore we opted 
to use a stronger promoter to increase the level of expression of the 18kD/FMDV 
fusion. A detailed study comparing the strength of the 18kD Small promoter used in 
the rBCG/FMDV vaccine, to the BCG hsp60 promoter revealed that the latter is at 
least 50 fold stronger during in vitro growth (chapter 5). Although the M. leprae 
18kD gene promoter appears to be specifically activated during intracellular growth.
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the BCG hsp60 promoter is still considerably stronger also in this condition.
With this information available I decided to use the hsp6Q promoter to drive 
the expression of the 18-kDa antigen and the 18kD/FMDV fusion. The coding 
sequence for both genes was amplified by PCR and cloned in front of the BCG hsp60 
promoter. A high level o f expression of the 18kD and 18kD/FMDV was obtained in 
M. smegmatis and BCG after transformation with a shuttle vector carrying the fused 
genes.
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6.2 Material and methods
6.2.1 Cloning of die ltsp6Q promoter in front of the 18kD gene
The BCG hsp60 promoter sequence {Phsp6Qi) used to express the lacZ gene in 
pUS934 was cut with Sphl restriction endonuclease, blunt-ended with T4 DNA 
polymerase and cloned into Smal site of pUC18 originating pUS947. The 18kD and 
18kD/FMDV coding sequences were obtained by PCR amplification using primers Ml 
3 (5'-ATGGATCCTGATCAGTTCCGTGAACTGG-3') which has BamYll m d B c R  recognition 
sites near the 5' end, and Ml 2 (5 '-g c t g g a t c c g c a a a c a a c a g -3') that had been 
previously used to amplify the complete 18kD sequence from M. leprae contained in 
pUS919 and pUS920, and also has BamYH recognition site. The plasmids pUS920 
and pUS923 were used as template for the amplification of the 18kD and 
18kD/FMDV coding sequences respectively. PCR conditions used for amplification 
were as follow:
Dénaturation 94°C 1 min
94"C 1 min
55”C 1 min
72°C 2 min
1 cycle
Dénaturation
Annealing
Synthesis
30 cycles
Annealing
Synthesis
55°C 2 min 
72°C 5 min 1 cycle
Both PCR products were run on an agarose gel, Geneclean purified and cut
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with BamYQ.. The fragments were then cloned into BœnYil site of pUS947, generating 
the plasmids pUS953 (18kD) and pUS954 (18kD/FMDV).
6.2.2 Cloning of the P/wp60-18kD into a integrative vector
The plasmids pUS953 and pUS954 were digested with XhcH and Sacl and the 
845 bp fragment containing the P/?5;?60-18kD sequence from pUS953, and the 921 
bp fragment corresponding to the P/?ap60-18kD/FMDV from pUS954 were cloned into 
pUS903 cut with the same enzymes. This resulted in the integrative vectors named 
pUS937 and pUS939 respectively. The 2.6 kb Hpdl-EcoBN  fragment from pAL5000 
was then cloned into SccH site of pUS937 and pUS939 generating plasmids named 
pUS941 and pUS943. The pAL5000 origin of replication {HpcH-EcdBN fragment) was 
also cloned into Seal site of pUS920, and pUS923 originating pUS945, and pUS946 
respectively. Table 6-1 shows the plasmids used in this study and the relevant 
characteristics of each of them.
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Table 6-1. Plasmids used in this study.
Plasmid Relevant characteristics Source/Reference
pUC18 Cloning vector (Yanisch-Perron eW., 1985)
pALSGGO Plasmid isolated from M. fortuitum (Labidi ei al, 1985)
pUS934 Plasmid containing the lacZ gene under 
expression from the BCG hsp60 promoter
Chapter 5
pUS92G Mycobacterial Integrative vector carrying 
the 18kD with the large promoter
Chapter 3
pUS923 Mycobacterial integrative vector carrying 
the 18kD/FMDV fusion
Chapter 4
pUS947 pUC derivative carrying the BCG hsp60 
promoter
This Work
pUS9G3 Mycobacterial integrative vector Chapter 3
pUS953 pUC derivative carrying the fusion 
/?jp6G-18kD
This Work
pUS954 pUC derivative carrying the fusion 
/?j^6G-18kD/FMDV
This Work
pUS937 pUS9G3 derivative carrying the fusion 
/?f^6G-18kD
This Work
pUS939 pUS9G3 derivative carrying the fusion 
/;5:/?6G-18kD/FMDV
This Work
pUS941 pUS937 with the addition of the M-ori 
from pAL5GGG
This Work
pUS943 pUS939 with the addition of the M-ori 
from pAL 5GGG
This Work
pUS945 pUS92G with the addition of the M-ori 
from pAL5GGG
This Work
pUS946 pUS923 with the addition of the M-ori 
from pALSGGG
This Work
160
6.3 Results
The substitution of the 18kD promoter by the VhspSO was achieved by using 
a cloning strategy that involved amplification of the 18kD coding sequence by PCR 
and in frame ligation with the Vhsp60 previously cloned in pUC18. Primers were 
designed to allow amplification of the entire coding sequence of the 18kD gene with 
the addition of a Bam'Hl site for direct cloning in front o f the Yhsp60, resulting in the 
fusion of the fourth residue of the Hsp60 protein with the sixth residue of the 18-kDa 
protein (fig. 6-1).
BflwHI M Ï  Barnm
5’-ATG GCC AAG ACG GGG G A T C C fW C A G  TTC CGT. . . .  GCC TAA TCG ACT GTT GTT TGC GGAX<X-3'
G D P Q F R A,.,End
Hsp60 18kD
Figure 6-1. DNA and amino acid sequences at the junction of the P/z5/?60-18kD 
fusion.
One of the primers was designed to create a new Bell site in the beginning of 
the 18kD gene which will be useful as a cloning site (in addition to the B glll site 
already present) for cloning other epitopes or complete antigens. PCR amplification 
using pUS920 and pUS923 as template resulted in the amplification of the 18kD and 
the 18kD with the FMDV epitope respectively. Both fragments were separately 
cloned in front of the YhspôO originating plasmids pUS953 and pUS954 (fig. 6-2).
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Hind I
Vhsp6u
Bam HI
Sma [
385 bp 
Siii I Uunt-ended
EcoRl
Sma I
N del
Bam HI Bam HI
Promoterless 18kD
450 bp - PCR generated
Seal
Hind III/SphIX^bal
—  Bam HIpUS947
2696 bp
C  Sac I 
 ^ K pnl 
Eco RI
Bam HI
Promoterless I8kD + FMDV
532 bp - PCR generated
N co l
Hind IIISeal
Bam
pUS953
2696 Iç
-B e ll  
Bam HI
Seal
Bam HI
pUS954
2696 bp
- B d l  
Bam HI
Figure 6-2. Construction of P/25/?60-18kD and P/25/?60-18kD/FMDV fusions.
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The 18kD and 18kD/FMDV coding sequences, now under expression from the 
P/j5/?60, were subcloned using the integrative vector pUS903 which has 2 copies of 
ISPOO in parallel, plus the kanamycin resistance gene. The resulting vectors, pUS937 
and pUS939 (fig 6-3) were used to transform M  smegmatis and a relatively high level 
of expression of the fusion proteins was confirmed by Western blotting of kanamycin 
resistant transformants. To obtain an even higher level of expression of the 18kD and 
the 18kD/FMDV fusion, the EcoKV-Hpal fragment of pALSOOO which has been 
shown to contain the mycobacterial origin of replication (M-ori) and to be sufficient 
for replication of recombinants (Ranes et al, 1990) was cloned into both, pUS937 and 
pUS939 generating the plasmid vectors named pUS941 and pUS943 respectively (fig.
6-3). Previous expreiment has shown that an increase in the level of expression of 
approximately 10 fold may be obtained by using this strategy (Chapter 4). The M-ori 
was also cloned into pUS920 and pUS923 which are the same as pUS937 and pUS939 
with the exception that the expression of the 18kD gene is driven from its own 
promoter (Large promoter) and the gene is in the opposite orientation. The resulting 
plasmids were named pUS945 and pUS946. This allowed a direct comparison of the 
strength of the 2 different promoters. These plasmids were extracted in large scale 
and used to transform M. smegmatis and BCG. Figure 6-4 shows the expression of 
the 18kD and 18kD/FMDV in BCG as detected by Western blot. As expected, the in 
vitro expression from the Vhsp60 was significantly higher than from the 18kD 
promoter. Detection with the anti-FMDV15 antibody specifically recognized the 21kD 
band corresponding to the 18kD/FMDV fusion. The difference in the level of 
expression between the P//^/?60 and the 18kD Large promoter appears to be equivalent 
to the difference detected when these promoters were used to drive the expression of 
the reporter gene lacZ.
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Eco RI
'  PstI
HWIII
Hind III
SacJ Phsp60-18kD +FM D VSac: Phsp60-18kD
S acl
+
X bal
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+ 
X b al
Eco RIEco RI 
S acl pUS939pUS937
Hind III
Hind III
Hind HI
B g lll  
B g lll 
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P stl
Hind III
S ea l
Eco RV M-ori from pALSOOO Hpa 1
EcoRl K pnl
EcoRI
pUS941
Hind 111
Hind III
K pnl P stl
EcoRI
S ea l
K jn l
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pUS943
Hind 111
Hind 111
K pnl P s tl
Figure 6-3. Cloning of the Vhsp60 fusions into a integrative vector.
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Figure 6-4. Western blot analysis of expression of the 18kD and 18kD/FMDV in BCG 
transformed with shuttle vectors. A: lane 1, pre-stained molecular weight markers; 
lane 2, untransformed BCG; lanes 3 and 4, pUS941 transformants (P/7^/?60-18kD); 
lanes 5 and 6, pUS945 transformants (18kD Large promoter-18kD); lanes 7 and 8, 
pUS943 transformants (P/?5/?60-18kD/FMDV); lanes 9 and 10, pUS946 transformants 
(18kD Large promoter-18kD/FMDV). The anti-18-kDa mAh L5 was used for 
detection. B: The same as A, but detected with anti-FMDV15 polyclonal antibody.
165
6.4 Discussion
In an attempt to increase the level of expression of the 18kD and the 
ISkD/FMDV fusion, and consequently the immunogenicity of rBCG against FMDV, 
the 18kD regulatory sequence was replaced by 385 bp of regulatory sequence plus the 
first four codons from the BCG hspSO gene. The hsp60 promoter has been extensively 
used to express foreign genes in BCG (Stover et al, 1991b; Stover et al, 1993; 
Connell et al, 1993; Haeseleer et al, 1993), and immune responses against antigens 
expressed by this promoter have been demonstrated. The results described in chapter 
5 show that it is one of the strongest mycobacterial promoters examined, and that it 
is also active during intracellular growth. Although the 18kD promoter appears to be 
specifically activated during in vivo  growth, the hsp60 promoter has shown to be 
considerably stronger also under these conditions. Combining the strength of the 
hsp60 promoters with the immunogenic properties o f the 18-kDa antigen may result 
in an efficient expression system for foreign epitopes and small immunogenic 
peptides.
Immunization of guinea pigs with rBCG expressing the 18kD/FMDV fusion 
at a relatively low level has shown that the 18-kDa protein is potentially a good carrier 
for the FMDV V Pl 140-160 immunogenic site (chapter 4). The levels of anti-viral 
antibodies elicited by this construct were not achieved when the same immunogenic 
site was expressed fused to other carriers including the LacZ (Newton et al., 1986), 
the E. coli PhoE (Agterberg et al., 1990) and the OmpA of Shigella dysenteriae 
(Ruppert et al, 1994). The increase in the level of expression of the 18kD/FMDV 
resulting from the use of the Vhsp60 may be sufficient to induce solid protection
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against FMDV, not only in animal models, but also in susceptible domestic animals. 
This possibility is presently been investigated further.
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Conclusions
The use of integrative vectors based on 1S900 for obtaining stable expression 
of foreign genes in mycobacteria was demonstrated in this study. In contrast to site- 
specific integrative vectors based on the phage attachment system where the copy 
number is one per cell, the vectors described here have the potential o f being present 
in several copies per cell, enhancing the expression of foreign genes. Internal 
transposition of the IS900 composite transposon can lead to an increase in the vector 
copy number. This event is very rare, but can be selected for by increasing the 
concentration of the selectable antibiotic in the culture medium. 1S900 integrative 
vectors may be used to transform the same bacterium more than once, provided that 
a different selectable marker is used each time, a characteristic that adds to the 
versatility of this system. The transformation efficiency is higher with the vector with 
two copies of 1S900 in parallel, as it can integrate in M. smegmatis via simple 
insertion of the composite transposon as well as cointegrate formation. In BCG 
however, only simple insertion of the composite transposon was detected (recent data 
not presented). The mechanism of transposition of IS900 and its effect on integration 
and expression of foreign genes in mycobacteria remains to be investigated.
TheM . leprae gene encoding the 18-kDa antigen is efficiently expressed from 
its own promoter in different mycobacterial species, namely M. smegmatis, M. vaccae 
and M. bovis BCG. In M. smegmatis but not in M. vaccae and BCG, selection in 
high concentrations of kanamycin resulted in higher levels o f expression of the 18kD 
and/or internal transposition with increase in the copy number of the vector. Although
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the regulation mechanism is obscure, the high level of expression is maintained even 
when sub cultured in the absence of selection, which is an essential characteristic for 
a vector to be used in a recombinant vaccine. A more comprehensive study is 
required to elucidate the effects of selection with high concentrations of kanamycin 
on the expression of the 18kD gene in M. smegmatis.
The immunogenic properties o f the M. leprae 18-kDa were exploited as an 
expression system which allows the expression of small epitopes as well as complete 
genes. The system was used to express the major immunogenic site of FMDV VPl 
and recombinant BCG expressing the viral immunogenic site fused to the 18-kDa 
antigen elicited a high level of anti-FMDV antibodies in animal models. This 
indicates that antigenic determinants of the 18-kDa/FMDV fusion are efficiently 
recognized by B lymphocytes, and also presented on the surface of antigen presenting 
cells (APC) in association with MHC class II receptors and recognized by CD4^ T 
cells. It is not evident how an intracellular organism whose recombinant protein 
would presumably be subjected to proteolysis within the phagolysosomal compartment 
o f macrophages, can effectively elicit antibody responses, which generally recognize 
epitopes on intact antigens. It has been suggested that nonviable organisms contained 
in the rBCG vaccines are capable of releasing relatively intact recombinant antigens 
recognized by B cells (Stover et ah, 1991b). However, the fact that killed rBCG bacilli 
are not effective immunogens suggests that continuing production of antibodies is due 
to antigen molecules being released from the rBCG over long periods of time in vivo.
In this study, a system for testing mycobacterial promoter strength in both 
extracellularly and intracellularly growing mycobacteria, as well as in E. coli was 
developed. A promoter library constructed using M. hovis BCG chromosomal DNA
170
was screened in M. smegmatis and E. coli and the activity of each individual clone 
was measured in both, E. coli an d M  smegmatis. Many mycobacterial promoters are 
functional in E. coli. Some, including the M. leprae 18kD promoter, are stronger in 
E. coli than inM . smegmatis, but the majority do not work efficiently in E. coli. The 
18kD promoter is very weak if compared to the strength of the BCG hsp60 promoter, 
however, an increase in the size of the regulatory region from 136 bp to 256 bp 
resulted in a 4 fold increase in the level of expression. SI mapping or primer 
extension will be necessary to confirm the possibility of the existence of a second 
transcription start site present in the Large promoter.
The promoter strength in an intracellular environment was assessed by infecting 
murine macrophages with recombinant BCG containing the lacZ gene under 
expression from different promoters and measuring the level of P-galactosidase 
produced. This is the first report of a method to measure in vivo expression levels of 
mycobacterial promoters. Until now the level of expression could only be inferred 
from the immunogenicity of the protein product of the gene in question. Intracellular 
expression of the reporter gene was demonstrated for several mycobacterial promoters 
examined, indicating that the genes under their control are actively expressed during 
growth inside macrophages. The hsp60 promoter is expressed at a high level also 
during intracellular growth. The 18kD promoters (Large and Small) are relatively 
weak during in vitro growth, but give proportionally much higher activity during 
intracellular growth, indicating that they are specifically activated inside a macrophage 
cell. Mechanisms involved in mycobacterial gene regulation and regulation of 
virulence gene expression within macrophages are virtually completely unknown. 
Elucidation of the mechanism involved in the regulation of the M. leprae 18kD gene
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would be an important first step to understanding mycobacterial gene regulation.
As the BCG hsp60 promoter is the strongest of the mycobacterial promoters 
tested and it is also expressed at a high level during intracellular growth, it was used 
to replace the 18kD promoter and to drive the expression of the 18kD/FMDV fusion. 
A high level of expression was obtained in BCG that was at least 10 times higher than 
the expression driven by the 18kD Large promoter in vitro. The effect o f this 
increased expression of the fused antigens on the immunity induced by rBCG and the 
protection against FMDV is currently being investigated.
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